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Summary 
 
Glomerulonephritis (GN) is a major cause of progressive chronic renal failure (CRF) and 
accounts for less than 20% in the UK of patients requiring dialysis and transplantation. 
There are many forms of GN, of which IgA nephropathy (IgAN) is the most common, 
affecting  up  to  2%  of  the  adult  population.  GN  is  characterised  by  irreversible  and 
progressive glomerular and tubulointerstitial fibrosis, reduction in glomerular filtration rate 
(GFR),  and retention of uremic toxins. The rate of progression of GN is increased by 
various  clinical  factors  including  hypertension,  and  the  quantity  and  specificity  of 
proteinuria.  Although  albuminuria  is  most  widely  studied,  higher  molecular  weight 
proteins  such  as  immunoglobulins  (Ig)  are  more  associated  with  progression  of  renal 
disease. In this thesis I have explored the hypothesis that an interaction between tubular 
cells and filtered Ig/immuno complex (Ig/IC) may involve specific cellular receptors, and 
thus provide a novel mechanism for the initiation of tubular injury and fibrosis. 
Deposition of Ig and IC is seen in renal diseases such as membranous glomerulonephritis, 
and IgAN. Ig/IC are regarded as responsible for the initiation of glomerular injury in these 
diseases. However, whether Ig/IC contribute directly to tubular injury is unknown. We 
previously identified a novel IgA receptor, the Fcα/  receptor (Fcα/ R), in mesangial cells 
which may  contribute to  IgAN. This receptor  binds both  IgA  and  IgM but not  IgG.  I 
hypothesised that Ig and IC, filtered at the glomerulus, may act on Ig receptors in human 
proximal tubular epithelial cells (PTEC) and may play a direct pathophysiological role in 
the  development  of  interstitial  fibrosis.  Specifically,  that  filtered  IgA  may  bind  to  the 
Fcα/ R in IgAN. The activation of Ig receptors may stimulate tubular cells to alter cell 
proliferation  and  extracellular  matrix  formation  (e.g  fibronectin  (FN)),  which  are 
pathophysiological characteristics of tubulointerstitial fibrosis in GN. 
I  studied  primary  and  immortalised  human  PTEC  using  qualitative  RT-PCR  and 
quantitative  real-time  PCR  (qRT-PCR)  for  expression  of  candidate  Ig  receptors.  I 
investigated the expression of Ig receptors and their regulation by cytokines (e.g. IFN-γ, 
TGF-β1  and  IL-1α)  known  to  be  implicated  in  GN.  The  receptors  studied  include  the 
polymeric immunoglobulin receptor (pIgR), the neonatal receptor (FcRn), the Fcα/ R, the 
classical  IgG  receptors  (FcγR1,  γIIa,  γIIb,  γIII  and  the  related  FcR  γ-chain)  and  the 
classical  IgA  receptor  (FcαR).  None  of  the  classical  IgG  receptors  were  expressed  by S S Su u um m mm m ma a ar r ry y y, VI 
PTEC, nor was the classical IgA receptor. However, the FcRn, pIgR and the Fcα/ R were 
expressed. 
Gene expression of these receptors was investigated under cytokine regulation. IFN-γ, IL-
1α and TGF-β1 had no effect on FcRn gene expression. The expression of the pIgR gene 
was up-regulated by IFN-γ and the Fcα/ R transcript level was up-regulated by IL-1α and 
IFN-γ but down-regulated by TGF-β1. Expression of Fcα/µR protein by tubular cells was 
confirmed by western blot analysis by using specific Fcα/µR monoclonal antibody. 
Immunohistochemistry confirmed the expression of Fcα/µR by PTEC in both normal and 
diseased kidney and that IgG, IgA and IgM binding varies in parallel with gene expression 
of  related  Fc  receptors.  This  binding  was  associated  with  increased  FN  production 
(assessed  by  ELISA)  and  reduced  the  proliferation  of  PTEC,  demonstrated  by  [
3H]-
thymidine uptake assay. 
I screened the ability of PTEC to release cytokines under normal conditions and confirmed 
this by ProteoPlex cytokine array. Among these cytokines there was no significant effect of 
Ig/IC on IL-6, IL-8 and GM-CSF released by PTEC, and this was confirmed by specific 
ELISA  for  each  individual  cytokine.  The  phosphotyrosine/phospho-ERK  signalling 
pathway was unaffected by Ig/IC; however, IgM was able to activate the phospho-ERK 
pathway.  These  results  suggest  that  there  might  be  alternative  signalling  pathways 
activated by Ig/IC in PTEC. 
I then studied the effect of calcineurin inhibitor immunosuppressive drugs as a model of 
tubular toxicity, and statins as immunomodulatory drugs, reputed to protect renal function 
and known to have immunomodulatory effects. I hypothesised that immunosuppressant 
agents/statins either alone or in combination with LPS might affect Ig receptors expression, 
cytokine release, FN production and proliferation by PTEC. 
My  results  inferred  that  immunosuppressive  agents  alone  have  a  non-inflammatory 
response on Ig receptor expression. However, in combination with LPS, the study drugs 
showed a slight inhibitory effect on the expression of the pIgR on PTEC at the highest 
concentration only. There was no significant effect of immunosuppressant agents alone or 
in combination with LPS on IL-6, IL8 and GM-CSF released by PTEC. Cyclosporine, 
FK506 and sirolimus were shown to inhibit both the production of FN and the growth of 
PTEC at high doses, thereby exerting an antiproliferative effect. S S Su u um m mm m ma a ar r ry y y, VII 
Both simvastatin and fluvastatin inhibited LPS induced production of IL-6, IL-8 and GM-
CSF,  FN  and  proliferation  in  a  dose-dependent  manner.  1  micromolar 
simvastatin/fluvastatin  was  associated  with  a  35%  reduction  in  unstimulated  FN 
production, a 51% reduction in proliferation, and reduced production of IL-6 (58%), IL-8 
(65%)  and  GM-CSF  (57%).  The  expression  of  Ig  receptors  was  increased  in  a  dose-
dependent manner in PTEC treated with statins alone or in combination with LPS. 
In conclusion, the expression of tubular FcRn, pIgR and Fcα/µR by PTEC is regulated by 
proinflammatory cytokines. The binding of IgA and IgM, possibly through the Fcα/µR, by 
PTEC  may  contribute  to  immune-mediated  nephropathy.  The  FN  production  and  the 
proliferation  suggest  that  Ig/IC  binding  may  contribute  to  the  pathophysiology  of  IC-
mediated renal disease. The ability of immunosuppressant agents to reduce FN production, 
proliferation, and pIgR expression by PTEC may offer potential new strategies for the 
prevention and treatment of nephrotoxicity, proteinuria and chronic allograft nephropathy 
(CAN).  The  inhibitory  effect  of  statins  alone  or  in  combination  with  LPS  on  FN 
production,  proliferation  and  cytokines  released  suggest  that  statin  therapy  may  have 
potential benefit in interstitial nephritis and fibrosis. On other hand, statins alone or in 
combination with LPS increased the expression of Ig receptors by PTEC. 
This thesis shows that the novel human Fcα/µR in PTEC may play an important role in the 
immune mechanisms involved in the tubular response during renal injury associated with 
tubular Ig/IC deposits in renal disease. 
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1.1 Applied anatomy of the kidney 
As a vital component of the urinary system, the kidneys have numerous functions and play 
a crucial role in maintaining equilibrium of water and electrolyte concentrations in the 
body.  These  functions  include  the  production  and  secretion  of  urine,  hormones 
(erythropoietin)  and  enzymes  (renin,  an  important  enzyme  in  the  control  of  blood 
pressure). In this section I will briefly outline the anatomical structure of the kidneys. 
1.1.1 The nephron system 
Each  kidney  contains  approximately  1  million  functional  and  structural  units  called 
nephrons. Each nephron consists of a tubule that opens into a collecting duct at one end 
and is closed at the other and is responsible for the production of urine in response to 
secretions from other glands. The closed end of the nephron (the ‘glomerular corpuscle’) is 
indented to form Bowman’s capsule, a double-layered epithelial cup-shaped structure that 
almost completely surround the glomerulus, a network of 10–20 arterial capillary loops. 
Blood  flowing  through  these  capillary  loops  undergoes  the  first  step  in  the  filtration 
process, from which an initial urine filtrate is produced. This occurs because the walls of 
the  glomerulus  are  more  permeable  and  blood  pressure  (BP)  is  higher  than  in  other 
capillaries  (Mirpuri&Patel,  2000).  The  initial  urine  filtrate  then  passes  through  the 
remainder of the nephron: the proximal tubule, the loop of Henle and the distal tubule 
leading into a collecting duct. The structure and function of each of these components is 
described in more detail below. 
 
Figure   1-1 Nephron system anatomy 
Adapted from: http://www.mhhe.com/biosci/ap/dynamichuman2/content/gifs/0176.gif. 
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1.1.1.1  The glomerulus 
1.1.1.1.1 Podocytes 
The visceral layer of Bowman’s capsule is lined with podocytes, cells that are a crucial 
component of the glomerular filtration process. These cells and their pedicles (or ‘foot 
processes’) interdigitate with neighbouring cells to cover the thick basal pedicles lamina 
that joins the endothelium to the podocytes (the glomerular basement membrane (GBM), 
see below), leaving only narrow slits through which molecules can be filtered. The size and 
patency  of  these  filtration  slits  is  thought  to  be  regulated  by  a  large  number  of  actin 
microfilaments and by the presence of a thin membrane that spans the slits in a similar 
manner to the diaphragm of fenestrated capillaries (Mirpuri&Patel, 2000). 
1.1.1.1.2 Glomerular basement membrane (GBM) 
The  GBM  is  the  principal  component  of  the  filtration  barrier  and  contains  type  IV 
collagen,  sialoglycoproteins  and  other  non-collagenous  glycoproteins  (e.g.  laminin),  in 
addition to proteoglycans and glycosaminoglycans, particularly heparin sulphate. As well 
as acting as a physical barrier, the GBM is also an ion-selective filter and restricts the 
movement of particles, usually proteins, larger than approximately 70KDa (Mirpuri&Patel, 
2000). 
1.1.1.1.3 The mesangium 
Like podocytes, mesangial cells (MSC) are found in the outer layers of the GBM and are 
collectively  referred to along with their extracellular matrix (ECM) as the mesangium. 
Unlike podocytes, MSC can be found outside of the glomerular corpuscle as part of the 
juxtaglomerular apparatus. Here, they are sometimes also referred to as lacis cells (Ross et 
al., 1995). 
MSC  are  known  to  be  contractile,  phagocytic  and,  alongside  their  ECM,  to  provide 
structural  support  for  podocytes  where  the  GBM  is  absent.  They  help  to  keep  the 
glomerular filter free of debirs by removing trapped residues and aggregated proteins from 
the GBM and may also regulate blood flow in the glomerulus. Indeed, MSC have been 
observed to proliferate in renal diseases that involve excessive protein deposition in the 
GBM (Moura et al., 2004). C C Ch h ha a ap p pt tte e er r r    1 1 1          I IIn n nt ttr r ro o od d du u uc c ct tti iio o on n n, 23 
1.1.1.2  The proximal tubule 
The initial urine filtrate leaves the glomerular corpuscle through the proximal tubule, a 15-
mm  long  narrow  structure  lined  with  a  single  layer  of  cuboidal  cells.  These  cells 
interdigitise tightly and are connected by their luminal surfaces, each one consisting of 
millions of microvilli that are collectively referred to as an ‘apical brush border’. These 
densely packed structures vastly increase the surface area for absorption of the filtrate and 
help to distinguish proximal epithelial tubular cells (PTEC) from cells in other tubules. The 
brush borders of cells in the pars convolute (the first, convoluted part of the proximal 
tubule) tend to have a higher density and a larger number of mitochondria than those of 
cells in the pars recta (the second, straight part of the proximal tubule), suggesting that 
transport functions in the former are more developed than in the latter (Ross et al., 1995). 
The proximal tubule is where most of the reabsorption process takes place and is regarded 
as the most vulnerable segment of the nephron (Bakoush et al., 2001). As such, it requires 
sufficient oxygenation to ensure enough metabolic energy is present to aid solute transport. 
In the pars convolute, proteins and peptides in the initial glomerular filtrate are usually 
reabsorbed by endocytosis and binding to the brush border membrane (Koeppen&Stanton, 
2007). Enzymes within the brush border cleave peptides at the amino site of hydrophobic 
amino acides The brush border contains enzymes that can cleave peptides at the amino site 
of  hydrophobic  amino  acids,  such  as  membrane  metallo-endopeptidase  (NEP;  neutral 
endopeptidase,  kidney-brush-border  neutral  proteinase,  enkephalinase,  EC  3.4.24.11) 
(Connelly et al., 1985; Inoue et al., 2003). 
1.1.1.2.1 Proximal tubular epithelial cells (PTEC) 
Like other transporting epithelial cells, PTEC have a basic polarised structure comprising 
an apical (luminal) membrane and a basolateral membrane. The former contains a number 
of  transmembrane  carriers  that  allow  solutes  to  enter  the  cell  from  the  tubular  lumen 
(Schnermann, 1998), while the latter contains other transporters (including the Na
+-K
+-
ATPase pump) and ion channels that return the filtered solutes back into the circulation 
(Burrow et al., 1999). The shape and polarity of PTEC is governed by the cytoskeleton, 
which also plays a vital role in the maintenance of cell:cell and cell:matrix interactions 
(Khurana, 2000). C C Ch h ha a ap p pt tte e er r r    1 1 1          I IIn n nt ttr r ro o od d du u uc c ct tti iio o on n n, 24 
1.1.1.3  Loop of Henle 
The descending limb of the proximal tubule is linked to the ascending limb of the distal 
tubule by the medullary loop (or ‘loop of Henle’), a thin-walled U-shaped structure with a 
hairpin  turn.  In  some  nephrons,  this  may  be  very  short  and  there  is  an  abrupt  change 
between the distal thin and thick ascending segments. Here, the luminal membrane does 
not contain a brush border and there are few folds in the basal membrane (Ross et al., 
1995). 
1.1.1.4  Distal tubule 
From  the  loop  of  Henle,  the  filtrate  proceeds  into  the  distal  convoluted  tubule.  This 
structure is typically only one-third of the size of the proximal tubule and leads to the 
collecting ducts. Here, the cells have no brush border and the number of basal infolds 
gradually decreases along the length of the tubule. This segment plays an important role in 
the reabsorption of Na
+ (with concomitant secretion of K
+) and the continued reabsorption 
of biocarbonate ion (with concomitant secretion of H
+). Thus, the urine becomes more 
acidic and ammonia is converted to ammonium ion; this then enters the urea cycle in order 
to avoid toxicity (Mirpuri&Patel, 2000). 
1.1.1.4.1 Juxtaglomerular apparatus 
Where the distal thick segment of the nephron is situated next to the glomerular vascular 
pole, the tubule is lined with a distinctive cell type collectively referred to as the macula 
densa. These cells are narrow and often more elongated than other cells in the distal tubule. 
In this same region, the smooth muscle cells of the afferent (and sometimes the efferent) 
arteriole are modified. These modified cells (or ‘juxtaglomerular cells’) synthesise, store 
and  release  renin  into  the  blood,  and  are  distinguished  by  their  spherical  nuclei  and 
granulated cytoplasm. Currently, it is believed that a reduction in either blood volume or 
Cl
– concentration in the blood stimulates the release of renin by these cells. Thus, the 
juxtaglomerular apparatus acts as both a regulator and sensor of blood composition and 
volume (Koeppen&Stanton, 2007). C C Ch h ha a ap p pt tte e er r r    1 1 1          I IIn n nt ttr r ro o od d du u uc c ct tti iio o on n n, 25 
 
Figure   1-2 Schematic diagram of renal glomerulus 
Adapted from:  
http://anatomy.iupui.edu/courses/histo_D502/D502f04/lecture.f04/urinaryf04/glom.jpg. 
 
1.1.1.5  Collecting ducts 
The final segment of the nephron is the cortical collecting duct. These are approximately 
20 mm long and are lined with cuboidal cells, only a small number of which project onto 
the luminal surface. Before draining the urine into the renal pelvis, the collecting ducts 
pass through the renal cortex and medulla. In the former, each duct drains approximately 
six distal tubules, while in the latter the distal tubules combine in pairs to form a duct of 
Bellini. The urine is subsequently drained into the renal calyx, the renal pelvis, the ureter 
and into the bladder (Ross et al., 1995). 
1.2 Applied physiology of the kidney 
The overall composition of urine is first and foremost a reflection of the filtration process, 
the  exchange  of  molecules  between  the  nephron  and  the  blood  that  takes  place  in  the 
glomerulus.  However,  as  filtration  is  nonselective  with  regard  to  small  molecules,  the 
selective reabsorption phase is crucial for returning any small molecules that the body 
needs back into the bloodstream. The final phase in the formation of urine is secretion . 
 C C Ch h ha a ap p pt tte e er r r    1 1 1          I IIn n nt ttr r ro o od d du u uc c ct tti iio o on n n, 26 
1.2.1 Filtration 
Glomerular filtration is a passive transport process that allows macromolecules to pass 
through  the  capillaries  and  into  the  nephron,  depending  upon  their  shape,  charge  and 
molecular weight. For instance, blood cells, plasma proteins and other large molecules 
remain in the capillaries while water and other small molecules <70 kDa (e.g. glucose, 
amino acids, Na
+, urea, K
+) pass through the filter, some of which are reabsorbed later. 
Other than the important exception of plasma proteins, the composition of the glomerular 
filtrate is not hugely different from that of the plasma. 
The difference in BP between the glomerulus and Bowman’s capsule aids the filtration 
process. The glomerular filtration rate (GFR) is often used to assess how well the kidneys 
are working and reflects the volume of filtrate produced by each kidney per minute. Where 
differences are seen in the volume and concentration of filtrate, this is due to the selective 
reabsorption of some molecules and tubular secretion of others (Koeppen&Stanton, 2007). 
1.2.2 Reabsorption 
The process of selective reabsorption returns the small molecules that the body needs from 
the  filtrate  to  the  interstitial  fluid  and  blood  plasma  by  transporting  them  across  the 
epithelium of the renal tubule. Once the initial filtrate leaves the glomerular corpuscle, 
reabsorption takes place throughout the rest of the nephron, mainly in the proximal tubule 
but also in the loop of Henle, the distal tubule and the collecting ducts. Almost all organic 
nutrients (such as sugar and vitamins) are reabsorbed from the initial filtrate, significantly 
modifying its composition by increasing concentrations of some substances and reducing 
the concentrations of others in the excreted urine. 
If  an  unusually  high  level  of  a  particular  substance  (e.g.  glucose)  is  in  the  blood,  the 
reabsorption  process  may  be  overloaded.  In  such  cases,  the  transport  maximum  (the 
kidney’s highest capacity for reabsorption of a substance) is exceeded and the substance 
will be detected on urinalysis. Active transport out of the tubules cannot occur because all 
the carrier sites are occupied; other substances reabsorbed by active transport include Na
+, 
K
+, PO4
– and Cl
–. Depending upon the nephron segment, Na
+ and Cl
– may be reabsorbed 
passively instead (Koeppen&Stanton, 2007). 
The  transport  maximum  typically  varies  according  to  needs  and  may  be  regulated  by 
hormones.  For  instance,  the  reabsorption  of  calcium  and  phosphate  depends  upon C C Ch h ha a ap p pt tte e er r r    1 1 1          I IIn n nt ttr r ro o od d du u uc c ct tti iio o on n n, 27 
parathyroid  hormone  and  calcitonin,  while  aldosterone  increases  the  reabsorption  of 
sodium and excretion of potassium. The reabsorption of water is influenced by antidiuretic 
hormone,  which  increases  the  permeability  of  the  distal  tubule  and  collecting  ducts. 
Nitrogenous waste products (e.g. urea and uric acid) and substances not normally found in 
blood (e.g. drugs) are reabsorbed in very small amounts or not at all. If filtration does not 
sufficiently  clean  these  substances  from  the  blood,  they  are  secreted  directly  into  the 
tubules and excreted in the urine (Mirpuri&Patel, 2000). 
1.2.3 Secretion 
The secretion of unwanted substances in plasma most commonly occurs in the proximal 
and  distal  convoluted  tubules.  Where  the  initial  filtration  process  is  relatively  non-
selective,  secretion  is  a  highly  selective  process  that  involves  both  passive  and  active 
transport. 
In order to maintain the normal pH in plasma, the cells that line the proximal tubule secrete 
H
+  ions  that  combine  with  buffers  –  bicarbonate  (forming  carbonic  acid),  ammonia 
(forming ammonium ions) and hydrogen phosphate (forming dihydrogen phosphate) – in 
the  filtrate.  The  normal  pH  of  urine  varies  from  4.5–8,  depending  on  a  wide  array  of 
factors, including time of day and diet (Koeppen&Stanton, 2007). 
1.3 Kidney diseases 
In the previous sections I have described the normal anatomy and physiology of the human 
kidney. Here, I describe how abnormalities in renal processes and structures can lead to 
one of several diseases. 
1.3.1 Renal failure 
1.3.1.1  Acute renal failure (ARF) 
Acute renal failure (ARF) is a sudden and dramatic drop in the GFR, reflecting a severe 
impairment of kidney function that is usually reversible on treatment. ARF may occur as a 
complication of a number of non-renal conditions; the causes are classified as follows: 
·  Pre-renal: caused by reduced blood flow, such as in severe and prolonged shock. C C Ch h ha a ap p pt tte e er r r    1 1 1          I IIn n nt ttr r ro o od d du u uc c ct tti iio o on n n, 28 
·  Renal:  caused  by  damage  to  the  kidney  itself,  for  example,  due  to 
glomerulonephritis (GN) or acute tubular necrosis. 
·  Post-renal:  caused  by  an  obstruction  in  urinary  outflow,  e.g.  kidney  stones  or 
tumour. 
1.3.1.2  Chronic renal failure (CRF) 
Chronic renal failure (CRF), defined as irreversible damage to three-quarters of nephrons 
in  the  kidney,  usually  develops  over  several  years,  slowly  and  asymptomatically.  It  is 
characterised by a severe impairment in GFR that allows waste products such as urea and 
creatinine to accumulate in the blood. The signs and symptoms of CRF include acidosis, 
electrolyte  imbalances,  anaemia  and  hypertension,  and  are  collectively  referred  to  as 
uraemia.  Common  causes  of  CRF  include  hypertension,  diabetes  mellitus,  reflux 
nephropathy and GN. 
1.3.2 IgA nephropathy (IgAN) 
First described in 1968, IgA nephropathy (IgAN) (Berger&Hinglais, 1968) is characterised 
by deposits of IgA1 in the mesangium, often alongside deposits of complement factor C3 
and IgG, IgM or both (Bairoch et al., 2005; Khan et al., 2003; Monteiro, 2005; Tomino, 
2005). In early studies, IgAN lesions were found in approximately one-quarter of renal 
biopsies (D'Amico et al., 1987), with later studies from all over the world confirming that 
IgAN is the most prevalent form of primary GN (Wiwanitkit, 2006). 
IgAN may present as a wide variety of glomerular lesions. When making a diagnosis, 
serum or plasma levels of IgA-containing immune complexes (IC) should be measured 
(Czerkinsky et al., 1986; Tomana et al., 1997). Approximately 35–50% of patients exhibit 
an elevated serum IgA; this elevation persists in some patients and declines to normal in 
others (Jia et al., 2004). An increase in serum IgA levels in itself does not result in IgAN. 
Although the IgA1 subclass is more common worldwide, African–American patients also 
show an elevated concentration of IgA2 (in accordance with the finding that over half of 
African–American patients with IgAN have IgA2 deposits in the mesangium). 
High titers of IgA-containing ICs are commonly found in patients with primary IgAN, 
occurring in 30–70% of patients (Coppo et al., 1995), while high serum concentrations of 
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both in acute disease and in remission; IgG-containing ICs are much less common and only 
seem to appear during relapses (Schena et al., 1989). 
Proliferation of MSC and fibrosis have been observed even in patients with mild clinical 
disease,  with  30–40%  of  patients  progressing  to  end-stage  renal  failure  (ESRF)  via 
progressive glomerular and interstitial sclerosis within 20 years of diagnosis (Emancipator, 
1998).  Although  the  clinical  course  and  impact  of  IgAN  are  well  documented,  the 
molecular pathogenesis of IgAN is as yet unknown. There is evidence to suggest that the 
condition is induced by factors outside of the kidney; IgAN recurs in around 50–60% of 
patients  who  receive  a  renal  allograft  (Coppo  et  al.,  1995;  Odum  et  al.,  1994),  while 
patients with non-IgAN renal disease who receive an inadvertent transplant from a donor 
with subclinical IgAN are able to clear the immune deposits within a matter of weeks. The 
risk of recurrence of IgA deposits in transplant recipients does not seem to be affected by 
the use of immunosuppressants and may be associated with recurrence of GN, which may 
lead  to  graft  failure  (Floege  et  al.,  1998).  In  addition,  the  idea  of  a  genetic  basis  for 
susceptibility to IgAN is being increasingly supported, with several families having been 
identified (Hsu et al., 2000). 
1.3.2.1  Clinical and histological features of IgAN 
The clinical and histological severity of IgAN can vary widely from patient to patient. 
Although typical cases experience a slow progression from mesangial proliferative GN to 
glomerulosclerosis  via  tubulointerstitial  fibrosis  and  atrophy,  sometimes  microscopic 
haematuria is the only clinical indication of illness (Smith&Feehally, 2003). Two other 
small  subgroups  of  patients  have  been  identified:  those  with  ARF  in  association  with 
crescentic nephritis and those with steroid-responsive nephrotic syndrome. 
Immunofluorescence techniques are required for a definitive diagnosis of IgAN. Specific 
antibodies that recognise IgA are used to highlight the deposits; these are usually found in 
the  glomerular  mesangium  but  may  also  occur  within  the  walls  of  the  glomerular 
capillaries (Figure 1-3). Immunofluorescence staining may also show C3, IgG and IgM co-
deposits sometimes associated with IgAN. IgA-containing ICs within the mesangium may 
be identified by granular electron-dense deposits using electron microscopy. 
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Figure   1-3 A biopsy from a patient with IgA nephropathy (Berger disease) 
Positive staining by immunofluorescence shows mesangial distribution of IgA in a 
glomerulus with IgAN.  
Adapted from: http://www.iganbio.com/images/glomerulus stained.jpg 
 
 
1.3.2.2  Pathogenesis of IgAN 
The molecular pathogenesis of IgAN is not yet fully understood, though various cytokines 
and growth factors have been implicated (Gomez-Chiarri et al., 1994; Horii et al., 1989; 
Lovett  et  al.,  1986;  Wardle,  1991).  Most  studies  to  date  have  been  of  limited  scope, 
focusing on no more than a few proinflammatory cytokines at a time, and whilst these 
molecules may indeed have an important role in the pathogenesis of IgAN, it is difficult to 
disentangle their influence on the induction and maintainence of the immunological insult. 
Various animal studies have shown that the blockade of some cytokines can attenuate renal 
injury. 
Experimental  studies  in  different  animal  models  support  the  role  of  cytokines  in 
development of renal injury. Transforming growth factor-b (TGF-b) antagonists have been 
shown to prevent glomerular sclerosis (Border et al., 1992), while interleukin-1 (IL-1) in 
combination  with  either  IL-6  or  interferon-g  (IFN-g)  has  been  implicated  in  the 
upregulation of MSC proliferation in the presence of  IgA-containing  IC deposits in an 
experimental model of IgAN (Feehally, 1997; Montinaro et al., 1992; Moura et al., 2004). 
Three  crucial  stages  are  involved  in  the  pathogenesis  of  IgAN  (Bairoch  et  al.,  2005; 
Monteiro, 2005): 
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·  Generation of abnormal IgA1 and formation of IgA1 IC. 
·  Mesangial injury mediated by the interaction of IgA1 IC with (as yet unidentified) 
MSC IgA1 receptors. 
·  Progression of IgA-mediated mesangial injury. 
A number of immunoregulatory abnormalities in the synthesis of IgA1 have been reported 
in patients with IgAN. These include overproduction of IgA1 by B-lymphocytes in vitro, 
elevated levels of IgA in serum, IgA-containing IC (Leung et al., 2003). A deficiency in 
the galactosylation of O-linked glycans in the hinge region of circulating IgA1 molecules 
in  IgAN  patients  has  also  been  proposed  (Allen&Feehally,  1998;  Couser,  1999; 
Floege&Feehally, 2000; Hiki et al., 1995; Tomana et al., 1997). 
These hinge-region glycopeptides lead to the formation of circulating ICs via antibodies 
specific to anti-glycan or anti-hinge region peptides (Kokubo et al., 1999; Tomana et al., 
1999). Circulating ICs containing Gal-deficient IgA1 from IgAN patients have been shown 
to bind more efficiently with MSC than non-multimer IC/IgA (Novak et al., 2005). The 
same  study  showed  that  circulating  ICs  from  IgAN  patients  bound  to  MSC  in  greater 
numbers than ICs from healthy controls. 
The results of Novak et al. therefore support the hypothesis that the pathogenesis of IgAN 
somehow  involves  abnormally  glycosylated  IgA1-containing  ICs.  Other  studies  have 
shown that binding of heat aggregated IgA (HA-IgA) to MSC activates the cells, mobilises 
intracellular calcium storage and induces both protein phosphorylation (Gomez-Guerrero 
et  al.,  1996)  and  the  release  of  IL-6  and  tumour  necrosis  factor-a  (TNF-a)  (Gomez-
Guerrero  et  al.,  1994).  Further  studies  have  shown  that  ECM  components  such  as 
fibronectin  (FN)  and  collagen  may  be  increased  associated  with  circulating  ICs  in  the 
serum of patients with IgAN (Moura et al., 2004; Novak et al., 2005). 
In relation to cytokine release, studies in experimental models of IgAN have suggested that 
T cells and macrophages have a pivotal influence on glomerular and interstitial injury (Lai 
et al., 1994). Enhanced gene expression of cytokines implicated in IgAN is seen in CD4-
positive T cells (Lai et al., 1994), while the degree of localised macrophage proliferation 
appears to correlate with the severity of the insult. Whilst these mechanisms are certainly 
feasible,  more  research  is  needed  to  further  elucidate  the  manner  in  which  glomerular 
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1.3.3 Membranous glomerulonephropathy (MGN) 
Membranous glomerulonephropathy (MGN) is the most common cause of the nephrotic 
syndrome,  with  up  to  one-half  of  all  patients  progressing  to  ESRF  within  10  years 
(Glassock et al., 1991). It is distinguished by the accumulation of small IC deposits in the 
lamina rara externa of the GBM that eventually results in large deposits encapsulated in 
GBM matrix (Bohle et al., 1994) (Figure 1-4). As with IgAN, the pathogenesis of MGN is 
not yet fully understood. A popular proposed mechanism is that of an autoimmune disease 
in which autoantibodies specific for visceral epithelial cells develop; these antibodies then 
permeate through the GBM and deposit subepithelial IC (Schena et al., 1997). 
If the above mechanism holds then mesangial or subendothelial deposits are not possible 
due to ultrafiltration moving away from the lumen. Thus, a secondary mechanism has been 
proposed in which MGN is caused by IC composed of circulating antigens and antibodies; 
once permeated through the GBM, some of these antibodies will bind with antigens in the 
subepithelial zone and some will form IC in subendothelial or mesangial regions. This 
secondary MGN may be caused by infection, systemic autoimmune disease or tumour. 
 
Figure   1-4 Membranous nephropathy 
Electron  micrograph  illustrates  feature  of  MGN  showing  thickened  glomerular 
basement  membrane  (arrow)  representing  deposits  of  ICs  in  the  mesangium. 
Adapted from: www.gamewood.net/rnet/renalpath/ch7.htm 
 
1.3.4 Other forms of glomerulonephritis (GN) 
From its first description in the literature by Klebs (Stratta et al., 1999), GN has developed 
into an umbrella term for any primary renal disorder or a secondary renal complication of 
systemic disease (Couser, 1999), and is one of the primary causes of ESRF. Although the 
 C C Ch h ha a ap p pt tte e er r r    1 1 1          I IIn n nt ttr r ro o od d du u uc c ct tti iio o on n n, 33 
term  itself  implies  some  degree  of  inflammation,  this  is  not  always  the  case.  Besides 
glomerular injury caused by ICs, other immune mechanisms have been implicated in GN. 
Microscopy is necessary to differentiate between different forms of GN, as well as any 
immunological characteristics and known causes. Microscopy findings distinguish between 
the different forms of GN by evaluating the extent of the damage (diffuse or focal) and 
glomerular appearance (e.g. cell proliferation or thickening of the GBM). 
1.3.4.1  Immune-complex glomerulonephritis 
It is widely accepted that the pathogenesis of many common forms of idiopathic GN (e.g. 
IgAN, MGN) are related to ICs, whether as circulating multimers or as in situ deposits 
(Cohen et al., 1979). At present, these diseases can only be classified by morphological 
means;  subepithelial  deposits  indicate  primary  MGN,  while  IgA  antibodies  in  deposits 
defines IgAN. Where GN occurs secondary to infectious diseases, the associated antigenic 
stimuli are known. Thus, in order to establish a causal link between the infection and GN, 
the circulating ICs must contain both the specific antigen and the antibody directed against 
it. In addition, glomerular IC deposits should be both evident and contain the infectious 
agent (Javaid&Quigg, 2005). 
Inflammation within the glomerulus is a fundamental factor of IC-GN. It is unlikely that IC 
formation can be uncoupled from the inflammatory response due to the complexity of the 
inflammatory cascade induced by these deposits (Clynes et al., 1998). Studies have shown 
that  the  size  and  blood  clearance  kinetics  of  ICs  are  influenced  by  the  biochemical 
characteristics of the circulating antigen (Doekes et al., 1984) (Figure 1-5). Small, soluble 
ICs are generated when excess antigen or oligovalent antigen is present; these ICs are often 
essentially  inert  as  they  are  inefficient  at  activating  complement  and  attaching  to  Ig 
receptors. Large, soluble ICs are formed when the ratio of antigen to antibody approaches 
equivalence  and  cross-linking  is  maximised;  these  ICs  are  quickly  removed  from  the 
circulation by phagocytosis as they bind with high affinity to Ig receptors and efficiently 
activate complement (Nangaku&Couser, 2005). 
Thus,  it  is  the  medium-sized  complexes  that  cause  problems  as  they  can  activate 
complement and bind to Ig receptors but are less easily cleared from the bloodstream; 
therefore, they tend to deposit in tissues and induce glomerular injury. In MGN, these 
deposits are found between the GBM and the visceral glomerular epithelial cells (GEC). 
Consequently,  there  has  been  a  considerable  research  effort  to  identify  a  specific  IgG 
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IgG and Fc fragments, but not F(ab’2) fragments, were able to bind GEC both in culture 
(Mancilla-Jimenez  et  al.,  1984)  and  in  tissue  sections  (Mizoguchi&Horiuchi,  1982), 
investigators were unable to identify the receptors responsible for this binding. Further 
studies also failed to find expression of FcgRI, FcgRII or FcgRIII receptors on the surface 
of GEC (Aarli et al., 1991; Morcos et al., 1994; Tuijnman et al., 1993), suggesting that 
alternative receptors may be involved. 
The  presence  of  complement  components  in  renal  biopsies  provide  further,  indirect 
evidence of IC-GN, as well as changes in serum complement levels and the presence of 
circulating complement breakdown products. 
 
 
 
 
 
 
 
 
 
Figure   1-5 Immune complex deposion 
This diagram shows that chronic exposure to an antigen causes the formation of 
ICs  between  the  antigen  and  antibodies  raised  against  it.  These  accumulate  in 
specific areas of the kidney and elicit an inflammatory response that damages the 
surrounding tissue. Adapted from: 
http://www.bact.wisc.edu/Microtextbook/images/book_4/chapter_15/15 30.gif. 
 
1.3.5 Tubulointerstitial inflammation 
Studies have identified four different mechanisms of tubulointerstitial injury (Barratt et al., 
2004; Chan et al., 2005): 
·  Monocytic/macrophage infiltration. 
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·  Proteinuria. 
·  Inflammation as a direct consequence of IgA (or other Ig) deposits. 
·  Glomerulotubular cross-talk. 
The infiltration of inflammatory cells into the tubulointerstitium plays an important role in 
the mediation of renal fibrosis and tubular injury (Wu et al., 2004). Studies have shown 
that PTEC can induce this infiltration and, when activated as a consequence of this, can 
contribute to fibrosis by producing an array of inflammatory mediators (van Kooten et al., 
1999). A vicious cycle occurs in which mediators released by infiltrating cells directly 
activate PTEC, which in turn release other proinflammatory mediators that can amplify the 
inflammatory cascade. This positive feedback loop can lead to excessive production of 
ECM components and, subsequently, renal fibrosis. It has therefore been proposed that a 
cytokine ‘cross-talk’ network exists between PTEC and immunocompetent cells within the 
interstitium and is the key inducing factor in tubulointerstitial injury. 
In most glomerular diseases, proteinuria can be considered as the primary cause of PTEC 
activation  (Tang  et  al.,  2003),  and  is  associated  with  the  release  of  vasoactive  and 
inflammatory  mediators,  including  endothelin-1,  monocyte  chemoattractant  protein-1 
(MCP-1) and RANTES (regulated upon activation, normal T-cell expressed and secreted) 
(Praga&Morales, 2002). Heavy proteinuria (i.e. urine containing a high content of high-
molecular-weight IgM and IgG proteins) has been associated with eventual progression to 
ESRF  (Tencer  et  al.,  2000).  Although  IgG  and  complement  components  are  often  co-
deposited, IgA alone can provoke glomerular injury in some patients. 
1.3.6 Tubulointerstitial fibrosis 
Whatever the initial renal insult, tubulointerstitial fibrosis is regarded as the common final 
pathway leading to ESRF (Becker&Hewitson, 2000; Eddy, 2000) and is a better predictor 
of functional impairment than glomerular damage (Nath, 1992). In CRF patients, the rate 
of decline in GFR is strongly correlated with the severity of fibrosis (Bohle et al., 1996). In 
older patients, structural changes in otherwise healthy kidneys involves some degree of 
tubulointerstitial  fibrosis  (Ruiz-Torres  et  al.,  1998),  while  in  transplant  recipients 
tubulointerstitial fibrosis is characteristic of chronic allograft nephropathy (CAN), the most 
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Tubulointerstitial fibrosis is a direct effect of the overproduction and blunted degradation 
of ECM (Heidland et al., 1997). The accumulation of ECM has been associated with a 
number  of  cytokines,  which  also  compound  the  process  by  stimulating  macrophage 
infiltration and the proliferation/transdifferentiation of fibroblasts (Eddy, 1996b). Aberrant 
TGF-b  signalling  has  been  identified  in  various  proliferative  disorders,  including  GN, 
cancer and atherosclerosis (Bottinger et al., 1997; Hu et al., 1998). There is significant 
evidence  to  suggest  that  TGF-b1  expression  is  closely  linked  to  the  progression  of 
tubulointerstitial fibrosis (Border et al., 1996), and that renal PTEC may contribute to this 
by releasing TGF-b1 when activated (Johnson et al., 1998). By reducing the expression of 
metalloproteinase enzymes that degrade interstitial proteins (e.g. the ECM components FN 
and collagen) and by stimulating the production of metalloproteinase inhibitors in tissue, 
TGF-b effectively promotes the accumulation of these proteins in the interstitium (Grande 
et al., 2002). 
Studies in rats have suggested that, in addition to modulating ECM turnover, TGF-b1 may 
have an important role in mediating the differentiation of PTEC into α-smooth muscle 
actin (α-SMA)-positive cells (Tian et al., 2003). Other studies have proposed that TGF-b1 
induces changes in the phenotype of PTEC, though the mechanisms by which this occurs 
remain to be clarified. 
1.3.7 Proteinuria  
Proteinuria is a well recognised risk factor for disease progression in GN and occurs by 
two distinct mechanisms: increased permeability of the glomerular filtration slits causing 
abnormal  passage  of  proteins,  and  impaired  reabsorption  by  PTEC  (D'Amico&Bazzi, 
2003b). By the time proteinuria becomes clinically detectable (i.e. urinary excretion of 
low-  and  high-molecular-weight  proteins  is  significantly  elevated),  many  patients  will 
already  have  structural  damage  to  the  podocytes  in  the  glomerulus  and  to  the 
tubulointerstitium.  Recent  clinical  studies  have  suggested  that  the  urinary  excretion  of 
some  high-molecular-weight  proteins  (IgG,  IgM)  and  of  some  low-molecular-weight 
proteins (b1- and b2-microglobulin) is a better predictor of the histological severity of 
disease than the overall quantity of proteinuria. Compared with other forms of GN, IgAN 
presents  a  unique  complication  when  assessing  the  prognostic  value  of  high-grade 
proteinuria as heavy proteinuria is not common in IgAN and nephrotic syndrome occurs in 
only 5% of patients (Lai et al., 2005; Tomino&Sakai, 2003). C C Ch h ha a ap p pt tte e er r r    1 1 1          I IIn n nt ttr r ro o od d du u uc c ct tti iio o on n n, 37 
1.3.8 Nephrotic syndrome 
The nephrotic syndrome is not a disease in itself; instead, it is a term applied to a group of 
abnormalities,  including  proteinuria,  hypoalbuminaemia,  generalised  oedema  and 
hyperlipidaemia, which occur in several forms of renal disease. Damage to the glomeruli 
results  in  increased  permeability  of  the  glomerular  membrane  and  plasma  proteins  are 
filtered out of the bloodstream. Albumin, the smallest and most common of the plasma 
proteins,  is  most  affected,  and  when  the  daily  loss  of  albumin  exceeds  the  hepatic 
production,  a  significant  drop  in  total  plasma  protein  level  occurs  (D'Amico&Bazzi, 
2003a). This is accompanied by widespread oedema and reduced plasma volume, which 
reduces  renal  blood  flow  and  stimulates  the  renin–angiotensin–aldosterone  system 
(RAAS), causing increased reabsorption of water and sodium in the tubules. This increase 
in water reabsorption further reduces the osmotic pressure and worsens the swelling. This 
damaging  cycle  continues  as  long  as  albumin  is  depleted  throughout  the  glomerular 
membrane.  Nitrogenous  waste  products  usually  remain  at  normal  levels.  The  cause  of 
hyperlipidaemia, especially hypercholesterolaemia, in the nephrotic syndrome is unknown. 
1.4 Therapeutic strategies 
At present, there is no effective or specific treatment for IgAN and intervention has relied 
upon  attempting  to  slow  the  rate  of  disease  progression.  In  order  to  do  this,  the 
inflammatory cascade must be prevented and thus the pro-inflammatory signals generated 
by  cytokines  and  growth  factors  are  suitable  targets.  As  with  other  glomerular  and 
progressive  renal  diseases,  attempts  must  be  made  to  control  hypertension  and  reduce 
proteinuria using agents that inhibit the RAAS (Russo et al., 2001). Immunosuppressants 
are often used with the aim of reducing Ig/IC formation, but there is no clear consensus on 
how effective these are. Commonly used agents include corticosteroids (Katafuchi et al., 
2003; Pozzi et al., 1999), azathioprine (AZA) (Yoshikawa et al., 1999), cyclosporine A 
(Cattran, 1991) and mycophenolate mofetil (MMF). Various studies have shown that while 
these drugs may effectively reduce proteinuria (Tang et al., 2005), they do not prevent 
progression to ESRF (Frisch et al., 2005). Two exceptions to this lack of consensus exist: 
IgAN patients with nephrotic syndrome clearly benefit from corticosteroid therapy, while 
patients  with  rapidly  progressing  IgAN  with  crescent  formation  may  benefit  from  the 
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Other  pharmacological  interventions  include  the  use  of  angiotensin-converting  enyme 
(ACE)  inhibitors  and  low-molecular-weight  heparins  (LMWH).  In  vitro  studies  have 
shown  that  ACE  inhibitors  reduce  the  expression  of  TGF-b  mRNA  (which,  alongside 
platelet-derived growth factor [PDGF], is stimulated by angiotensin II) (Kagami et al., 
1994; Ruiz-Ortega et al., 1995). Clinical trials of ACE inhibitors and angiotensin receptor 
blockers (ARBs) have been carried out in patients with either primary or secondary GN 
with subsequent attenuation of the disease progression (Gansevoort et al., 1995). LMWH 
have been shown to have several anti-inflammatory properties, including the blockade of 
TGF-a and fibroblast growth factor (FGF) (Wardle, 1996), and to inhibit the proliferation 
of  mesenchymal  cells.  They  also  inhibit  complement  activation  and  the  secretion  of 
elastane and other lysosomal enzymes from polymorphonuclear (PMN) cells. 
Non-pharmacological interventions have also been proposed. First suggested in 1984, the 
hypothesis that omega-3 fatty acids in fish oils may benefit cell membrane fluidity and 
slow the rate of disease progression (Hamazaki et al., 1984) has yielded conflicting results. 
In 1994, a randomised clinical trial supported this effect and suggested that it occurred 
independently of changes in proteinuria and BP (Donadio et al., 1994). However, in 1997, 
a meta-analysis concluded that fish oils do not confer a significant benefit in the treatment 
of  IgAN  (Dillon,  1997).  A  protein-restricted  diet  has  long  been  recommended  for  the 
reduction of glomerular hyperfiltration and to slow the progression of renal damage. In 
addition,  a  study  in  rats  with  MGN  recently  demonstrated  that  a  low-protein  diet 
significantly reduced TGF-b expression (Okuda et al., 1991). 
Although most of these therapeutic options are still in development, they are representative 
of  a  new  paradigm  for  slowing  the  progression  to  ESRF  in  IgAN  by  ameliorating 
tubulointerstitial injury. 
1.5 The immune system 
In order to understand the involvement of PTEC in the development of renal disease, it is 
necessary first to discuss some aspects of the immune system, a complex network that 
guards  against  invading  pathogenic  microorganisms.  The  immune  system  network 
comprises two different branches: innate (non-specific) immunity and adaptive (specific) 
immunity (Takeda et al., 2003). The former is present from birth and does not develop 
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Innate  immunity  has  two  components:  cellular  and  soluble.  The  cellular  component 
includes the phagocytic system, which encompasses and digests invading microorganisms 
and includes neutrophils and monocytes in serum and macrophages in tissue, and natural 
killer (NK) cells, which attack certain tumours, microorganisms and virus-infected cells. 
Complement proteins, acute phase reactants and cytokines make up the soluble component. 
When challenged, the innate immune system activates the adaptive immune system, which 
provides a potent defence against microbial infection by detecting ‘non-self’ using antigen 
receptors found on the surface of B and T cells. Once recognised, the adaptive immune 
system remembers specific pathogens and prepares itself for future challenges so that it can 
become  increasingly  effective  in  attacking  the  invading  microorganism  each  time  it  is 
encountered. The cellular and soluble components of adaptive immunity are lymphocytes 
and Igs, respectively. 
Adaptive  immune  responses  can  be  further  categorised  as  either  humoral  or  cellular 
immunity.  Humoral  immunity  is  mediated  by  antibodies  produced  by  B  cells,  while 
cellular immunity involves the activation of macrophages and NK cells and the release of 
cytokines in response to an antigen. The majority of antigens are T cell-dependent and 
need to be processed by antigen-presenting cells (APCs), which convey the antigens to 
both T and B cells. The T cells then release cytokines that induce the B cells to generate 
antibodies. 
1.5.1 Lipopolysaccharide (LPS)  
Lipopolysaccharide (LPS), also known as endotoxin, is the major Gram-negative bacterial 
surface component in mammalian cells and prompts the release of inflammatory mediators 
(Hajjar et al., 2002). Owing to their amphiphilic nature, these glycolipids are able to self-
aggregate and form membranes (Wiese et al., 2003). LPS is recognised by elements of the 
innate  immune  system  called  toll-like  receptors  (TLRs)  expressed  on  the  surfaces  of 
macrophages,  neutrophils  and  epithelial  cells,  especially  TLR4.  When  activated,  TLRs 
generate an immune response primarily through gene regulation via the nuclear factor-kB 
(NF-kB) transcription factor system (Takeda et al., 2003). 
In  addition  to  TLR4,  the  recognition  of  LPS  involves  CD14,  a 
glycosylphosphatidylinositol-anchored  molecule  usually  expressed  in  macrophages  and 
neutrophils. Several studies have suggested that an interaction between CD14 and TLR4 
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appear to become physically closer following LPS stimulation. This stimulation occurs 
when LPS binds to LPS-binding protein present in serum and the resulting complex is 
recognised by CD14 (Hedlund et al., 2001; Hoshino et al., 1999; Lien et al., 2000). 
A  number  of  cytokines  regulate  the  expression  of  TLRs.  In  renal  epithelial  cells,  the 
expression of TLR2 and TLR4 is prompted by IFN-g and TNF-a, inducing inflammation 
and the detection of bacterial invasion (Wolfs et al., 2002). IFN-g also enhances surface 
expression  of  TLR4  in  human  monocytes  and  macrophages,  effectively  priming 
phagocytes to respond to LPS (Bosisio et al., 2002). Following a challenge with LPS or 
infection  in  vivo,  colony-stimulating  factor-1  (CSF-1)  is  induced  and  can  prime 
macrophages to release even more inflammatory cytokines in response to continued LPS 
stimulation. The expression of the TLR2 gene on macrophages is induced by LPS and 
inflammatory cytokines, including IL-1, IL-2, IFN-g and TNF-a (Matsuguchi et al., 2000). 
ECM  components,  including  FN,  are  produced  in  response  to  tissue  injury  and  play 
important roles in tissue remodelling (Hedlund et al., 2001). This dual role of LPS as target 
and effector makes it a fascinating molecule, which, even though first described more than 
100 years ago, still hides many miracles. 
1.5.2 Phagocytes 
Phagocytes (monocytes and macrophages) are vital to both the innate and adaptive immune 
systems  (Abbas,  2000;  Gordon,  1999).  The  innate  functions  of  these  molecules 
(specifically, the internalisation and digestion of pathogens bound to receptors on the cell 
surface)  represent  the  first  line  of  defence  against  invading  microorganisms.  In  the 
adaptive response, B cells produce antigen-specific antibodies that then either form ICs or 
lead to the opsonisation of the pathogen. The antibodies are subsequently recognised by Ig 
receptors  and  are  internalised  by  either  endocytosis  (ICs)  or  phagocytosis  (opsonised 
particles).  Macrophages  participate  in  the  production,  activation  and  regulation  of  all 
immune effector cells, play a key role in tissue homeostasis and are highly heterogeneous. 
1.5.3 Natural killer (NK) cells 
There are various types of killer cells and these can be neatly dichotomised into those that 
are  restricted  by  major  histocompatibility  complex  (MHC),  for  example,  cytotoxic  T 
lymphocytes  (CTLs),  and  those  that  are  not.  Cells  in  either  category  do  not  require 
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target cell and deliver the lytic signal through the membrane. NK cells are of the latter type 
and make up approximately 5–30% of lymphocytes in normal peripheral blood (Trinchieri, 
1989). Despite being lymphocytes, NK cells belong to neither the T nor B cell lineage and 
do not express either surface Ig or T cell receptor/CD3 on their surface. It is possible to 
increase target cell susceptibility to killing by NK cells by increasing MHC expression, for 
example, by transfection or by stimulation with IFN-g (Zompi&Colucci, 2005). 
Some tumour cells are killed by NK cells regardless of whether they express MHC, and 
there is some evidence to suggest that these cells may preferentially kill target cells that do 
not express class I MHC, or do so in small amounts. This apparent inhibition of NK killing 
activity  by  class  I  MHC  expression  led  to  the  identification  of  several  class  I  MHC 
receptors on the surface of NK cells. These receptors are structurally different from the T 
cell receptors (TCR) and are generally referred to as killer cell inhibitory receptors (KIRs). 
While engagement of MHC by the TCR on T cells leads to T cell activation, engagement 
of the MHC by most KIR leads to inhibition of NK activity, although there are some KIRs 
that can lead to activation. 
NK cells express the Ig receptor FcgRIII and can use this receptor to mediate another kind 
of  MHC-nonrestricted  killing.  Antibody-dependent  cell-mediated  cytotoxicity  (ADCC) 
depends on the presence of antibodies that recognise a target cell (ADCC specificity is 
therefore conferred by the specificity of the antibody). Upon binding its antigen, the Fc 
region of the antibody is exposed and will bind its receptor on the NK cell to form a 
bridge. Once the bridge is formed, a poorly understood lytic signal is delivered to the target 
cell, resulting in release of granzyme and perforine and, ultimately, the demise of the target 
cell (Perussia, 2000). 
Some forms of ADCC may prove useful for targeting tumor cells in vivo as a form of 
immunotherapy. 
1.5.4 Lymphocytes  
Lymphocytes originate from bone marrow lymphoid stem cells and are the principal cells 
of adaptive immunity, defending against invading pathogens and to preventing or reducing 
reinfection (Bradley, 2003). Lymphocytes mature in lymphoid organs: B cells are bone 
marrow-derived, while T cells migrate from the bone marrow to mature in the thymus. 
Lymphocytes can be divided into subsets either by function or by surface markers called 
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clonally distributed and each clone specialises in recognising a specific antigen by means 
of its antigen receptor. 
1.5.4.1  B cells 
As discussed above, the principal function of B cells is to make antibodies against soluble 
antigens. The first interaction between the antigen and the B cell comprises the primary 
immune  response,  and  the  B  cells  committed  to  respond  to  this  antigen  undergo 
differentiation  and  clonal  proliferation.  Some  become  memory  cells  while  others 
differentiate into mature antibody-synthesising plasma cells. The principal characteristics 
of the primary immune response are a latent period before the appearance of antibodies, 
the production of only a small amount of antibody, initially IgM, and then a switch of the 
Ig isotype (with T cell help) to IgG, IgA or IgE (Bradley, 2003). This process leads to the 
creation of numerous memory cells capable of generating a stronger response to the same 
antigen in the future. 
The  secondary  immune  response  takes  place  on  subsequent  encounters  with  the  same 
antigen. The principal characteristics are rapid proliferation of B cells, rapid differentiation 
into mature plasma cells and prompt production of large amounts of antibody, chiefly IgG, 
which  are  released  into  the  blood  and  other  body  tissues  where  they  can  effectively 
encounter  and  react  efficiently  with  the  antigen.  IgM,  IgG  and  IgA  may  be  generated 
against  the  same  antigen.  B  cells  derived  from  a  single  mature  naïve  B  cell  may 
differentiate into a family of B cells genetically programmed to synthesise antibodies of a 
single antigenic specificity, with representative clones committed to the production of each 
Ig class. 
1.5.4.2  T cells 
Once the TCR comes into contact with an APC, the T cell proliferates quickly and either 
differentiates in effector cells or matures into memory T cells that are stored in the spleen 
and at the site of first infection in preparation for a secondary response if and when it 
happens (Bradley, 2003; Daeron, 1997). Mature T cells can be divided into subclasses, the 
two most important being helpers (CD4+) and suppressors (CD8+) (Grunwelad, 1996). 
Studies have shown that there are two distinct subsets of T helper cells, namely Th1 and 
Th2, which regulate the cellular and humoral aspects of the specific immune response, 
respectively (Mosmann&Sad, 1996). The type of T helper cell appears to be determined in 
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secreting  proinflammatory  cytokines  such  as  IL-2  and  IFN-g,  Th1  cells  promote 
phagocytosis of intracellular microbes, whereas Th2 cells secrete cytokines including IL-4, 
-5, -10 and -13 to stimulate white blood cell/mast cell-mediated immune reactions and to 
downregulate the damaging effects of Th1 immune responses (Mosmann&Sad, 1996). T 
suppressor cells such as CTL recognise infected or cancerous cells and destroy them by 
releasing cytoplasmic granules containing membrane pore-forming proteins and enzymes. 
The pro-inflammatory effects of Th1 cells are powerful and occur both within the kidney 
and in the systemic circulation, activating not only monocytes/macrophages and T cells but 
also  resident  renal  epithelial  cells  (Mosmann  et  al.,  1991).  Thus,  T  cells  are  vitally 
important to the immunological processes involved in all forms of GN (Nolasco et al., 
1987; Schena et al., 1997). 
1.5.5 Cytokines 
Cytokines are the primary communicator between different immune system cells and also 
between immune system cells and cells belonging to other types of tissue. Once released in 
response to an immune stimulus, typically at very low concentrations, they tend to act over 
short distances and short time spans, binding to specific membrane receptors in the target 
cell  and  altering  its  gene  expression.  In  the  activation  phase  of  immune  responses, 
cytokines stimulate lymphocyte growth and differentiation, while in the effector phase they 
activate different effector cells in order to eradicate antigens. Cytokines also stimulate the 
development of hematopoietic cells. Different cell types may secrete the same cytokine; 
similarly, a single cytokine may have pleiotropic effects and act on several different cell 
types. Moreover, cytokine release often occurs  in a cascading manner  as one cytokine 
stimulates the target cell to produce additional cytokines. 
Cytokines can be classified according to various subtypes, including TNFs (α, β), ILs (IL-1 
to IL-8, IFNs (α, β, γ), TGFs and CSFs. In any given immune response, it is likely that 
numerous  cytokines  will  be  involved  and  that  they  may  act  synergistically  or 
antagonistically. A new family of cytokines, the chemokines, has been described. These 
induce chemotaxis and migration of leukocytes, acting as magnets for eosinophils and are 
consequently involved in lymphocyte, granulocyte and monocyte infiltration and activation 
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1.5.5.1  Tumour necrosis factor-a a a a (TNF-a a a a) 
LPS-activated mononuclear phagocytes are the major cellular source of TNF where it is 
initially  synthesised  as  a  non-glycosylated  transmembrane  protein  of  approximately 
25kDa, though antigen-stimulated T cells, activated NK cells and activated mast cells are 
also able to secrete this cytokine. The synthesis of TNF is augmented by IFN-g produced 
by  T  cells;  therefore,  TNF  can  be  considered  a  mediator  of  both  innate  and  acquired 
immunity and as such provides an important link between specific immune responses and 
acute inflammation. TNF acts as a regulator of leukocytes and endothelial cells, and many 
TNF responses involve upregulation of transcription of specific genes, often through NF-
kB activation (Abbas, 2000). 
1.5.5.2  Interleukin-1 (IL-1) 
Stimulated  macrophages  are  the  primary  cellular  source  of  IL-1  but  neutrophils, 
endothelial cells, smooth muscle cells, glial cells, astrocytes, B and T cells, fibroblasts and 
keratinocytes may also secrete this cytokine. Various processes can trigger the release of 
IL-1, for example, coming into contact with CD4+ T cells or bacterial products such as 
LPS, TNF or even IL-1 itself. The two IL-1 subtypes, a and b, are products of different 
genes and are <30% structurally homologous. However, both bind to the same cell surface 
receptors and have essentially identical biological effects. IL-1 is one of the most important 
immunomodulatory  ILs  and,  at  low  concentrations,  plays  a  regulatory  role  in  local 
inflammation.  IL-1  activation  of  T  cells  stimulates  the  release  of  IL-2,  establishing  an 
autocrine loop that further increases T cell activation. In addition, as with TNF-a, IL-1 
activation of T cells upregulates the expression of IFN-g. Another important effect of IL-1 
is the induction of proliferation in non-lymphocytes (Abbas, 2000). 
1.5.5.3  Interleukin-6 (IL-6) 
IL-6  is  secreted  by  several  different  cell  types  including  macrophages,  fibroblasts, 
endothelial cells and activated TH cells, and affects a number of target cells including 
resident  glomerular  and  tubular  cells  (Coleman&Ruef,  1992).  The  regulation  of  IL-6 
expression in monocytes is governed in part by a functional interaction between IFN-g and 
TNF-a, which, while often transient, causes rapid release (Sanceau et al., 1991). Following 
LPS  challenge,  IL-6  is  detectable  in  the  circulation  and  appears  to  be  secreted  as  a 
secondary  response  (e.g.  to  TNF  or  IL-1)  rather  than  as  a  consequence  of  LPS  itself. 
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cytokines and therefore serves mainly to enhance the immune response to other cytokines. 
IL-6  acts  as  a  second  signal  for  IL-2  release  and  promotes  IL-2-dependent  T  cell 
proliferation (Smyth et al., 1990). Moreover, both in vitro and in vivo studies have shown 
that IL-6 stimulates the proliferation of MSC (Horii et al., 1989). lL-6 also acts as a co-
factor with other cytokines to promote the early growth of haematopoietic stem cells in 
bone marrow. Furthermore, in the liver, IL-6 is the primary stimulator of the acute phase 
response. Other effects of IL-6 include enhancing B cell differentation and Ig receptors 
expression and enhancing the synthesis of glucocorticosteroids. 
1.5.5.4  Interleukin-8 (IL-8) 
Of the known chemokines, IL-8 is the most studied and is produced by monocytes and 
other lymphoid cells, endothelial cells, keratinocytes, epithelial cells and various tumours 
(Baggiolini et al., 1989; Cubitt et al., 1993). The synthesis of IL-8 is stimulated by LPS, 
TNF-a and IL-1a. As well as promoting the generation of reactive oxygen intermediates, 
degranulation and an increase in cystolic calcium levels in neutrophils in vitro (Peveri et 
al.,  1988),  IL-8  acts  as  a  chemoattractant  and  engineers  the  migration  of  neutrophils, 
basophils and T cells to the site of inflammation. Further in vitro studies have shown that 
IL-8 production occurs locally in glomerular cells, including MSC (Brown et al., 1991) 
and podocytes (Huber et al., 2002), PTEC (Gerritsma et al., 1996b; Schmouder et al., 
1992) and kidney-derived fibroblasts (Lonnemann et al., 1995). In vivo, the effects of IL-8 
are commonly associated with the localised accumulation of neutrophils at sites of acute or 
chronic inflammation (Niemir et al., 2004; Swensson et al., 1991). 
1.5.5.5  Interferons (IFN) 
There are two types of interferons – type I (IFN-a, IFN-b) and type II (IFN-g) – the latter 
of which plays an important role in immunity. The major cellular source of IFN-g is CD8+ 
T cells, though nearly all cells express receptors for IFN-g and, after binding with IFN-g, 
promote APC interaction with T helper cells by increasing the surface expression of class I 
MHC (Abbas, 2000). IFN-g also increases the expression of class II MHC proteins, further 
enhancing  the  APC–T  cell  interaction.  The  overall  affect  of  IFN-g  is  to  promote  Th1 
inflammatory responses, while suppressing Th2 reactions. IFN-g also can modulate the 
activity of polymorphonuclear neutrophils (PMN) and preincubation of normal PMN with 
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1.5.5.6  Transforming growth factor-b b b b (TGF-b b b b) 
TGF-b plays a major role in the pathogenesis of progressive renal fibrosis in various types 
of GN (Schena et al., 1997). When first synthesised, the protein is expressed in a latent 
form that must be activated by proteases (Tian&Phillips, 2003). Once activated, TGF-b 
exerts  highly  pleiotropic  actions,  inhibiting  the  growth  of  several  cell  types  while 
promoting it in others, including a potent antiproliferative action. In vitro studies have 
shown that TGF-b inhibits renal PTEC proliferation and stimulates the synthesis of ECM 
components  (including  FN)  as  well  as  promoting  apoptosis  (Basile  et  al.,  1998; 
Nowak&Schnellmann, 1996). In addition, TGF-b appears to have an inhibitory effect on 
immune  system  activation,  antagonising  several  facets  of  lymphocyte  response  to 
infection. TGF-b also acts on other cells, such as PMN and endothelial cells, primarily in a 
protective response to pro-inflammatory cytokines and generates signals that downregulate 
immune responses. 
1.5.5.7  Granulocyte macrophage colony-stimulating factor (GM-CSF) 
Granulocyte–macrophage  CSF  (GM-CSF)  promotes  the  proliferation  of  lymphoid  cells 
and is part of the inflammatory cascade. In humans, GM-CSF promotes the growth of 
leukocyte precursors such as platelets and erythrocyte progenitors, as well as activating 
mature leukocytes. It is not detectable in the circulation and is presumably limited to local 
actions.  Accordingly,  it  has  been  proposed  that  the  primary  function  of  macrophage-
derived GM-CSF is to activate mature leukocytes at the site of the inflammatory immune 
response.  In  bone  marrow,  it  has  been  suggested  that  GM-CSF  produced  by  T  cells, 
endothelial cells or stromal fibroblasts plays a  role in the mediation of haematopoietic 
effects (Abbas, 2000). 
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Factor  Size  Principal Source  Primary Activity 
TNF-a  14 kDa  Macrophages, T cells 
mast cells, NK cells 
 
Activation of neutrophils, synthesis of acute-
phase proteins and induce apoptosis in 
several cell types. 
IL-1a  17kDa  Monocytes, macrophages, 
B cells, APCs 
Co-stimulates the maturation, proliferation 
and activation of APCs and T cells; induces 
inflammation, acute phase response and 
haematopoiesis. 
IL-6  19-26kDa  Monocytes, macrophages, 
activated Th2 cells, 
APCs, other somatic cells 
Promotes differentiation into plasma cells, 
antibody secretion, acute phase response and 
thrombopoiesis; synergistic with IL-1 and 
TNF on T cells. 
IL-8  8.9kDa  Macrophages, endothelial 
cells, other somatic cells 
Chemoattractant for neutrophils and T cells, 
chemotaxis 
IFN-g  25kDa  Th1 cells, T cells, NK 
cells 
 
Induces class I and II MHC on APCs and 
somatic cells; activates macrophages, 
neutrophils and NK cells; promotes cell-
mediated immunity, antiviral state, viral 
replication, Ig class switch to IgG2a, 
proliferation and pathogen elimination 
TGF-b  25kDa  T cells, monocytes 
 
Anti-inflammatory; promotes chemotaxis, 
proliferation and the synthesis of IL-1 and 
IgA; suppresses cytokine production and 
class II MHC expression; promotes wound 
healing; inhibits macrophages and 
lymphocyte proliferation 
GM-CSF  14 kDa  Macrophages, Th cells  Stimulates stem cells to produce 
granulocytes (neutrophils, eosinophils, 
basophils) and macrophages; promotes the 
growth and differentiation of monocytes and 
denteric cells. 
Table   1-1 Selected cytokines and their properties. 
 
1.5.6 Immunoglobulins (Ig) 
Ig antibodies are large proteins composed of four polypeptide chains (two identical heavy 
chains  and  two  identical  light  chains)  joined  together  by  disulphide  bonds.  Each  Ig 
recognises a specific antigen unique to its target and is used by the immune system to 
locate and destroy invading microorganisms. The family of Igs includes proteins in the 
IgG, IgA, IgM, IgD and IgE subclasses, all of which share the same basic, monomeric 
structure but have unique features that determine their specific effects (Fig. 1-6) (Takai, 
2002).  The  heavy  chains  have  a  molecular  weight  of  50–70  kDa,  compared  with 
approximately  23  kDa  for  the  light  chains.  The  Y-shaped  Ig  molecule  is  divided  into 
variable (V) and constant (C) regions. The V region is located at the distal ends of the Y 
arms where the diversity of amino acids is high (thereby determining the antigen-binding 
capacity of the molecule), while the C region, proximal to the antigen-combining site, 
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Each Ig antibody has two functional fragments: Fab, which binds antigen, and Fc, which 
crystallises when stored at 4 ºC. Only two different amino acid sequences, κ and λ, are 
found in the constant regions of light chains, while there are five common sequences in the 
heavy chain constant regions; µ, γ, α, ε, and δ heavy chains are found in IgM, IgG, IgA, 
IgE, and IgD, respectively. Therefore, it is the constant region of the Ig heavy chain that 
determines the isotype of the antibody. IgG, IgA and IgD have heavy chains containing a 
hinge region, a proline-rich domain that allows for greater flexibility of the Fab. With the 
added advantage of being able to make contact at various angles, there is an increased 
likelihood of binding to the antigen. 
1.5.6.1  IgG 
IgG is a large monomeric Ig of approximately 150 kDa and is naturally found in serum at 
levels  of  8–16  g/L.  Having  two  antigen  binding  sites,  IgG  binds  to  a  wide  variety  of 
pathogens,  including  bacteria,  viruses  and  fungi,  combating  them  by  activating 
complement,  opsonisation  for  phagocytosis  and  neutralisation  of  their  toxins 
(Rojas&Apodaca, 2002). As the only Ig isotype to be able to pass through the placenta, it 
provides  vital  protection  to  the  foetus  before  its  own  immune  system  has  had  time  to 
develop. 
In humans, the four IgG subclasses (IgG1, IgG2, IgG3 and IgG4) can be differentiated by 
the size of their hinge region and by the location and number of disulphide bonds, as well 
as by function. IgG2 is the only one unable to cross the placenta, IgG3 is the most effective 
at activating complement and IgG4 cannot activate complement at all. IgG1 and IgG3 are 
associated with opsonisation as they bind FcRs on phagocytic cells. 
1.5.6.2  IgM 
In its pentameric form (i.e. with five subunits), IgM is larger than IgG with a molecular 
mass of approximately 900 kDa and is present in serum at levels of 0.7–3.0 g/L. The five 
subunits of IgM are linked by an Fc-linked polypeptide called the joining chain (J chain). 
Due to the size of the molecule, its diffusion is limited. Thus, it is primarily found in serum 
(accounting for 5–10% of all serum antibodies) and is only seen in very small quantities in 
the interstitium. Due to the J chain, which is necessary for pentameric IgM to form and is 
added just prior to secretion, IgM is an important secretory Ig. It is the first isotype to be 
generated  during  a  primary  immune  response  and  is  a  highly  effective  activator  of C C Ch h ha a ap p pt tte e er r r    1 1 1          I IIn n nt ttr r ro o od d du u uc c ct tti iio o on n n, 49 
complement. By virtue of its pentameric structure, IgM has 10 antigen binding sites and 
thus each antibody can bind up to five molecules of antigen. 
1.5.6.3  IgA 
The human body produces more IgA daily than any other antibody isotype (approximately 
70 mg/kg). IgA has an approximate molecular mass of 160 kDa and, after IgG, is the 
second most prevalent antibody in the bloodsteam at concentrations of approximately 2–4 
g/L (Woof&Mestecky, 2005). IgA is found in most external secretions that bathe mucosal 
surfaces, for example, saliva, tears, mucus and breast milk, and is principally dimeric (i.e. 
composed of two monomeric IgA subunitys and a J chain) (van Egmond et al., 2001). The 
total  area  of  these  mucosal  surfaces  is  vast  and  they  are  vulnerable  to  exposure  to 
pathogens. As the primary antibody isotype present at these locations, secretory IgA is an 
important defence mechanism against invading antigens. Serum IgA acts as both a pro- and 
an anti-inflammatory mediator. By engaging cellular IgA receptors it can deliver antigens 
to the immune system, while engaging effector leukocytes can result in either protective or 
pathological inflammatory reactions (Wines&Hogarth, 2006). 
Two different gene product subclasses of IgA exist in humans: IgA1 and IgA2. In serum, 
IgA  is  mainly  composed  of  the  former.  There  is  good  homology  between  the  two 
subclasses, with the exception of a short mucin-like hinge region, unique to primate IgA1, 
that gives the molecule its unique receptor and lectin-binding properties. Receptors for IgA 
were first described more than 25 years ago (Lawrence et al., 1975). At present, there are 
five  known  types  of  IgA  receptor:  FcαRI  (CD89),  the  polymeric  Ig  receptor  (pIgR), 
Fcα/µR, the transferrin receptor (CD71) and the asialoglycoprotein receptor (Ding et al., 
2003). 
1.5.6.4  IgD 
IgD  is  a  monomeric  antibody  with  a  molecular  mass  of  approximately  184  kDa.  It 
circulates in serum at very low concentrations (<80 mg/L) and its function has yet to be 
determined. Studies have shown that IgD is expressed on the surface of developing B cells 
and it may therefore play an important role in their growth and development. Experimental 
models have shown that mice deficient in IgD appear to generate normal immune response 
and IgD is simply no longer expressed on activated B cells. Further research is needed to 
determine  whether  IgD  functions  as  a  regulatory  antigen  receptor  or  if  it  is  simply 
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1.5.6.5  IgE 
Like IgD, IgE (molecular mass approximately 188 kDa) is present in serum only at very 
low  concentrations  of  roughly  0.1–0.4  mg/L.  Unlike  IgD,  however,  IgE  is  capable  of 
triggering powerful immune reactions even in small amounts. When two IgE molecules are 
bridged  by  an  allergen  when  interacting  with  mast  cells,  degranulation  of  these  cells 
follows  with  the  subsequent  release  of  inflammatory  mediators  that  trigger  an  allergic 
reaction. 
 
Figure   1-6 Structures of the five immunoglobulin classes 
The five classes of immunoglobulin share the same basic, monomeric structure but 
feature unique characteristics that allow them to carry out their specific functions 
within the immune system. Adapted from (Rojas&Apodaca, 2002).  
 
1.5.7 Fc receptors 
FcRs are specialised receptors that recognise and bind to the Fc fragment (constant region) 
of Ig heavy chains, providing an important link between the humoral and cellular branches 
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of the specific immune system. Each Ig isotype binds specifically to at least one FcR, 
activating the receptor and initiating a range of responses, including antigen presentation, 
ADCC,  phagocytosis,  production  of  reactive  oxygen  species  (ROS)  and  release  of 
cytokines and other mediators of inflammation (Miller et al., 1996; Phillips-Quagliata et 
al., 2000). Among the FcRs, the most studied include the high- and low-affinity receptors 
for IgG (FcgRI, FcgRII and FcgRIII), the medium-affinity receptor for IgA (FcaRI) and the 
high-affinity receptor for IgE (FceRI) on mast cells (Raghavan&Bjorkman, 1996). 
In addition to these receptors, other FcRs have been identified and each is structurally and 
functionally distinct. These include the neonatal IgG transporter receptor (FcRn) and the 
polymeric  Ig  transporter  receptor  (pIgR)  for  IgM  and  IgA  (Daeron,  1997; 
Raghavan&Bjorkman, 1996; Ravetch&Kinet, 1991). In general, these receptors exist as 
complexes with numerous subunits and comprise a ligand binding a-chain and associated 
signalling  chains  (g-chains).  The  FcRg-chain  is  a  membrane-spanning  protein  with  an 
immunoreceptor tyrosine-based activation motif (ITAM). Once the receptor is activated, 
the  ITAM  is  phosphorylated  and  subsequently  promotes  the  release  of  additional 
downstream signalling molecules. 
The  main  focus  of  this  thesis  will  be  on  Fca/m  receptors  (Fca/mR)  of  IgA  and  IgM. 
However, due to some analagous functions and mechanisms of action, FcRn and pIgR will 
also be discussed in some detail. 
1.5.7.1  Fc receptor effector functions 
Although Fc-mediated activation and suppression of the immune response has been studied 
since the 1960s (Sinclair, 2001), the past decade has seen a significant leap forward in our 
understanding of FcRs at the molecular level (Launay et al., 1998; Takai, 2002). Three 
main functional categories have been identified: the regulation of immune cell responses, 
the  internalisation  and  degradation  of  ICs  and  the  transcellular  transfer  of  antibodies 
(though this really only applies to pIgR and FcRn). 
The major function of FcRs is the regulation of cellular immune responses, such as B cell 
proliferation,  phagocytosis  by  macrophages  and  the  degranulation  of  mast  cells.  Once 
activated, FcRs can initiate the inflammatory cascades evident in various forms of GN by 
transcriptionally activating cytokine-encoding genes. The internalisation and elimination of 
circulating ICs is efficiently carried out by macrophages, which also direct the antigenic 
peptides  along  either  the  MHC  class  I  or  class  II  antigen-presentation  pathways C C Ch h ha a ap p pt tte e er r r    1 1 1          I IIn n nt ttr r ro o od d du u uc c ct tti iio o on n n, 52 
(Amigorena&Bonnerot, 1999). In addition to the three main functions of FcRs, there is 
growing  evidence  that  soluble  FcRs  in  the  blood  may  also  have  immunomodulatory 
properties (Fridman et al., 1992). 
The concept of FcRs as a major, if not the major, effector of antibody-based inflammation 
has  become  more  popular  over  the  last  decade  in  particular  (Hogarth,  2002).  Current 
thinking favours the idea that the biological response to FcR activation depends more upon 
the cell type than the receptor itself; indeed, different receptors expressed in the same cell 
often generate the same response. Accordingly, when expressed in different cell types, 
FcRs typically respond in a cell-specific manner (Daeron, 1997). 
1.5.7.1.1 Phagocytosis 
The process of phagocytosis involves the internalisation of large particles (≥0.5 mm) and is 
mediated by reorganisation of the actin-based cytoskeleton (Silverstein et al., 1989). In 
humans,  phagocytosis  is  limited  to  specific  phagocytic  cells,  such  as  monocytes, 
macrophages and neutrophils. FcR-mediated phagocytosis involves the internalisation and 
elimination of Ig opsonised pathogens and is initiated by interactions between specialised 
cell  surface  receptors  and  ligand-coated  particles.  These  interactions  cause  local  actin 
rearrangements  resulting  in  pseudopod  extension  and  breakdown  of  the  particle  into 
antigenic peptide products that may then be presented to T cells via the MHC class II 
pathway. Degradation of the internalised phagosomes occurs by exposing them to acidic 
conditions and hydrolytic enzymes following fusion with endosomes and/or lysozomes. 
1.5.7.1.2 Endocytosis 
Unlike  phagocytosis,  endocytosis  does  not  involve  actin  rearrangements  and  can  be 
mediated by most FcRs. Small particles and soluble complexes are internalised purely via 
receptor–ligand  interactions,  which  typically  occurs  through  the  formation  of  clathrin-
coated pits in the plasma membrane. These pits contain ligand–receptor complexes and 
merge into the cytoplasm where the internalised microbes are fused with early endosomes. 
Once  endocytosed,  ICs  are  directed  to  subcellular  compartments  where  they  are  either 
degraded or presented to T cells (Fig. 1-7). It is worth noting that different FcRs may have 
different requirements for endocytosis to occur (Lauffenburger&Linderman, 1993). C C Ch h ha a ap p pt tte e er r r    1 1 1          I IIn n nt ttr r ro o od d du u uc c ct tti iio o on n n, 53 
 
Figure   1-7 A simple model of synthetic IC endocytosis 
Synthetic  receptors  embedded  in  the  cellular  plasma  membrane  rapidly  cycle 
between  the  cell  surface  and  intracellular  endosomes.  These  receptors  become 
incorporated  in  cellular  plasma  membranes,  enabling  the  cellular  uptake  of 
cognate  ligand,  such  as  Ig,  bound  to  antigen  by  synthetic  receptor mediated 
endocytosis to form IC. This results in uptake of IC by endocytosis whereupon the 
endosomes free the receptor to return to the cell surface. The receptors  in the 
centre of the cell represent the population in intracellular endosomes in dynamic 
exchange  with  receptors  on  the  cell  surface.  Adapted  from 
http://probes.invitrogen.com/handbook/figures/1534.html. 
 
1.5.7.2  Fcg g g g receptors (Fcg g g gR) 
At least eight separate genes for the FcgRs have been identified so far, all of which map to 
chromosome 1 and have multiple splice variants (Hulett&Hogarth, 1994; Ravetch, 1994), 
making  them  the  most  diverse  group  of  FcRs.  Each  of  the  FcgRs  is  composed  of  an 
extracellular  region,  a  membrane-spanning  region  and  a  cytoplasmic  region.  The  FcγR 
consists of three Ig superfamily domains, namely FcγRI, FcγRII and FcγRIII. 
1.5.7.2.1 FcγRI (CD64) 
FcγRI has the unique property of binding monomeric IgG with high affinity (association 
constant [Ka] 10
8–10
9 M
-1) and is constitutively expressed on monocytes and macrophages 
(Flesch&Neppert,  2000;  Hulett&Hogarth,  1994).  Furthermore,  FcγRI  expression  on 
neutrophils and eosinophils may be enhanced by IFN-g or GM-CSF. The ability to bind 
monomeric IgG implies a potential role for FcγRI in initiating effector functions even at 
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low concentrations of IgG (Shen et al., 1987). Moreover, studies have proposed that this 
ability is associated with the presence of a third extracellular domain that is lacking in all 
other  human  FcgRI  (Allen&Seed,  1989).  At  present,  three  FcγRI  genes  have  been 
identified in humans and mapped to chromosome 1q21.1, namely FcgRIA, FcgRIB and 
FcgRIC  (Hulett&Hogarth,  1994).  So  far  only  FcγRIA  protein  has  been  detected  on 
haematopoietic cells. It is thought that FcγRIB and FcγRIC exist purely as soluble proteins 
due to a stop codon in the exon encoding the third extracellular domain preventing the 
development of a transmembrane region (Flesch&Neppert, 2000). 
FcγR signalling acts along a cascade of events common to several other immune system 
receptors. However, no signalling motif has yet been found in the cytoplasmic tail of FcγRI 
(Allen&Seed, 1989), meaning that it must recruit accessory molecules that contain these 
sequences in order to activate intracellular signalling molecules such as soluble tyrosine 
kinases. In order to join the signalling pathways, FcgRI associates at the cell surface with 
g-chain homodimers (Ernst et al., 1993). The g-chain, initially found in association with 
FceRI, contains a cytoplasmic ITAM responsible for the recruitment of tyrosine kinase-
dependent signalling pathways (Cambier, 1995). 
1.5.7.2.2 Fcg g g gRII (CD32) 
Of all the FcγR, FcγRII is expressed in the widest range of cell types, including monocytes, 
macrophages,  neutrophils,  eosinophils,  basophils,  B  cells,  platelets,  and  dendritic  cells 
(Ravetch&Kinet, 1991; van de Winkel&Capel, 1993). Unlike FcgRI, it has low affinity for 
IgG  binding  (Ka  <10
7  M
–1)  and  even  then  this  occurs  only  with  complexes  and  not 
monomeric IgG (van de Winkel&Capel, 1993). IgG binding directly involves the second 
extracellular domain, whereas the first domain plays an important role in optimal ligand 
binding (Hulett&Hogarth, 1994; Hulett et al., 1995). 
In  humans,  three  different  FcgRII  genes  (FcgRIIA,  FcgRIIB  and  FcgRIIC)  have  been 
located  on  chromosome  1q23-24,  each  with  multiple  splice  variants  (Ravetch&Kinet, 
1991;  van  de  Winkel&Anderson,  1991).  The  FcgRIIA  gene  encodes  FcgRIIA1,  a 
transmembrane  receptor  molecule  with  cytoplasmic  portion,  while  FcgRIIA2  lacks  a 
transmembrane  region  and  is  presumed  to  be  soluble  (Brooks  et  al.,  1989).  FcgRIIB 
molecules are preferentially expressed on monocytes and macrophages but can also be 
found on B cells (Cassel et al., 1993), while the FcgRIIC gene codes for a protein that is 
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due  to  an  unequal  crossover  between  the  FcgRIIA  and  IIB  genes  (Warmerdam  et  al., 
1993). Although the cellular expression of FcgRIIC has yet to be studied in detail, gene 
transcripts  have  been  found  on  the  membranes  of  B  cells  and  myelomonocytic  cells 
(Cassel et al., 1993). 
Each of the FcgRII isoforms consists of two extracellular domains, and all but FcgRIIA2 
have a cell membrane and a cytoplasmic region (Stuart et al., 1989). Unlike the other 
FcgRs, FcgRII encode signalling motifs within their cytoplasmic tails and are therefore 
able  to  initiate  a  signalling  cascade  (Van  den  Herik-Oudijk  et  al.,  1995).  Both  the 
FcgRIIA1 and FcgRIIC isoforms contain a unique ITAM copy in their cytoplasmic tail that 
is critical for phagocytosis and tyrosine phosphorylation, but not for the internalisation of 
ICs (Indik et al., 1995; Van den Herik-Oudijk et al., 1995). It has been proposed that the 
association of FcgRIIA with an FcR g-chain unit may mediate this and other functions (e.g. 
cytokine release and antigen presentation) (Masuda et al., 1993). Although the FcR g-chain 
ITAM is much more effective at triggering cytokine release and antigen presentation than 
the FcRIIA ITAM, the latter appears to exert a bigger influence on phagocytosis (Van den 
Herik-Oudijk et al., 1995). The FcgRIIB1 and FcgRIIB2 isoforms are the only receptors 
with  an  immunoreceptor  tyrosine-based  inhibition  motif  (ITIM),  which  recruits  an 
inhibitory signalling pathway (Daeron, 1997; Van den Herik-Oudijk et al., 1995). Reports 
have suggested that FcgRIIC and FcgRIIIA are co-expressed by NK cells (Metes et al., 
1994; Metes et al., 1999). 
1.5.7.2.3 Fcg g g gRIII (CD16) 
Two genes encoding FcgRIII have been discovered in humans – FcgRIIIA and FcgRIIIB – 
both of which  are located on chromosome 1q23-24 (Qiu  et al., 1990;  Ravetch&Kinet, 
1991). FcgRIIIA is expressed on macrophages, NK cells and mast cells, while FcgRIIIB 
expression  is  limited  to  neutrophils  alone.  Both  gene  products  have  two  extracellular 
domains  and  are  highly  homologous  in  these  regions;  elsewhere,  however,  they  are 
completely  different  (Ravetch&Perussia,  1989).  FcgRIIIB  has  no  transmembrane  or 
cytoplasmic region and thus cannot associate with either g-chain homodimers or the related 
z-chain. There is no evidence that a deficiency of FcgRIIIB causes disease. Similarly to 
FcgRI, FcgRIIIA associates with the g-chain. Interestingly, however, it can also associate 
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1.5.7.2.4 The g g g g-chain 
The FcR γ-chain is a 7 kDa, type I membrane-spanning polypeptide normally found as a 
homodimer in the membrane, linked with the α-chain by a single disulphide bridge (Takai, 
2002). The α-chain binds IgE and was first identified as a component of the multi-subunit, 
high-affinity IgE receptor on mast cells (Perez-Montfort et al., 1983). The γ-chain belongs 
to a family of membrane-associated signal transduction molecules that also includes the ζ-
chain  component  of  the  TCR  (Orloff  et  al.,  1990).  Accordingly,  it  shares  the  distinct 
structural characteristics associated with these molecules; the membrane-spanning region 
is  a  single  α-helix  through  which  the  γ-chain  associates  with  FcγRI  via  non-covalent 
interactions  (Ernst  et  al.,  1993;  Harrison  et  al.,  1995),  while  the  intracellular  domain 
contains a classic ITAM signalling motif (Samelson&Klausner, 1992). 
1.5.7.3  FcαR (CD89) 
First cloned in 1990, FcaRI (CD89) is the only known receptor for IgA (Daeron, 1997; 
Maliszewski  et  al.,  1990)  and  is  constitutively  expressed  on  a  wide  variety  of  cells, 
including  neutrophils  (the  largest  source  of  FcaRI  in  blood  and  tissues  (Hamre  et  al., 
2003)), monocytes, eosinophils, some macrophages and Kupffer cells (Woof&Kerr, 2006). 
As with most FcRs, FcαRI contains two extracellular regions, a transmembrane region 
(associated  with  the  FcRg-chain)  and  a  cytoplasmic  tail  that  regulates  cytoskeletal 
association of the receptor (Bracke et al., 2001). Overall, the extracellular regions contain 
206 amino acids, the transmembrane domain contains 19 and the cytoplasmic tail contains 
41 (Ding et al., 2003; Maliszewski et al., 1990). 
In contrast to FcgR and FceRI, whose α-chain genes map to a cluster on chromosome 1, the 
FcαRI α-chain genes map to chromosome 19 (Ding et al., 2003; Woof&Kerr, 2006). When 
the FcαRI α-chain is engaged by ligand and effectively becomes cross-linked, the γ-chain 
ITAM tyrosines are phosphorylated, representing the first step in a signalling cascade that 
ultimately leads to the assembly of lipid rafts within the plasma membrane that serve as 
platforms for the initiation of signal transduction (Lang et al., 1999; Lang et al., 2002). 
Cross-linking  of  FcαRI  on  myeloid  cells  has  been  shown  to  initiate  a  wide  range  of 
functional processes, including phagocytosis, ROS generation, ADCC and the release of 
inflammatory mediators (Morton et al., 1996; van Zandbergen et al., 1999). Moreover, the 
cell surface expression of FcαRI is upregulated by cytokines (TNF-α, GM-CSF, IFN-g, IL-
1b, IL-4, IL-5, IL-6, IL-8), LPS and HAg-IgA (Hostoffer et al., 1994; Monteiro et al., 
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enhanced  IgA-mediated  phagocytosis.  In  contrast,  TGF-b  appears  to  downregulate  the 
expression of FcαRI in cultured monocytes (Reterink et al., 1996). 
Similarly to the observed actions of many other FcRs, FcaRI has been shown to associate 
with g-chain homodimers (Morton et al., 1995). Researchers have described two spliced 
variant  messages  encoding  smaller  variants  of  the  receptor  protein,  but  the  biological 
characteristics of these is as yet unclear (Monteiro&Van De Winkel, 2003). Ligand binding 
by  FcαRI  differs  from  that  by  FceRI  and  FcgRs  since  binding  occurs  via  the  first 
extracellular region (Morton&Brandtzaeg, 2001; Wines et al., 1999) and not the second or 
the linking region. Thus, altered FcαRI expression may have a direct effect on the effector 
function of FcαRI-expressing cells. Furthermore, although there is no available data on the 
existence or otherwise of soluble forms of FcαR, should they exist it has been proposed 
that  these  soluble  receptors  may  have  a  pathophysiological  role  in  several  diseases 
(Huizinga et al., 1990; Koene et al., 1998). 
FcaRI  receptor  possesses  medium-to-high  affinity  for  IgA  (Ka  ~  1x10
7  M
-1)  and  can 
therefore bind either the monomeric or polymeric forms of both IgA1 and IgA2 (Monteiro 
et al., 1990). FcaRI binds the IgA Fc region at the hydrophobic interface. Studies of the 
binding reaction have found that the monomeric receptor binds IgA with low micromolar 
affinity,  as  befits  a  receptor  that  functions  as  a  sensor  for  IgA  ICs  by  avidly  binding 
aggregates  of  IgA  (Wines&Hogarth,  2006).  This  affinity  switch  appears  to  involve  a 
cytokine-triggered  serine  dephosphorylation  in  the  cytoplasmic  domain  of  FcαRI. 
Consequently,  the  receptor  is  released  from  its  cytoskeletal  base,  presumably  allowing 
bivalent ligand binding to occur (Bracke et al., 2001). Moreover, mutations in the alanine 
residues of the apical loops in the first extracellular region inhibit receptor binding, even 
when cytokines are present (Wines et al., 2001). It has thus been proposed that cytokine 
activation alters the receptor organisation leading to an increase in IgA binding without 
altering the overall number of receptors (Weisbart et al., 1988). 
1.5.7.4  Fc neonatal receptor (FcRn) 
FcRn was first isolated from the intestine of foetal rats (Simister&Rees, 1985) and, in 
humans, is found in epithelial cells, some vascular endothelial cells (Junghans&Anderson, 
1996), in the placenta (Simister&Story, 1997) and in both foetal and adult intestine (Israel 
et  al.,  1997).  The  gene  encoding  FcRn  has  been  mapped  to  chromosome  19q13.3 
(Junghans&Anderson, 1996). FcRn is a heterodimer comprising a glycosylated heavy α-
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(Claypool et al., 2002). The extracellular region of the a-chain is composed of three Ig-like 
domains (homologous to MHC class I), a transmembrane region and a cytoplasmic region. 
The site of MHC peptide binding is distinct from the site of IgG Fc binding (Burmeister et 
al., 1994). Thus, FcRn is structurally very different from the FcgRs and the functional 
receptor  is  likely  to  be  a  dimer  of  heterodimers  that  binds  a  single  IgG  molecule 
(Burmeister et al., 1994; Kim et al., 1994). 
A key role of FcRn in immunity is the absorption of maternal IgG and the subsequent bi-
directional trafficking of the bound complex across the epithelial cells that line the lumen 
of various tissues (Claypool et al., 2004; Kobayashi et al., 2002; McCarthy et al., 2001). 
These  tissues  include  the  human  placenta,  the  yolk  sac  in  rabbits  and  rodents  and  the 
proximal small intestine in neonatal rodents (Firan et al., 2001; Medesan et al., 1996). 
FcRn also regulates IgG levels in plasma and is sometimes referred to as the specific IgG 
‘protection receptor’ (Flesch&Neppert, 2000; Ghetie&Ward, 1997). Once antigen-bound 
IgG is internalised by the plasma membrane the complex is uncoupled, leaving IgG free to 
bind to FcRn which then redirects it back to the circulation so that only the antigen is 
catabolised in lysosomes. FcRn binds IgG at acidic pH (£6.5) but not at or above neutral 
pH (³7.0); the IgG and the receptor uncouple at neutral pH (Claypool et al., 2004). When 
IgG levels in plasma are high there is greater competition for FcRn binding, the capacity 
for IgG transport back to the circulation is overstretched and so more IgG is degraded by 
lysosomes. When IgG levels in plasma are low, a higher proportion of IgG is returned to 
the circulation. Ligand binding to FcRn occurs both within the acidic endosome and at the 
cell surface (Claypool et al., 2004; Kobayashi et al., 2002), though the bulk of FcRn is 
stored intracellularly at steady state (Dickinson et al., 1999; Ober et al., 2001). 
Studies in rats have shown that the trafficking  of FcRn is dependent upon the sorting 
motifs  found  in  the  cytoplasmic  tail  (McCarthy  et  al.,  2001;  Wu&Simister,  2001).  A 
mutation  and  a  tryptophan  residue  in  the  cytoplasmic  tail  of  rat  FcRn  that  impairs 
endocytosis has been identified (Wu&Simister, 2001). This affects both the apical and 
basolateral membrane domains, with a more severe reduction in endocytosis in the former. 
Removal  of  the  cytoplasmic  tails  significantly  impairs  the  transport  of  IgG  in  the 
basolateral direction but not in the apical direction (Wu&Simister, 2001). However, there 
are conflicting data on whether or not the FcRn cytoplasmic tail has an impact on sorting in 
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1.5.7.5  Polymeric immunoglobulin receptor (pIgR) 
pIgR is an important transmembrane glycoprotein expressed on the basolateral surface of 
most human secretory epithelial cells, including those in the intestine, bronchus, salivary 
glands,  gallbladder,  renal  tubules,  pancreas,  lactating  mammary  glands  and  the  uterus 
(Brandtzaeg P. et al., 1994).  As such, pIgR is crucial to the first line of defence at mucosal 
surfaces, neutralising both extra- and intracellular pathogens in these membranes by the 
epithelial  transport  of  pIgA–pathogen  ICs  that  are  mucosally  secreted  via  epithelial 
transcytosis (Mostov et al., 1984; Rojas&Apodaca, 2002). 
pIgRs are formed when IgA and IgM are oligomerised by the J-chain cross-linking the 
homodimeric Fc regions of multiple molecules (two for IgA and five for IgM) (Mestecky 
et al., 1971). After synthesis in the endoplasmic reticulum, pIgR is delivered directly from 
the trans-Golgi network to the basolateral surface where it binds dIgA. The pIgR–dIgA 
complex  undergoes  endocytosis  and  is  then  transported  through  a  series  of  endosomal 
compartments across the cell to the apical surface (Rojas&Apodaca, 2002). The secretory 
component (i.e. the ectoplasmic domain) of pIgR is secreted luminally in its bound (with 
pIgA)  or  unbound  forms  (Piskurich  et  al.,  1997).  Thus,  pIgR  is  not  only  capable  of 
delivering pIgA into mucosal secretions, but also aids the transportation of locally-formed 
ICs containing pIgA across the epithelium from the lamina propria (Robinson et al., 2001; 
Woof&Kerr, 2006). 
Studies have shown that the pIgR transcription gene is upregulated by proinflammatory 
cytokines (e.g. IFN-g, TNF-a, IL-1 and IL-4), bacterial products (e.g. LPS) and hormones 
(Schneeman et al., 2005). Moreover, the neutralisation of LPS by secretory IgA controls 
pIgR  expression  levels  via  a  negative  feedback  cycle.  These  findings  suggest  that 
transcriptional regulatory mechanisms may be involved in the function of pIgR and that 
IFN-g may induce transcription factor synthesis in epithelial cells. 
1.5.7.5.1 J-chain 
As  discussed  above,  the  binding  of  human  pIgR  to  pIgA  or  IgM  is  dependent  on  the 
presence of the J-chain (Vaerman et al., 1998a), a polypeptide sequence of approximately 
137  amino  acid  residues  with  a  total  molecular  mass  of  15–16  kDa  that  links  the  Fc 
fragments of antibodies by disulphide bridges (Koshland, 1985; Mestecky et al., 2005). In 
humans, a single N-linked glycan accounts for approximately 8% of the molecular mass of 
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polymers  between  the  J-chain  and  monomeric  IgA  (mIgA)  subunits  (Krugmann  et  al., 
1997; Woof&Mestecky, 2005). 
1.5.7.6  Fc alpha/mu receptor (Fca a a a/m m m mR) 
The  novel  receptor  Fca/mR  was  first  isolated  on  B  cells  and  macrophages  in  murine 
(Shibuya et al., 2000) and in human homologues and is capable of binding both IgA and 
IgM. Mapped to chromosome 1q32.3, adjacent to the pIgR, FcgR and FceRI genes, the 
Fca/mR gene encodes a single glycopolypeptide with a molecular mass of approximately 
70 kDa and was isolated using an expression library from the T-cell line and selection of 
an IgM-binding clone (Shibuya et al., 2000). Structurally, Fca/mR consists of a single Ig 
superfamily domain (most similar to the first extracellular region of pIgR), an extended 
mucin-like membrane proximal region, a transmembrane region and a small cytoplasmic 
tail. It is preferentially expressed on most B cells and macrophages but not on T cells, NK 
cells or granulocytes (Sakamoto et al., 2001; Shibuya et al., 2000). As such, Fca/mR is 
widely expressed in non-haematopoietic tissues, mainly in the kidney and intestine, but 
also in the lung, liver and heart at lower levels. It is also expressed in lymphoid cells, 
including the lymph nodes, spleen and appendix (Sakamoto et al., 2001). Fca/mR binds 
IgM  with  high  affinity  (Ka  ~  10
9  M
-1)  and  IgA  with  lower  affinity  (Ka  ~10
8  M
-1) 
(Wines&Hogarth, 2006). 
The functions of Fca/mR in vivo have yet to be fully determined, though the generation of 
Fca/mR knockout mice will ensure that research in this area will continue to develop. The 
relatively high binding affinities of Fca/mR suggests a role in the early stages of a primary 
immune response. Studies in mice have shown that Fcα/µR mediates B-cell endocytosis of 
IgM opsonised bacterial targets. A similar uptake of IgA-coated targets has been proposed. 
In addition, a role for Fca/mR in IgM-mediated antigen presentation to T cells in the early 
stages of immune response has been proposed; mice deficient in secretory IgM display 
impaired  T-cell-dependent  antibody  responses  (Sakamoto  et  al.,  2001).  Alternatively, 
deficiencies in either IgA or IgM have been linked with the production of autoantibodies; 
therefore, there may be a role for an IgA/IgM receptor that passively removes ICs without 
significant presentation of antigens. 
Following the initial finding of Fca/mR expression in the kidney (Sakamoto et al., 2001), it 
was reported that human MSC express this receptor and that this expression is upregulated 
by  IL-1a  (McDonald et al., 2002).  It was therefore hypothesised that Fca/mR may be C C Ch h ha a ap p pt tte e er r r    1 1 1          I IIn n nt ttr r ro o od d du u uc c ct tti iio o on n n, 61 
responsible for the deposition of pIgA-containing  ICs in  IgAN; however, other studies 
conducted in MSC have indicated that Fca/mR may not bind IgM in these cells (Moura et 
al., 2001; Moura et al., 2004; Wines&Hogarth, 2006). 
1.5.7.7  Transferrin receptor (CD71) 
First described as a receptor for transferrin, CD71 is an IgA receptor comprising a 180 kDa 
disulphide-linked homodimer that binds polymeric human IgA1 (rather than monomeric) 
but not IgA2 (Monteiro et al., 2002; van der Boog et al., 2004; Woof&Mestecky, 2005). 
The receptor is expressed on mononuclear haemopoietic cells in the foetus but is often 
undetectable on either adult mononuclear or PMN cells. Expression of CD71 has also been 
found on certain lymphocytic and myeloid cells (Woof&Kerr, 2006). The expression of 
CD71 on human MSC is upregulated in IgAN, leading to suggestions that the receptor may 
be linked to IgA deposition in the tubulointerstitium (Moura et al., 2001). A recent study 
showed that interstitial dendritic cells also express CD71 and that the receptor mediates 
endocytosis of IgA-containing ICs in immature but not in activated monocyte-derived cells 
(Pasquier et al., 2004). 
1.5.7.8  Asialoglycoprotein receptor (ASGPR) 
The ASGPR is a C-type lectin involved in the endocytosis of serum glycoproteins due to 
its  ability  to  recognise  galactose  and  N-acetylgalactosamine  residues  of  desialylated 
glycoproteins (Stockert, 1995). Thus, ASGPR may represent a degradative pathway with 
an important role in maintaining the homeostasis of glycoprotein levels. Whilst ASGPR 
has long been associated with hepatic cells, studies in rats have shown that ASGPR mRNA 
is widely expressed in various tissues and cell lines (Leung et al., 2000; Park et al., 1998a).C C Ch h ha a ap p pt tte e er r r    1 1 1                                                  I IIn n nt ttr r ro o od d du u uc c ct tti iio o on n n, ,, 62 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure   1-8 Fc receptors structure 
Immunoglobulin  receptors:  the  upper  panel  shows  receptors  for  IgG,  and  the  lower  panel  receptors  for  other  Ig  isotype.  Each  Ig like 
extracellular domain (EC, or D) is shown as a circle, and the domain are numbered from the amino terminus of the receptor molecule. Note 
that FcgRIIB is linked to the membrane via a glycophosphotidylinositol (GPI) anchor. ITAM and ITIM intracellular domains are represented as 
filled and opened rectangles, respectively. Intracellular domains with no or undefined signals functions are shown as open ovals. FceRI is 
depicted in a ‘lying down’ orientation for FceRII, the C type lectin domain is depicted as ‘C’ and the oval domain represent the stalk region. 
Adapted from (Cushley, 2005) 
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Table   1-2 Molecular properties of human Fc receptors 
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1.6 PTEC  functions  and  immune  mechanism  in  renal 
disease 
1.6.1 Fc receptors expression 
The important functional effects of FcRs in immunity include interacting with ICs and 
mediating  antigen  presentation,  ADCC  and  release  of  inflammatory  mediators 
(Hulett&Hogarth,  1994).  The  reabsorption  of  filtered  ICs  in  the  proximal  tubule  is 
primarily a receptor-mediated process. FcRs appear to be somehow involved in the IC-
mediated  activation  of  PTEC  and  a  common  binding  site  for  low-molecular-weight 
proteins in these cells has been suggested. When renal conditions are impaired, higher 
levels of  Ig are observed in the urine and some studies have proposed that, like other 
proteins, Igs themselves may damage the tubules (Abbate et al., 1998; Zoja et al., 1995). 
However, the mechanisms by which this process may occur are not yet clear. 
FcRn-mediated  IgG transcytosis  appears to be localised to the brush border of PTECs 
(Haymann et al., 2000; Kobayashi et al., 2002) and so any injury resulting in the loss of 
PTEC will impair IgG reabsorption because of insufficient endocytosis. When PTEC are 
exposed to higher levels of IgG, an upregulation of ROS and NF-kB activation has been 
reported  (Ronda  et  al.,  2005).  In  patients  with  GN,  the  cationic  fragment  of  the  IgG 
molecule  is  preferentially  reabsorbed  from  the  filtrate,  suggesting  that  FcRn-mediated 
endocytosis may not be the only mechanism involved in IgG transcytosis and that IgG 
reabsorption in PTEC is also charge-induced (Takahashi et al., 2004). 
Although there were several early reports of FcαRI expression in MSC (Gomez-Guerrero 
et al., 1993; Kashem et al., 1997), it is now generally accepted that this is not the case 
(Barratt et al., 2000; Westerhuis et al., 1999) and a number of other receptors have been 
proposed. MSC expression of ASGPR has been reported, although this finding was later 
refuted in an important study which also showed that MSC do not express pIgR under 
normal  conditions  or  even  when  exposed  to  proinflammatory  cytokines  known  to 
upregulate the transcription of pIgR (including IFN-g, TNF-a, IL-1 and IL-4 (Leung et al., 
2000;  Schjerven  et  al.,  2004).  These  findings  also  extended  to  include  FcαRI  and  the 
ASGPR,  despite  the  known  upregulation  of  MSC  IgA  binding  when  exposed  to 
proinflammatory cytokines (Barratt et al., 2000; Leung et al., 2000). Subsequently, IL-la, 
IFN-g and TGF-b were used in my study as proinflammatory cytokines to demonstrate the 
expression of Ig receptors in PTEC that may have a specific role in IgAN. C C Ch h ha a ap p pt tte e er r r    1 1 1          I IIn n nt ttr r ro o od d du u uc c ct tti iio o on n n, 65 
Although Fca/mR-mediated endocytosis has been proposed, the mechanism by which this 
occurs is not yet clear. MSC cultured in vitro have been shown to bind both monomeric 
IgA and pIgA. They express pIgR and Fcα/µR, but not the IgA receptor FcaR (McDonald 
et al., 2002; Smith&Feehally, 2003; Westerhuis et al., 1999). A human homologue of 
Fca/mR was recently identified in MSC on the basis of sequence similarity with murine 
Fca/mR (McDonald et al., 2002). However, whilst the Fcα/µR is an interesting candidate 
for IgA binding in MSC, additional receptors may be required as some studies have shown 
that the IgA binding is Fcα-specific and cannot be blocked by excess IgM (Barratt et al., 
2000). 
CD71 is one such candidate and has been shown to bind IgA1 in MSC. Renal biopsies 
from IgAN patients have indicated CD71 expression (Moura et al., 2001). However, as this 
receptor is IgA1 selective and binds to polymeric forms more efficiently than monomeric 
forms, it also cannot fully account for the specific FcαR binding of MSC. However, it is 
possible  that  MSC  and  PTEC  contain  a  novel  Fca/mR  isotype  that  has  yet  to  be 
characterised. Other FcR families have multiple members and the possibility that others 
await discovery cannot be excluded. 
1.6.2 ECM production 
1.6.2.1  ECM overview 
ECM  is  a  complex  aggregate  structure  composed  of  four  different  classes  of 
macromolecules:  collagens,  proteoglycans,  structural  glycoproteins  (including  FN)  and 
elastin (Johansson et al., 1997). Abnormalities in ECM biosynthesis and catabolism occur 
in both inherited and acquired diseases, and are sometimes seen in wound healing. The 
maintenance  of  normal  tissue  architecture  and  the  integrity  of  other  tissue-specific 
functions such as formation and remodelling depend upon ECM. It is also involved in the 
recirculation of lymphocytes, blood clot formation and tumour growth and metastasis. To 
date, two major families of cell surface receptors have been identified: the integrins and the 
syndecans (Johansson et al., 1997). These receptors appear to mediate the influence of 
ECM  and  its  components  on  cell  growth,  differentiation,  development  and  metabolic 
response.  Specific  cell  surface  receptors  for  ECM  components  have  been  identified, 
providing a link between ECM and cell biology. 
The  integrin  receptors  are  a  family  of  heterodimeric  transmembrane  glycoproteins  that 
mediate the adhesion and interaction of cells with ECM, modulating changes in cell shape C C Ch h ha a ap p pt tte e er r r    1 1 1          I IIn n nt ttr r ro o od d du u uc c ct tti iio o on n n, 66 
(Hornberger et al., 2000). In the absence of growth factors, integrins have been shown to 
mediate cell signalling (Moro et al., 1998). Even more importantly, these glycoproteins 
appear to both directly  (Jones et al., 1997; Miyamoto et al., 1996) and indirectly  (via 
modulation of focal adhesions (Cary&Guan, 1999) enhance the cell response to growth 
factors. 
Over the past two decades, changes in the ECM have come to be recognised as critical 
events  for  the  initiation  and  progression  of  many  renal  diseases,  including  GN, 
glomerulosclerosis  and  tubulointerstitial  fibrosis.  Much  more  than  simply  providing  a 
structural support for cells, ECM should be considered a dynamic complex with several 
important functions in both normal and injured kidneys. 
1.6.2.2  Fibronectin (FN) 
FN  is  one  of  the  major  structural  glycoproteins  of  ECM,  alongside  laminin,  entactin, 
tenascin, thrombospondin, vitronectin and fibrillin, and promotes cell adhesion (Hynes et 
al., 1992). As well as being present in ECM, FN is also found in plasma and is known to 
be  involved  in  cell  differentiation,  wound  repair,  thrombosis  and  cytoskeletal 
reorganisation. FN contains two subunits, each with a molecular mass of approximately 
250 kDa, and binding domains for cells and fibrin (Haralson&Hassell, 1995). 
1.6.2.3  PTEC and FN 
In IgAN, the release of inflammatory cytokines from MSC after binding to IgA activates 
PTEC, which, in turn, may release even more pro-inflammatory molecules (including IL-6, 
TNF-a, soluble intercellular adhesion molecule-1 [ICAM-1] and angiotensin II) that attract 
further inflammatory competent cells (Arrizabalaga et al., 1997; Ranieri et al., 1996). This 
positive  feedback  loop  in  the  renal  tubules  leads  to  the  excessive  production  of  ECM 
components,  including  FN  and  various  collagens,  resulting  in  fibrosis  and,  ultimately, 
tubulointerstitial scarring. 
The  accumulation  of  FN  and  other  proteins  in  the  interstitium  of  the  kidney,  due  to 
increased  synthesis,  reduced  degradation  or  both,  is  fundamental  to  tubulointerstitial 
fibrosis (Norman&Fine, 1999). The increased production of interstitial proteins is largely 
mediated by fibroblasts, which proliferate during fibrosis. Interestingly, in vitro studies 
have  shown  that  fibroblasts  from  injured  kidneys  appear  to  synthesise  more  FN  and 
collagens  than  do  fibroblasts  from  healthy  kidneys  (Rodemann&Muller,  1991).  As C C Ch h ha a ap p pt tte e er r r    1 1 1          I IIn n nt ttr r ro o od d du u uc c ct tti iio o on n n, 67 
tubulointerstitial fibrosis has a peritubular organisation, it has been suggested that PTEC 
themselves  may  have  an  important  pathogenic  role.  Primary  insults  to  the  PTEC  (e.g. 
hypoxia)  or  sustained  exposure  to  factors  in  the  glomerular  ultrafiltrate  (e.g.  proteins, 
cytokines, glucose) or complement proteins and their activation products in the glomerular 
filtrate (e.g. during states of non-selective proteinuria (Zhou et al., 2001)) may lead to the 
release of chemoattractants that promote the infiltration of monocytes into the interstitium, 
releasing  yet  more  inflammatory  mediators,  stimulating  fibroblast  proliferation  and 
upregulating the production of interstitial proteins (Peake et al., 2002; Tian et al., 2003). 
As high-grade proteinuria is infrequent in IgAN and it remains to be confirmed whether 
there is a specific binding of IgA to PTEC, an alternative pathway for tubulointerstitial 
atrophy  and  fibrosis  dependent  upon  IgA-containing  ICs  in  the  mesangium  has  been 
hypothesised. In this thesis, I examined the possibility that these Ig/ICs cause accumulation 
of FN in the proximal tubule. 
1.6.3 Proliferation 
1.6.3.1  The cell cycle 
The cell cycle consists of four distinct phases, G1 (gap 1), S (synthesis), G2 (gap 2) and M 
(mitosis), the first three of which are collectively known as the ‘interphase’ (Fig. 1-9). An 
additional  phase,  G0,  is  reserved  for  cells  that  have  temporarily  or  reversibly  stopped 
dividing; senescent cells are those that have permanently stopped dividing due to age or 
accumulated DNA damage. In mature organisms, some cell types enter the G0 phase semi-
permanently (e.g. parenchymal cells in the liver and kidney) and only re-enter the cell 
cycle under highly specific conditions. The G1 and G2 phases are characterised by protein 
and RNA synthesis and S by DNA synthesis. The M phase comprises two distinct but 
tightly coupled processes: mitosis (where the cell nucleus divides and its chromosomes are 
allocated  to  the  two  daughter  cells)  and  cytokinesis  (the  physical  division  of  the 
cytoplasm).  The  timing  of  the  cell  cycle  is  cell-specific  and  also  depends  upon  local 
conditions. C C Ch h ha a ap p pt tte e er r r    1 1 1          I IIn n nt ttr r ro o od d du u uc c ct tti iio o on n n, 68 
 
Figure   1-9 The cell cycle 
1.6.3.2  Cellular proliferation 
The proliferation and dedifferentiation of renal PTEC is crucial to the regulation of renal 
repair,  particularly  early  on  in  the  injury  recovery  process  where  the  denuded  tubular 
basement  membrane  begins  to  be  replenished.  However,  the  exact  nature  of  the 
relationship between cellular proliferation and dedifferentiation is unclear, for example, the 
timing of PTEC reversion and how this ‘remodelling’ process relates temporally to the 
initial  insult,  cellular  proliferation  and  the  eventual  redifferentiation  of  the  cell  are 
unconfirmed (Bard, 2002; Bonventre, 2003). Renal repair within the proximal tubule also 
depends on cell migration across the basement membrane, hypertrophy and apoptosis of 
hyperplastic PTEC in order to restore normal morphology, cell–cell contact and transport 
capacity (Bonventre, 1993). Current data estimate that complete structural and functional 
recovery may take 4–6 weeks (Basile et al., 1998; Witzgall et al., 1994). 
In vitro studies have shown that MSC proliferation in an experimental model of MGN is 
accompanied by a reduction in the accumulation of ECM proteins and an improvement in 
renal  function  (Pippin  et  al.,  1997).  Although  this  thesis  focuses  primarily  on  the 
proliferation of PTEC, some renal diseases (e.g. IgAN (Moeller et al., 2004)) also involve 
the  proliferation  MSC.  Induction  of  proliferation  is  a  receptor-mediated  process  that 
involves the stimulation of the cells to re-enter the cell cycle (Kurogi, 2003). Proliferation 
may  be  limited  by  blockading  specific  growth  factors  or,  more  generally,  by  targeting 
angiotensin II receptors, calcium channels and 3-hydroxy, 3-methylglutaryl Coenzyme A 
(HMG-CoA) (Guan&Breyer, 2001; Javaid&Quigg, 2005). The clinical relevance of these 
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potential  therapeutic  strategies  is  only  just  becoming  apparent  and  further  research  is 
needed. 
1.6.4 Cytokine production 
At present, few data exist on the specific effects of inflammatory cytokines on PTEC. 
PTEC are known to release a wide variety of inflammatory mediators, including ECM 
components, chemokines and cytokines, and that this process occurs in response to various 
stimuli including cytokines (particularly IL-1a, TNF-a and IFN-g (Boswell et al., 1994; 
Gerritsma  et  al.,  1996a;  Gerritsma  et  al.,  1996b;  Schmouder  et  al.,  1992),  hypoxia, 
proteinuria  and  LPS  (Frank  et  al.,  1993;  Glynne  et  al.,  2001).  The  release  of  these 
mediators  is  thought  to  worsen  interstitial  disease  by  recruiting  and  activating  various 
inflammatory competent cells, including macrophages and lymphocytes (Jevnikar et al., 
1990), though this has yet to be rigorously proven. Moreover, only some of the mediators 
released by PTEC have pro-inflammatory signals, while others are anti-inflammatory. So 
while the effects of some single mediators (including TNF-a, IL-6, IL-8 and RANTES) are 
well  studied  (Chen&Lin,  1994;  Wang  et  al.,  2004),  the  net  effects  of  activated  PTEC 
require further study. 
In  various  forms  of  GN  and  tubulointerstitial  nephritis,  both  the  infiltrating  cells  and 
resident  PTEC  appear  to  have  upregulated  levels  of  TNF-a  and  IL-6  (Leonard  et  al., 
1999).  In  vitro  studies  conducted  in  MSC  and  PTEC  have  demonstrated  that  IL-6 
production  is  increased  in  these  cells  in  response  to  stimulation  by  various  stimuli, 
including LPS, TNF-a and IL-1 (Abbott et al., 1991; Boswell et al., 1994). Infection with 
Gram-negative bacteria causes LPS toxicity, which is widely assumed to upregulate the 
generation of TNF-a  and may subsequently initiate an inflammatory cascade that may 
ultimately lead to either apoptotic or necrotic cell death (Jones et al., 2000; Yamaoka et al., 
2002;  Zager,  1986).  A  logical  hypothesis,  therefore,  is  that  if  acute  injury  to  PTEC 
increases  LPS-mediated  TNF-a  production,  the  severity  of  the  injury  may  worsen. 
Moreover, if renal TNF-a production leads to systemic TNF-a release, additional damage 
may occur in extrarenal tissues. 
Expression of the IL-8 gene and protein has been detected throughout the glomeruli in 
some proliferative forms of GN (Cockwell et al., 1999), though this is sometimes limited 
to mesangial areas (Lim et al., 2003; Mezzano et al., 1997). IL-8 caused sequestration of 
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extravascular IL-8 and other neutrophils and chemoattractants (Hechtman et al., 1991). IL-
1 and TNF-a are among the most potent inducers of IL-8 (Gerritsma et al., 1996b; Kusner 
et al., 1991; Lonnemann et al., 1995; Niemir et al., 2004), while IFN-g has been shown to 
downregulate  IL-8  production.  Both  spontaneous  and  LPS-induced  release  of  IL-8  is 
significantly higher in patients with either proliferative or non-proliferative GN than in 
healthy controls (Matsumoto, 1995). Thus, it seems likely that human PTEC are a potential 
renal source of IL-8 and that various inflammatory mediators can induce the release of IL-
8 in the proximal tubule. 
Whilst  the  above  cytokines  are  thought  to  play  a  role  in  both  the  initiation  and 
amplification phases of the immune response, RANTES appears to be involved only in the 
latter. Studies have shown that the release of RANTES by PTEC is more pronounced in the 
presence of T-cell-derived IFN-g (in combination with either IL-la or TNF-a) (Deckers et 
al., 1998). 
1.6.5 Fc receptor signalling 
Our understanding of FcR and antigen receptor signals have developed at a comparable 
rate  as  their  respective  multiple  signal  transduction  pathways  are  remarkably  similar 
(Ravetch,  1997).  The  initiation  of  FcR  and  antigen  receptor  signalling  depends  upon 
phosphotyrosine  and  extracellular  signal-regulated  kinase  (ERK).  Mitogen-activated 
protein kinases (MAPKs), which include ERK and c-jun N-terminal kinase (JNK), mediate 
signal  transduction  from  the  cell  surface  to  the  nucleus  (Cano&Mahadevan,  1995; 
Su&Karin, 1996). Phosphotyrosine is important in the early stages of signalling, while the 
Ras–Raf–MAPK/ERK  kinase–ERK  pathway  influences  cellular  proliferation, 
differentiation and survival (Kolch, 2000). The identification of the signalling pathways 
involved  in  the  regulation  of  cytokine  gene  expression  by  PTEC  may  lead  to  novel 
therapeutic interventions. 
MAPK activation involves the dual phosphorylation of conserved threonine and tyrosine 
residues,  leading  to  the  downstream  phosphorylation  and  activation  of  target  proteins, 
which  may  subsequently  lead  to  altered  gene  expression.  In  renal  diseases,  MAPK 
activation  has  been  shown  to  occur  in  response  to  both  growth  factors  and  pro-
inflammatory  cytokines  (Schramek  et  al.,  1996;  Schramek  et  al.,  1997).  A  study 
investigating how MAPK activation regulates the release of IL-6 in cultured human PTEC 
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suggested that the JNK pathway may interfere with other signalling pathways involving 
NF-kB and possibly ERK (Javaid&Quigg, 2005). 
Ligand binding of TGF-b with its cell surface receptors generates a heteromeric complex 
that results in the activation of signalling intermediates and initiates the transcriptional 
activation of various target genes (Tian et al., 2003). Owing to its highly pleiotropic nature, 
TGF-b1 is known to activate other signalling pathways in addition to the Smad proteins 
(Edlund et al., 2002; Hocevar et al., 1999). In a study by Zhang et al., IL-1b-induced 
transdifferentiation of renal PTEC is characterised by an upregulation of a-SMA and of 
cell migration, in addition to increased activity of ERK, JNK and p38 MAPK, suggesting 
that the JNK and p38 MAPK signalling pathways may mediate this process (Zhang et al., 
2005).  The MAPK signalling pathway depends upon the early activation of PTEC by IgG 
and  the  subsequent  expression  and  activation  of  ERK.  Studies  in  experimental  animal 
models have reported that bovine IgG induces endothelin-1 secretion in rabbit PTEC (Zoja 
et al., 1995) and RANTES production and NF-kB activation in pigs (Zoja et al., 1998). A 
recent study in humans reported increased ROS and NF-kB activation in PTEC stimulated 
with human IgG and albumin (Morigi et al., 2002). Studies of renal biopsies from patients 
with IgG proteinuria have suggested that in vivo events appear to correspond with those 
observed in vitro. 
1.7 Aim of the study 
The main aim of this thesis was to investigate the expression of the Ig receptors involved in 
the pathogenesis of renal disease involving PTEC-induced primary GN and whether the 
expression  of  these  receptors  were  stimulated  by  pro-inflammatory  cytokines.  I 
hypothesised that renal tubular cells might be exposed to, and in turn activated by ICs, and 
thus may contribute to tubular damage, fibrosis and enhance GN. Depending on whether 
the  Igs  bind  to  their  specific  receptor,  I  sought  to  elucidate  the  effect  of  binding  on 
cytokine production, FN production, signalling pathways and proliferation of PTECs. In 
particular,  this  project  aimed  to  expand  our  knowledge  about  the  novel  IgA  receptor, 
Fca/mR. In addition, I examined two different models of nephrotoxicity in PTEC: (a) the 
effect of immunosuppressive agents, and (b) the effect of HMG-CoA inhibitors (statins), 
which  have  known  immunomodulatory  effects.  I  hypothesised  that  immunosuppressant 
agents/statins either alone or in combination with LPS might affect Ig receptors expression, 
cytokine release, FN production and proliferation by PTEC (Figure 1-10). C C Ch h ha a ap p pt tte e er r r    1 1 1          I IIn n nt ttr r ro o od d du u uc c ct tti iio o on n n, 72 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure   1-10 Summary of the experiments undertaken and hypotheses made relating to this 
thesis.
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2  Outline of experimental plan 
In  GN  and  experimental  models  of  renal  disease,  the  deposition  of  Ig  and  ICs  in  the 
glomeruli and tubulointerstitium of the kidney is an important factor in determining the 
severity and progression of disease. For example, in IgAN, mesangial IgA deposition is 
associated with mesangial proliferation and matrix production, in some cases leading to 
glomerulosclerosis and renal failure. However, the mechanism by which this occurs is not 
fully understood. Our group discovered a novel IgA receptor, the Fcα/ R, on mesangial 
cells, which might be involved in IgAN. This receptor binds both IgA and IgM (the latter 
more strongly) but not IgG (McDonald et al., 2002). Rather than proteinuria being a non-
specific effect of renal injury we have developed a hypothesis that Ig and IC, filtered at the 
glomerulus,  may  act  on  Ig  receptors  in  human  PTEC,  which  are  a  pathological 
characteristic of glomerular and tubular damage. 
This project aimed to unravel the Fc receptors (FcγRI, FcγRIIA, FcγRIIB and FcγRIII, 
FcαR,  g-chain,  FcRn,  pIgR,  Fcα/µR)  expressed  by  primary  and  immortalised  (HK-2) 
human PTEC, using techniques like semi qualitative reverse transcriptase-PCR (RT-PCR), 
quantitative real-time PCR (qRT-PCR), immunoblotting and immunohistochemistry (IHC) 
to characterise the receptors present in these cells. 
Receptor expression and their regulation by cytokines implicated in primary renal disease 
and the effect of receptor engagement to PTEC was studied using RT-PCR, qRT-PCR and 
IHC followed by which, the role of cytokines (e.g. IL1-α, TGF-β1, IFN-γ) in GN was then 
investigated. 
Finally  functional  effects of  Ig/IC binding may alter  cell proliferation, ECM (e.g.  FN) 
formation and cytokine release, which are a pathological characteristic of glomerular and 
tubular damage on PTEC and were assessed by ELISA and [
3H]-thymidine incorporation 
respectively. 
I  also sought to determine the effect of immunomodulators such  as immuosuppressive 
agents and statin therapy alone or in combination with the role of proinflammatory LPS 
action  to  determine  Ig  receptors  expression,  proliferation,  cytokines  release  and  FN 
production on PTEC. This was studied in vitro by techniques such as qRT-PCR, [
3H]-
thymidine incorporation and ELISA. 
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2.1 Material 
2.1.1 Biochemicals 
Unless otherwise stated, all chemicals were purchased from Sigma-Aldrich (Irvine, UK). 
Tissue  culture  products  were  purchased  from  Gibco
Ô  Invitrogen  Corporation  (Paisley, 
UK). 
2.1.2 Immunochemicals 
A full list of all commercial antibodies and other immunochemicals used in this study is 
given in Table 2-1. 
2.2 Cell biology techniques 
2.2.1 Cell culture 
All cells were grown at 37°C in a water-saturated atmosphere containing 5% CO2 and were 
typically maintained in 75 cm
2 tissue culture flasks in a 20 ml volume. 
2.2.1.1  Human Proximal Tubular cells (PTEC) 
Human  PTEC  were  derived  from  the  normal  pole  of  human  nephrectomy  specimens, 
characterised and cultured as described by Mistry et al. (2001) and kindly provided as a 
gift  by  Dr.  James  McLay  (Department  of  Medicine  and  Therapeutics,  University  of 
Aberdeen, Aberdeen, UK). PTEC were cultured in Dulbecco’s DMEM/NUT mixed with 
F12  Ham’s  media  in  a  1:1  ratio,  supplemented  with  5%  foetal  calf  serum  (FCS),  L-
glutamine  (2  mM),  penicillin  (100  U/ml)  and  streptomycin  (10  mg/ml).  The  human 
transformed PTEC cell line HK-2 (American Type Culture Collection [ATCC], Manassas, 
VA, USA) was cultured in keratinocyte-serum free medium supplemented with epidermal 
growth  factor  (0.1–0.2  ng/ml),  bovine  pituitary  extract  (20–30  mg/ml),  L-glutamine  (2 
mM), penicillin (100 U/ml) and streptomycin (10 mg/ml). Cells were routinely subpassaged 
twice weekly, during which they were centrifuged for 5 min at (400 g) and re-suspended in 
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2.2.1.2  U937 cell line 
U937 cells (Sundstrom&Nilsson, 1976) were routinely cultured in RPMI 1640 medium 
(JRH  Biosciences,  Andover,  UK)  supplemented  with  10%  FCS,  glutamine  (2  mM), 
penicillin (10 U/ml) and streptomycin (10 µg/ml). Cells were maintained at a density of 
between 500,000–2,000,000 cells/ml, as measured using a Neubauer haemocytometer, and 
were routinely subpassaged twice weekly by the method described above. 
2.2.1.3  NK-92 cell line 
The NK-92 cell line (Gong et al., 1994) were routinely cultured in a-minimum essential 
media without ribonucleoside and deoxyribonucleoside but containing glutamine (2 mM), 
sodium bicarbonate (1.5 g/L), inositol (2 mM), 2-mercaptoethanol (0.1 mM), folic acid 
(0.02 mM), 12.5% horse serum, 12.5% foetal bovine serum, penicillin (100 U/ml) and 
streptomycin (10 mg/ml). 
2.2.1.4  COS-7 cell line and CHO cells 
The COS-7 human fibroblast cell line (ATCC, Manassas, VA, USA) was maintained in 
Dulbecco’s modified eagle medium (DMEM) supplemented with 10% FCS, L-glutamine 
(2 mM), penicillin (100 U/ml) and streptomycin (10 mg/ml). Chinese hamster ovary (CHO-
K1) cells (European Collection of Cell Cultures, Salisbury, UK) were cultured in RPMI 
1640 media and supplemented as above. 
2.3 Molecular biology 
The  work  presented  in  this  chapter  focuses  on  attempting  to  quantify  the  levels  of  Ig 
receptors in immortalised HK-2 cell lines and primary PTEC. Cells were cultured in 6-well 
plates and stimulated with the IFN-g (at concentrations of 20 and 200 ng/ml), TGF-b1 (at 
concentrations of 5 and 50 ng/ml) and IL-1a (at a concentration of 50 ng/ml) for 24 hrs 
using a RT-PCR assay and qRT-PCR. 
2.3.1 Reverse transcription-PCR (RT-PCR)  
RT-PCR  rather  than  PCR  alone  is  often  used  in  expression  mapping,  isolating  and 
identifying a specific sequence, and is essentially normal PCR with a preceding step during 
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(mRNA) to convert it back to complementary DNA (cDNA). Operating on a single strand 
of mRNA, reverse transcriptase generates cDNA by combining the RNA base pairs (A, U, 
G, C) with their DNA complements (T, A, C, G). As this cDNA cannot be degraded by the 
RNase  enzymes  found  in  most  reagents  and  on  most  surfaces  in  the  laboratory,  it  is 
considerably more stable than RNA. 
2.3.1.1  RNA extraction for RT-PCR 
Total cellular RNA was isolated from the cultured HK-2 cells using TRIzol
Ò LS Reagent 
(Invitrogen Life Technologies, Paisley, UK) extraction. During this process, cells were 
lysed by resuspending with 1 ml TRIzol
Ò LS Reagent through pipetting. Samples were 
then  incubated  for  5  min  at  room  temperature  (15–30°C)  to  permit  the  complete 
dissociation of nucleoprotein complexes before the addition of 0.2 ml chloroform per 1 ml 
of TRIzol
Ò LS Reagent. Tubes were shaken vigorously by hand for 15 sec then incubated 
for 3 min at room temperature to ensure good chloroform phase separation. Tubes were 
centrifuged at 13,000 rpm (11,000 g) for 15 min at 4°C. The aqueous layer, which contains 
the RNA, was then transferred to a fresh tube and 0.5 ml of isopropanol was added to 
precipitate RNA followed by centrifugation (11,000 g for 10 min) at 4°C. The samples 
were incubated at room temperature for 10 min followed by centrifugation (13,000 rpm 
[11,000 g] for 10 min) at 4°C. The RNA pellet was then washed with 1 ml of 75% ethanol 
in diethylpyrocarbonate (DEPC)-treated water followed by vortexing and centrifugation at 
7,500 g for 5 min at 4°C. The RNA pellet was allowed to dry in air for 5–10 min then 
resuspended in 30 ml of DEPC-treated water and stored at –70°C. 
2.3.1.2  RNA concentration measurement 
The concentration of a known volume of RNA was determined by measuring absorbance 
at 260 nm and 280 nm as estimated using a Beckman DU640B spectrophotometer blanked 
against  DEPC  water.  RNA  quality  was  estimated  by  looking  at  the  absorbance  ratio 
A260/A280.  Pure  RNA  has  an  absorbance  ratio  of  approximately  2.  RNA  samples  were 
stored at –70°C. 
2.3.1.3  cDNA synthesis for RT-PCR  
For RT-PCR, first-strand cDNA synthesis was prepared using oligo(dT), a Superscript
Ô 
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Less than 5 mg of total RNA was incubated with 1 ml of 10 mM dNTP mix and 1 ml of 
oligo (dT) (0.5 mg/ml) in a total volume of 10 ml for 5 min at 65°C, before being placed on 
ice for 1 min. A reaction mixture containing 10´ RT buffer (2 ml), 25 mM MgCl2 (4 ml), 
0.1M DTT (2 ml) and RNaseOut
Ô Recombinant RNase Inhibitor (1 ml) per sample was 
prepared and added. The samples were then incubated at 42°C for 2 min before 1 ml (50 
units) of Superscript
Ô II RT was added. The reactions were continued at 42°C for 50 min 
and terminated after reacting at 70°C for 15 min. The samples then were placed on ice 
before being diluted by adding 80 ml of distilled water to give a final volume of 100 ml. 
They were then stored at –20°C. 
2.3.1.4  RT-PCR reaction 
The cDNA generated in the first phase of RT-PCR can be used as a template for the second 
phase, the PCR reaction. This reaction also relies on a non-mammalian enzyme, in this 
case a bacteria-derived DNA polymerase called Taq, the thermostable properties of which 
means it can resist being denatured even at the very high temperatures at which DNA 
strands can be separated. In the PCR reaction, the length of the amplified DNA sequence 
can be extended using forward and reverse primers. In doing this, millions of copies of the 
original sequence can be produced. 
PCR was performed using a PTC-100 programmable Thermal Controller or Minicycler
Ô 
(MJ  Research  Inc).  PCR  reactions  were  carried  out  in  a  50  ml  volume.  A  mastermix 
containing 10´ PCR buffer, 2.5mM MgCl2, dNTP mix (final concentration 200 mM of 
each dNTP) and 20 pM of each primer was prepared and added to each tube (Table 2-2). 
Template cDNA in a 5 ml volume (or distilled water as a control) was then added before 
the addition of Taq. Taq DNA polymerase was added at a volume of 1 ml per reaction and 
the samples were subsequently kept on ice before being placed in the cycler with the block 
already heated to a denaturing temperature. 
The  reaction  was  conducted  according  to  the  following  programme:  samples  were 
denatured at 94°C for 90 sec, followed by 30–36 cycles of denaturation at 94°C for 30 sec, 
primer  annealing  for  60  sec  at  a  temperature  determined  by  the  specific  primer 
combination (Table 2.3) and DNA extension at 72°C for at least 60 sec. A final extension 
at 72°C was then performed for 5–10 min. 
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2.3.1.5  Agarose gel and electrophoresis of DNA 
 PCR products were typically electrophoresed at 70 V through 1–2% (w/v) agarose gels, 
depending on the product size required in the 1´ tris-acetate (TAE) electrophoresis buffer 
(40 mM Tris-acetate, 1 mM EDTA, pH 8). For this, 20 ml of the sample were mixed with 
6´ blue/orange loading buffer (Promega, UK) and loaded on the agarose gels. The gels 
were then stained for 15–20 min in a solution containing 2–3 ml/ml ethidium bromide in 
distilled water. Bands were visualised on an ultraviolet transilluminator and photographed 
with  a  Fluro-S
Ò  MultiImager  using  Multi-analyst  software  (Bio-RAD  Laboratories, 
Hertfordshire, UK). 
2.3.2 Quantitative Real Time PCR (qRT-PCR) 
Quantitative real-time PCR is used to determine the presence and the number of copies of a 
specific DNA sequence in a given sample. The ‘real-time’ aspect of this process refers to 
the fact that, unlike in normal PCR, the DNA is quantified after each amplification cycle. 
Combining real-time PCR with RT-PCR enables us to quantify low-abundance mRNA 
using fluourescent dyes and to estimate relative gene expression in a particular cell or 
tissue type at a particular time. 
2.3.2.1  RNA extraction for Real time PCR 
The  relative  levels  of  mRNA  expression  for  a  range  of  Ig  receptors  were  assessed  by 
fluorescent real-time PCR. Total RNA was extracted using a Qiagen column extraction 
system (Table 2-1) in order to obtain a purer RNA than is possible to achieve using the 
TRIzol protocol. When used for normal extraction, the TRIzol protocol and ethanol can 
affect the fluorescein SYBER green in gene amplification and may give erroneous results. 
As previously stated, HK-2 cells were grown on 6-well plate to confluence before the 
addition of the proinflammatory cytokines IFN-g, TGF-b and IL-1a to each well for 24 
hrs.  The  samples  were  disrupted  and  lysed  by  adding  300  ml  of  lysis  buffer  (b-
mercaptoethanol  added  to  GITC-containing  buffer  RLT).  The  samples  were  then 
homogenised in order to shear genomic DNA and reduce the viscosity of the lysate by 
passing it through a 20-gauge needle fitted to a syringe for at least 5–10 min. RNase-free 
water  (590  ml)  and  proteinase  K  (10  ml)  were  then  added  to  digest  and  remove  any 
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incubation in the water bath at 55°C, the samples were centrifuged (10,000 g for 3 min) at 
20–22°C to ensure that the debris was pelleted. The supernatant (approximately 900 ml) 
was then pipetted into a new 1.5-ml tube before 450 ml of ethanol was added to the cleared 
lysate and mixed well by pipetting. 
Of this sample, 700 ml was pipetted into an RNase Mini Spin Column in a 2 ml collecting 
tube and the samples centrifuged (8500 g for 15 sec) at 20–22°C. In doing this, the RNA 
bound to the RNeasy silica gel membrane. 350 ml of RW1 buffer was added to the column 
and centrifuged (8500 g for 15 sec) at 20–22°C before being applied to the RNeasy spin 
column to aid absorption of RNA to membrane. A stock solution (10 ml DNase I to 70 ml 
buffer RDD) was prepared and then the total volume pipetted directly onto the RNase 
silica  gel  membrane  so  that  any  traces  of  DNA  that  may  copurify  were  removed. 
Following incubation at room temperature for 15 min, the column was washed clean of 
DNase and other contaminants using a 350 ml RW1 buffer centrifuged for 15 sec at 8500 g 
at 20–22°C. The column was then transferred into a new 2-ml collecting tube and, by 
adding 500 ml buffer RPE, was washed by centrifuging (8500 g for 2 min) at 20–22°C. 
This step was repeated twice. The column was then transferred to a new 1.5-ml collecting 
tube by pipetting 30 ml RNase-free water directly onto the RNase silica gel membrane. 
Finally, the samples were centrifuged (8500 g for 1 min) at 20–22°C to elute ready-to-use 
RNA in RNase-free water (Fig. 2-1). C C Ch h ha a ap p pt tte e er r r    2 2 2          M M Ma a at tte e er r ri iia a al ll    a a an n nd d d    M M Me e et tth h ho o od d ds s s, 81 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure   2-1 The principles of RNA extraction. 
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2.3.2.2  cDNA synthesis for real-time PCR 
 For  cDNA  synthesis,  a  machine  manufactured  by  iGene  Legends  was  used. 
Approximately  300  ng  was  reverse  transcribed  to  cDNA  using  the  Iscrip
TM  cDNA 
synthesis  kit  according  to  the  manufacturer’s  protocol  (Bio-RAD  Laboratories, 
Hertfordshire, UK). 
2.3.2.3  Real-time PCR 
Identification of Ig receptor genes differentially expressed in immortalised and primary 
PTEC was quantitatively verified by RT-PCR. The relative quantities of the Ig receptor 
gene  transcripts  in  PTEC  cells  were  measured  before  and  after  stimulation  with 
proinflammatory cytokines for 24 hrs by semi-qRT-PCR. Total RNA was extracted  as 
described in section 2.3.2.1 and was processed directly to cDNA synthesis as described in 
section  2.3.2.2.  The  primer  for  Ig  receptors  and  the  housekeeping  gene  b-actin  were 
designed (http://frodo.wi.mit.edu/cgi-bin/primer3) and synthesised by TAGN Ltd. showed 
in table 2-4. The primers were designed to be across different exons to completely abolish 
amplification from genomic contamination. The house-keeping gene b-actin is widely used 
as standard because this protein, essential for maintenance of cell function, is generally 
constitutively expressed at similar level in all cell types and tissues. cDNA was amplified 
using qRT-PCR with fluorescence using SYBR Green which fluoresces on binding to all 
newly synthesized double stranded DNA (ds)DNA. An increase in fluorescence intensity is 
measured, thus allowing initial concentrations to be determined. In this system primers are 
designed to generate a small DNA product to maximise reaction efficiency and the reaction 
takes place in the presence of SYBR Green dye. However, SYBR Green will label all 
dsDNA including any unexpected PCR products, leading to potential complications. 
Fluorescence is measured at the end of each PCR cycle and increases exponentially as the 
reaction progresses. For each reaction the threshold cycles (Ct) is calculated based on the 
point at which a statistically significant increase in the amount of PCR product is detected. 
The Ct inversely reflects the number of target sequences present in each sample prior to 
amplification (Higuchi et al., 1993). 
Five reactions were performed in triplicate, and the mean of five Ct were determined. To 
determine sensitivity of the expression, the amplification of known mRNA concentration 
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generating an mRNA titration curve showing Ct values of these amplifications; these were 
plotted against the logarithm of the relative initial amount of cDNA. The slope of the 
straight line obtained provided a measure of PCR efficiency. The transcription efficiency 
was between 80–100%, thus, at different concentrations of proinflammatory cytokines the 
Ig  receptor  genes  present  at  low  expression  levels  would  be  reliably  quantified.  The 
correlation coefficients obtained were all in excess of 0.999. 
Fluorescent real-time PCR was performed using an iQ SYBER green supermix (Bio-RAD) 
on a Bio-Rad iQ light cycler. Amplification of cDNA aliquots was carried out in 25 ml 
reaction volumes containing 3µl cDNA, and 0.5 µl of each appropriate primer added to 
12.5 µl of the Supermix and brought to a final reaction volume of 25 µl with RNase-free 
water. The thermal cycler conditions included an initial denaturation step at 95°C for 3 min 
followed by 60 cycles at 95°C for 30 s and 60°C for 30 s. In order to assess specificity of 
amplified  product  and  avoid  spurious  results  from  “primer-dimer”  formation  and 
amplification,  dissociation  curves  showing  product  melting  points  were  assessed.  PCR 
products were run on agarose gels to confirm that their size corresponded to the expected 
length. 
2.4 Biochemical assay and methods 
2.4.1 Signalling pathway or Ig-IC cross-linking 
HK-2 cells were grown overnight on a Petri dish and incubated at 37°C. To cross-link 
specific receptors, cells were washed and incubated with specific antibodies (Table 2-1) for 
45  min  at  4°C.  Cells  were  washed  three  times  with  fresh  media  to  remove  unbound 
antibodies and the receptors were cross-linked by the addition specific of anti-Igs (1:50 
dilution; Sigma). Cells were then warmed to 37°C for the specified durations (0, 2, 5, 10 
and 30 min). 
2.4.2 Cell lysate preparation 
In general, cells were lysed by the addition of an ice-cold lysis buffer (1% (v/v) Triton X-
100, 50mM Tris-HCl pH 7.5, 0.25% (w/v) sodium deoxycholate, 150mM sodium chloride, 
1mM  EDTA,  1mM  vanadate  and  1mM  NaF)  containing  protease  inhibitors  (1mM 
phenylmethylsulfonyl fluoride and 1 mg/ml each of chymostatin, leupeptin, antipain and 
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15 min to remove insoluble cell debris. Any medium was removed prior to the addition of 
the  lysis  buffer.  After  30  min  of  tumbling  motion  at  4°C,  lysates  were  either  used 
immediately or stored at –20
 oC prior to electrophoresis. 
2.4.3 Protein quantification (Bradford assay) 
Protein concentrations were determined using the Bio-RAD Protein Assay System for all 
cell lysates, which is based on the Bradford Coomassie brilliant blue dye binding system. 
A range of bovine serum albumin concentrations (0, 2, 5, 10 and 15 mg/ml) was used to 
construct a standard curve and samples were suitably diluted to allow their protein level to 
fall within the linear range of this curve. Light absorbance at 595 nM was measured on a 
Beckman DU640B spectrophotometer. All samples were measured in duplicate. 
 
2.4.4 Sodium  dodecyl  sulphate–polyacrylamide  electrophoresis 
(SDS–PAGE) 
SDS–PAGE was carried out using the NuPAGE
Ô Pre-Cast Gel System. The NuPAGE
Ô 
system  works  with  bis-tris  buffered  (pH  6.4)  polyacrylamide  gels,  available  at  three 
different acrylamide concentrations (10% w/v, 12% and 4–12% gradient gels) allowing 
different separation ranges to be selected. The running buffer used was 20x NuPAGE
Ô 
MOPS SDS. After heating to 70°C for 10 min, protein samples were  denatured in 4´ 
NuPAGE
Ô LDS (lithium dodecyl sulphate) sample buffer. For reduced proteins, 50 mM 
dithiothreitol was added prior to sample denaturing. 
2.4.5 Western blot analysis 
In Western blot analysis, gel electrophoresis is used to separate denatured proteins by mass 
before they are transferred onto nitrocellulose membrane where they are investigated using 
antibodies  specific  to  the  protein.  Phosphotyrosine,  phospho-ERK  and  Fca/µR  were 
detected by western blot using a monoclonal antibody as described in Table 2-1. Using the 
standard blotting profile outlined in section 2.4.4, the antibody gave a low signal and high 
background and it was therefore necessary to develop a modified protocol. 
The SDS–PAGE gel was prepared and cleaned as per the manufacturer’s instructions and a 
running buffer was used to clean the individual wells of non-polymerised gel solution to 
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buffer (20´). Samples prepared in SDS sample buffer (as described in section 2.4.4) were 
loaded  into  wells  and  the  ladder  was  pipetted  into  the  first  well.  Proteins  were  then 
electrophoresed using a Bio-RAD power PAC 300 gel unit at a constant voltage of 200 V 
for 1 hr until the bromophenol blue tracking dye reached the bottom of the gel. 
For  Western  blotting,  proteins  were  transferred  to  nitrocellulose  membrane  using  the 
Novex XCell II Surelock™ blotting apparatus. To confirm adequate transfer and equal 
loading of lanes, membrane was washed with Panceau S solution for 5 min to visualise the 
proteins, followed by washing with dH2O and TBS (20 mM Tris.HCl [pH 7.6] and 136 
mM  NaCl)  containing  0.1%  (v/v)  Tween  20  (TBST).  A  nitrocellulose  membrane  was 
blocked in TBST with 4% non-fat milk (Marvel) for 1 hr at room temperature and washed 
in wash buffer three times. Typically, blots were incubated with primary antibodies (Table 
2.1) diluted 1:200 in 4% milk-TBST overnight at 4°C. Membrane was washed three times 
for 10 min each in wash buffer at room temperature in a shaker and incubated with the 
appropriate horseradish peroxidase conjugated secondary antibody diluted 1:2000 in 4% 
milk-TBST  for  2  hrs  at  room  temperature  with  shaking.  Blots  were  then  washed 
extensively with large volumes of TBST (typically 5×5 min washes) followed by a final 
wash  in  dH2O  prior  to  developing.  For  development  using  the  enhanced 
chemiluminescence  detection  system  ECL-Detection,  equal  volumes  of  reagent  1  with 
reagent 2 were used. Under red light in a dark room the X-ray film was developed using a 
Kodak X-Omat 2000 Processor. For quantification of expressed protein, radiographs were 
scanned and densitometry of expressed band was performed using Kodak ID software. 
2.4.6 Anti-Fcα/  receptor antibodies purification 
Fca/mR antibody was provided by the Chinese Academy of Medical Sciences, Beijing, 
China (Wei Zhang, Ying Fu). An IgG1 monoclonal antibody (clone 10C4) against human 
Fcα/ R was produced using  cDNA coding  for the EC2 exon (McDonald et al., 2002) 
ligated into a pET-30a vector (Novagen) and expressed in E. coli. The expressed protein 
was used for immunization of BALB/c mice. The first immunization used 30  g of protein 
in complete Freund's adjuvant and subsequent injections were given at 3-week intervals 
using antigen in incomplete Freund's adjuvant.  Five weeks after the last injection, one 
mouse was challenged intravenously with 30  g of antigen and fusion was done three days 
later using mouse spleen cells and myeloma Sp2/0 cells. Successfully fused cells were 
screened  for  antibody  production  against  Fcα/ R  and  positive  cells  were  further  sub-C C Ch h ha a ap p pt tte e er r r    2 2 2          M M Ma a at tte e er r ri iia a al ll    a a an n nd d d    M M Me e et tth h ho o od d ds s s, 86 
cloned.  Antibodies  secreted  in  culture  supernatants  were  purified  using  a  protein  A 
column. 
2.4.7 Fc receptor aggregation 
2.4.7.1  Preparation of heat-aggregated IgG (HAg-IgG) 
IgG was heat aggregated by heating human IgG at a concentration of 50 mg/ml to 65°C for 
30 min.  The aggregated IgG was pelleted by micro centrifugation at 13,000 rpm (11,000 
g)  for  30  min,  and  then  washed  three  times  with  phosphate  buffered  saline  (1×PBS) 
(0.07M NaCl, 75 mM disodium hydrogen orthophosphate and 5 mM sodium dihydrogen 
orthophosphate, pH 7.2). The protein concentration was measured by Bradford’s assay (as 
described  in  section  2.4.3).  The  measured  protein  concentration  of  28  mg/ml  was 
equivalent to actual concentration of 50 mg/ml of IgG. The concentration of HAg–IgG 
used on HK-2 cells was 100 µg/ml. 
2.4.7.2  Preparation of heat-aggregated IgA (HAg–IgA) 
IgA was heat aggregated by heating human IgA at a concentration of 2.4 mg/ml to 65°C 
for 1 hr. The aggregated IgA was pelleted by microcentrifugation at 13,000 rpm (11,000 g) 
for  30  min,  and  then  washed  once  with  1×PBS.  Again,  the  protein  concentration  was 
measured  by  Bradford’s  assay.  The  measured  protein  concentration  of  1.4  mg/ml  was 
equivalent to actual concentration of 2.4 mg/ml of IgA. The concentration of HAg-IgA 
used on HK-2 cells was 100 µg/ml. 
2.4.8 Immunofluorescence  and  laser  scanning  confocal 
microscopy 
Cells  stained  with  fluorescent  dyes  are  said  to  contain  immunofluorescently  labelled 
antibodies and antigens and are studied either by using a fluorescence microscope or by 
confocal microscopy. Human monozygotic U937 cells primed in fresh medium with 1 mM 
dibutyryl cyclic AMP (dbcAMP) for 48 hrs prior to experiments as per Cameron et al. 
(Cameron et al., 2002) were used as a positive control for the experiments. Differentiation 
of these cells to a macrophage phenotype with dbcAMP induces both mRNA and protein 
expression of the inhibitory IgG (FcgRIIA) receptor. Typically, one million U937 cells 
were washed with ice-cold PBS and resuspended in 100 ml PBS with 1 mg the appropriate 
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antibodies with the Fc receptors, 3 mM monomeric human IgG was added if needed. After 
being  incubated  on  ice  for  45  min,  the  cells  were  washed  three  times  with  PBS  and 
incubated  for  a  further  45  min  with  a  fluorescrin  isothiocyanate  conjugated  goat  anti-
mouse  IgG secondary antibody (1:100 dilution). Nonspecific isotype control antibodies 
were used to control for nonspecific labelling. Cells were harvested by centrifugation (400 
g for 5 min) at 4°C onto chrome/alum coated glass slides. 
HK-2 cells were grown on glass coverslips for 24 hrs. The cells were washed with 0.2% 
bovine serum albumin (BSA) in PBS  and incubated at 4°C with 100  mg/ml of biotin-
conjugated IgG, monomeric IgA or IgM (Table 2-1). Cells were also incubated with biotin-
conjugated IgM Fc-m fragment in 0.2% BSA for 45 min. Washed cells were then incubated 
with 90 mg/ml of fluorescein (DTAF)-conjugated streptavidin (Jackson Immuno Research 
Laboratories) at 4°C for 45 min and subsequently lightly stained with propidium iodide 
(0.1 mg/ml, for 10–15 mins at 4°C) to heavily stain the nuclei, which also lightly stained 
the cytoplasm. The cells were then washed once with PBS. The coverslips were mounted 
using Vectorshield mounting medium. 
For specific Fcα/ R staining, washed cells were incubated in a 1:50 dilution of mouse anti-
Fcα/ R antibody (Table 2-1) at 4°C for 45 min. After further washing, a FITC-labelled 
goat anti-mouse antibody was added for 45 min at 4°C before visualisation. Nonspecific 
isotype control antibodies were used to control for nonspecific labelling. Ig binding was 
analyzed  using  a  laser  scanning  confocal  microscopy  imaging  system  (Bio-RAD, 
Hertfordshire, UK; excitation: 488 nm, emission: 515 nm). 
 
2.4.9 Immunohistochemistry for the Fcα/  (DAB) staining 
Immunohistochemistry  is  a  widely  used  technique  that  allows  us  to  visualise  binding 
between  antibodies  and  antigens  by  using  antibodies  conjugated  to  enzyme  (e.g. 
peroxidase)  or  fluorophore  (e.g.  FITC).  This  technique  was  kindly  performed  by  Ian 
Downie,  a  pathologist  at  the  Royal  Infirmary  Glasgow.  Immunohistochemistry  was 
performed on isolated cells grown on glass coverslips or on sections of human kidney 
extracted from the normal pole of tumour nephrectomy specimens (the latter was used for 
staining with human anti-Fca/mR, diluted 1:2000). Three-micron paraffin sections were 
dewaxed  for  10  min  in  xylene  and  then  dipped  in  graded  alcohols.  Prior  to 
immunostaining, heat-mediated antigen retrieval was performed using Tris buffer/EDTA C C Ch h ha a ap p pt tte e er r r    2 2 2          M M Ma a at tte e er r ri iia a al ll    a a an n nd d d    M M Me e et tth h ho o od d ds s s, 88 
(pH 8) in a pressure cooker. The solution was brought to boil before immersing slides for 5 
min  at  full  pressure.  The  slides  were  allowed  to  cool  for  20  min  and  then  washed  in 
running water. 
The sections were immunostained in a Dako Autostainer using Envision Peroxidase. The 
slides were washed with TBS/10% Tween buffer for 30 s before treatment with blocking 
serum  (1:20  normal  goat  serum)  for  20  min  and  subsequently  anti-Fca/mR  primary 
antibody. After rinsing, slides were incubated in Dako Envision for 30 min and visualised 
using 3,3-diaminobenzidine (DAB substrate KIT for peroxidase) for 10 min.  
Finally,  after  30-s  rinses with TBS/Tween buffer, the location of the antigen–antibody 
complex was visualised using 3,3-diaminobenzidine. The slides were then washed with 
water, counterstained using haematoxylin (nuclear stain), placed in copper sulphate for 5 
min and then dehydrated, cleared and coverslipped. 
2.4.10  PTEC proliferation assay 
The  first  indirect  use  of  [
3H]-thymidine  uptake  assay  in  biochemical  research  was  the 
identification of dividing cells by incorporation of radiolabelled thymidine and subsequent 
measurement of the radioactivity to identify the dividing cells. For this purpose, tritiated 
thymidine is included in the growth medium. In spite of errors in the technique it is still 
used to determine the growth rate of the cells. Thymidine (or deoxythymidine) is a DNA 
nucleoside with a key function in the synthesis of DNA and therefore in cell division. 
Deoxythymidine is present in the body fluids as a result of degradation of DNA from live 
and from dead cells. 
The total number of cells was calculated using a standard haemocytometer. Suspension 
cells  were  diluted  in  trypan  blue  1:1  (v:v)  and  injected  under  a  coverslip  on  a 
haemocytometer. Cells were counted in four defined areas and the mean calculated. Next, 
cells were seeded onto 96-well plates in replicates of six at a confluency of 5×10
4 cells/ml 
for  48  hrs.  Proliferation  was  measured  by  [
3H]-thymidine  uptake  using  standard 
methodology. For the final 18 hrs, 1 mCi [
3H]-thymidine was added to each well. Cells 
were harvested onto filter paper using an automated cell harvester and the amount of [
3H]-
thymidine incorporated into replicating DNA counted by Betaplate (1205) flatbed liquid 
scintillation counter. C C Ch h ha a ap p pt tte e er r r    2 2 2          M M Ma a at tte e er r ri iia a al ll    a a an n nd d d    M M Me e et tth h ho o od d ds s s, 89 
2.4.10.1  Morphology of PTEC 
The cells were grown in four chambers mounted on a glass slide with cover (Lab-Tek
®II 
Chamber Slide™ Systemat, USA) at a confluency of 5×10
4 cells/ml. The pictures were 
taken at magnification ×100. 
2.4.10.2  H & E staining 
This technique was kindly performed by Dr Barbra Young in the pathology department at 
Glasgow University using standard protocol for H & E staining. 
 
2.5 Manufactured kits 
2.5.1 FN measurement 
The human FN ELISA kit is a 96-well system that allows the easy measurement of FN 
from  most  samples.  There  are  two  incubation  steps:  the  first  with  specific  primary 
antiserum (rabbit polyclonal) raised against highly purified human FN and the second with 
an alkaline phosphatase human FN conjugate. The wells are pre-coated with antibody that 
causes a separation of bound and free fractions and permits the estimation of the amount of 
bound enzyme by absorption at 400–410 nm after incubation. This information is desirable 
as it is known to be inversely proportional to FN concentration, which ranges from 25–
2000 ng/ml as standard. 
FN  production  by  PTEC  was  measured  in  response  to  Ig  cross-linking  or 
immunomodulatory agents using ELISA. PTEC were grown to confluency in 6-well plates. 
In studies of matrix production, TGF-b (50 ng/ml) was used as a positive control. Cells 
were incubated at 37°C for 72 hrs, followed by three washes with 0.05M Tris Cl in 15M 
NaCl at pH 7.5. Matrix was removed from the plate using the same buffer (50 mM Tris 
HCl in 150mM NaCl at pH 7.5). Cell pellets were collected by centrifugation at 13,000 
rpm (11,000 g) for 15 min and resuspendend in the above buffer with the addition of 
aprotinin  5  µg/ml,  phenylmethylsulfonyl  fluoride  0.5  mM  and  urea  in  a  0.6  g/ml 
suspension. The samples were mixed by vortexing and incubated in a heat block at 37°C 
for 2 hrs to dissolve the urea before being transferred to a dialysis tube. Dialysis against 
0.01M 3-(cyclohexylamino)-1-propane sulfonic acid (CAPS), pH 11, at room temperature 
for 24 hrs purified the FN. Next, the samples were neutralised by the addition of 1/10 C C Ch h ha a ap p pt tte e er r r    2 2 2          M M Ma a at tte e er r ri iia a al ll    a a an n nd d d    M M Me e et tth h ho o od d ds s s, 90 
volume of 0.5M Tris Cl, pH 7. The ELISA was performed according to the manufacture’s 
instructions. 
2.5.2 Measurement of cytokine release 
Cytokine release  was studied using ELISA techniques with the aim of quantifying the 
amount of protein in cell culture media after 24-hrs stimulation with IgG, XL-IgG, HAg-
IgG, IgA, IgA-XL, HAg-IgA and IgM. 
2.5.2.1  IL-6, IL-8, GM-CSF ELISA 
HK-2 cells were seeded onto a 24-well plate in 0.5 ml complete medium to confluency. 
Fresh media was supplemented with either a variety of Ig (with and without cross-linking), 
HA-Ig, growth factor or immunomodulatory agents or statins (Table 2-1). Cells treated 
with 10 mg/ml LPS alone were used as a positive control and untreated HK-2 cells served 
as a negative control. Cells were incubated at 37°C for 24 hrs. Supernatants were collected 
by centrifugation and assessed for IL-6, IL-8, GM-CSF, TNF-a and IFN-g in triplicate 
using  sandwich  ELISA.  The  cells  were  lysed  as  described  in  section  2.4.2  and  the 
concentration of protein measured as described in section 2.4.3 in order to calculate the 
ratio of cytokine release to the supernatant (stored at –20°C for each individual). 
The  cytokine  ELISA  assay  was  a  “sandwich”  enzyme  immunoassay  employing  two 
monoclonal antibodies. Anti-capture antibody is a monoclonal antibody specific for human 
IL-6, IL-8 and GM-CSF. This was diluted in ELISA coating buffer and 100 ml added to 
each well of a 96-well ELISA plate. Plates were sealed with wax paper and incubated for 
18 hrs at 4°C before being warmed to room temperature. Excess capture antibody was 
removed by washing with 2´PBS with 0.05% Tween-20. Non-specific peptide binding was 
blocked  by  incubating  each  well  for  2  hrs  at  room  temperature  with  100  ml  ELISA 
blocking  buffer.  Blocking  buffer  was  removed  by  three  washes  with  PBS  with  0.05% 
Tween-20. 
The samples and standards were prepared in assay diluent (PBS with 10% FCS). Standards 
were prepared in multiple dilutions with concentrations up to 120 ng for IL-6 and GM-CSF 
to  100  ng  for  IL-8.  100  ml  samples  and  standards  were  pipetted  into  wells  where  the 
capture antibody bound any cytokine protein. The plate was then sealed with wax paper C C Ch h ha a ap p pt tte e er r r    2 2 2          M M Ma a at tte e er r ri iia a al ll    a a an n nd d d    M M Me e et tth h ho o od d ds s s, 91 
and incubation was allowed to continue for a further 2 hrs. Unbound material was washed 
away five times with PBS with 0.05% Tween-20. 
Biotinylated  anti-IL-6,  IL-8,  and  GM-CSF  with  avidin-horseradish  peroxidase  (HRP)-
conjugated  was  diluted  1:250  in  assay  diluent,  and  100  ml  was  added  to  each  well. 
Incubation was allowed to continue for 1 hr at room temperature and plates were washed 
seven  times  with  PBS  with  0.05%  Tween-20.  Following  incubation  and  washing,  the 
chromogenic substrate solution tetra-methylbenzidine (TMB) and hydrogen peroxide, was 
added 100 ml per well and incubated at room temperature in the dark until catalysed from a 
colourless solution to blue by the HRP, then yellow by adding the stop solution of 1M 
sulphuric acid (H3PO4). The intensity of colour was proportional to the amount of the 
cytokine protein present. Absorbance was measured at 450 nm within 30 min, standard 
curves were calculated and samples were measured in reference to these. 
2.5.2.2  Cytokine array kit (ProteoPlexÔ Ô Ô Ô) 
The  ProteoPlex  16-well  human  cytokine  array  is  designed  for  multiplex  detection  and 
measurement of 12 human cytokines in parallel from up to 16 experimental samples. The 
cytokines measured in the kit are pro- and anti-inflammatory cytokines important for the 
study of immune system regulation and diseases, namely IL-1a, IL1-b, IL-2, IL-4, IL-6, 
IL-7, IL-8, IL-10, IL12, GM-CSF, IFN-g and TNF-a. Each well on the slide contains a 
microarray  of  spotted  antibodies  with  four  ‘spots’  for  each  of  the  12  cytokines,  plus 
additional spots for positive and negative controls. The replicate spots provide reliable 
quantitative data from a single sample (Fig. 1-2A, B). 
The protocol for these experiments was identical to that described in section 2.5.2.1 for the 
incubation of Ig and cross-linking with HK-2 cell lines for 24 hrs. The cytokine array was 
performed according to the manufacturer’s instruction. The detection range was 5–2500 
pg/ml  and  the  standard  curve  range  from  15–800  pg/ml.  The  slides  were  scanned  and 
analysed by Merck Biosciences by using SensiLight™PBXL-3 (Cyc5 wavelengths 633 nm 
excitation; 660 nm emission). C C Ch h ha a ap p pt tte e er r r    2 2 2          M M Ma a at tte e er r ri iia a al ll    a a an n nd d d    M M Me e et tth h ho o od d ds s s, 92 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure   2-2 ProteoPlex slide map 
(a) This figure provides a map of each microarray, showing the arrangement of the 
12  capture  antibodies,  alignment  spots  (AS),  positive  control  spots  (PS),  and 
negative control spots (blank). 
Adapted from: http://www.genpromag.com/images/0505/arr3_lrg.jpg 
 
 
(B) Strategy of sandwich antibody–antigen binding 
In  the  assay  represented  in  this  figure  the  detection  strategy  is  a  standard 
“sandwich”  immunoassay that relies on biotinylated  detection  antibodies  and a 
streptavidin conjugated fluorophore for detection. Adapted from: 
http://www.emdbiosciences.com/SharedImages/Novagen/EMD_USD_71414 
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2.6 Statistics 
All statistical analyses were conducted using Microsoft Excel 2000. The statistical analysis 
for  qRT-PCR  was  calculated  by  taking  the  average  of  five  experiments  with  three 
replicates in each assay for all of the samples. Each of the experiments had six conditions: 
control (unstimulated PTEC), cells treated with IL-1a, TGF-b and IFN-g. In some cases a 
positive control was used, e.g. U937 or NK92 cells. In each experiment, the house-keeping 
gene (b-actin) was used to calculate the Ct. The mean Ct in the five experiments was 
calculated for b-actin and for each of the six conditions. The first step was to calculate the 
difference in average Ct between the expression of b-actin and the gene of interest (e.g. 
FcRn, pIgR) for the control. Secondly, the difference in mean Ct was calculated between 
the expression of the gene of interest for the treatment condition and  the control. The 
relative expression of the Ig receptor gene to the control gene was calculated by squaring 
the difference in mean Ct. 
For the FN, cytokine and proliferation assays, I conducted 3–4 experiments, each with 2–3 
replicates on each plate. In the control condition (unstimulated PTEC), I set the variables 
of interest (FN production, cytokine release and thymidine uptake) to 100% and expressed 
the  results  of  each  treatment  condition  as  a  percentage  of  this  by  calculating  the  ratio 
between the treatment condition and the control. For each sample, I then calculated the 
average percentage across all experiments. Using MINITAB I confirmed that the spread of 
my data followed a Normal distribution. Then, in Excel, I calculated the standard deviation 
(SD)  of  each  variable  and  plotted  the  results.  Each  graph  shows  the  mean  ±  SD  and 
statistically significant differences are indicated where they exist. Significance at the 95% 
level was determined using two-sided t-tests comparing the treatment conditions to the 
control. A value of p<0.05 was considered to be significant. 
As my experiments involved making multiple comparisons, it was appropriate to apply a 
Bonferroni correction to the results of the statistical tests. The Bonferroni correction is 
calculated  by  dividing  the  statistical  significance  of  one  experiment  (ie  0.05)  by  the 
number  of  hypothesis  being  compared.    For  example,  for  experiments  conducted  five 
times, the significance level was adjusted accordingly to 0.01. For experiments conducted 
three times, the significance level was 0.017. For experiments conducted only twice, the 
significance level was 0.025. The Bonferroni correction is a conservative way of ensuring 
that the number of false-positives (i.e. significant associations that occur by chance) is kept 
to a minimum. C C Ch h ha a ap p pt tte e er r r    2 2 2          M M Ma a at tte e er r ri iia a al ll    a a an n nd d d    M M Me e et tth h ho o od d ds s s, 94 
 
Specificity  Usage  Product Provenance 
(ERK) Phospho-p44/42 Map 
Kinase (Thr202/Tyr204) (rabbit)  
WB  Cell Signalling Technology, 
U.K 
[
3H]-thymidine  Proliferation  Amersham PharmicaBiotech, 
Little Chalfont, U.K 
1205 Betaplate scintillation 
counter 
Proliferation  Wallace Oy, Turku, Finland 
20x NuPAGE
Ô MOPS SDS   WB  Invitrogen, Paisley, UK 
Anti-human IgG (rabbit)  WB, FN, Cytokine 
production, Proliferation 
Jackson Immuno Research 
Laboratories, West Grove, 
PA, USA 
Anti-human IgM Fc5m. F(ab')2 
(goat) 
WB, FN, Cytokine 
production Proliferation 
Jackson Immuno Research 
Laboratories, West Grove, 
PA, USA 
Anti-human serum IgA [a chain 
specific] (rabbit) 
WB, FN, Cytokine 
production, Proliferation 
Jackson Immuno Research 
Laboratories, West Grove, 
PA, USA 
Anti-mouse IgG:HRP (sheep)  WB secondary Ab   ECLÔ Amersham 
Biosciences, U.K 
Anti-Phosphotyrosine, mouse 
monolocolonal IgG2bk (4G10
Ò) 
WB  Upstate, U.K 
Bio-Rad iQ light cycler  Real Time PCR  Bio-RAD Laboratories, 
Hertfordshire, U.K 
Bio-Rad Protein Assay  WB, Cytokine 
Production 
Bio-RAD Laboratories, 
Hertfordshire, U.K 
Biotin-conjugated IgA  IHC  Jackson Immuno Research 
Laboratories, West Grove, 
PA, USA 
Biotin-conjugated IgG  IHC  Jackson Immuno Research 
Laboratories, West Grove, 
PA, USA 
Biotin-conjugated IgM  IHC  Jackson Immuno Research 
Laboratories, West Grove, 
PA, USA 
Biotin-conjugated IgM Fc-m 
fragment  
IHC  Jackson Immuno Research 
Laboratories, West Grove, PA, 
USA 
Blocking serum (goat)  IHC  Novocastra, UK 
Bovine serum albumin (BSA)  IHC  Sigma-Aldrich, Irvine, U.K 
CAPS  FN Production  Sigma-Aldrich, Irvine, U.K 
Cell harvester  Proliferation  Wallace Oy, Turku, Finland 
Cyclosporin A  Real Time PCR, 
Cytokine Production, 
FN, Proliferation 
Novartis, Basel, Switzerland 
DAB substrate KIT  IHC  Dako Ltd., Ely, U.K 
Dialysis Tubing  FN Production  Medicall International Ltd., 
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ECL-Detection   WB  Amersham Biosciences, 
Buckinghamshire, UK 
Envision Peroxidase  IHC  Dako Ltd., Ely, U.K 
Ethidium bromide   RT-PCR  Invitrogen, Paisley, UK 
Fcα/ R (clone 10C4 anti-EC2) 
(mouse) 
IHC  Chinese Academy of Medical 
Sciences, Beijing, China (Wei 
Zhang, Ying Fu) 
Fcα/ R (clone 10E8 anti-EC3) 
(mouse)  
WB  Chinese Academy of Medical 
Sciences, Beijing, China (Wei 
Zhang, Ying Fu) 
FITC-labelled goat anti-mouse   IHC  Sigma-Aldrich, Irvine, U.K 
Fluorescein (DTAF)-conjugated 
streptavidin 
IHC  Jackson Immuno Research 
Laboratories, West Grove, 
PA, USA 
Fluvastatin  Real Time PCR, 
Cytokine Production, 
FN, Proliferation 
Novartis, Basel, Switzerland 
FN ELISA kit  FN Production  Biomedical Technologies Inc, 
Stoughton, USA 
Haematoxylin  IHC  Cellpath, UK 
Human GM-CSF ELISA kit  Cytokine Production  BD OptEIAÔBiosciences, 
Oxford, U.K 
Human IFN-g ELISA kit   Cytokine Production  BD OptEIAÔBiosciences, 
Oxford, U.K 
Human IgA  WB, FN, Cytokine 
production, 
Proliferation, IHC 
Jackson Immuno Research 
Laboratories, West Grove, 
PA, USA 
Human IgG  WB, FN, Cytokine 
production, Proliferation 
Jackson Immuno Research 
Laboratories, West Grove, 
PA, USA 
Human IgM  WB, FN, Cytokine 
production, Proliferation 
Jackson Immuno Research 
Laboratories, West Grove, 
PA, USA 
Human IL-6 ELISA kit  Cytokine Production  BD OptEIAÔBiosciences, 
Oxford, U.K 
Human IL-8 ELISA kit  Cytokine Production  BD OptEIAÔBiosciences, 
Oxford, U.K 
Human TNF-a ELISA kit  Cytokine Production  BD OptEIAÔBiosciences, 
Oxford, U.K 
IFN-g  RT-PCR, Real Time 
PCR 
Serotec, Oxford, UK 
IL-1a  RT-PCR, Real Time 
PCR 
Sigma-Aldrich, Irvine, U.K 
iQ SYBER green supermix  Real Time PCR  Bio-RAD Laboratories, 
Hertfordshire, U.K 
IscripTM cDNA synthesis kit  Real Time PCR  Bio-RAD Laboratories, 
Hertfordshire, U.K 
LPS (from Escherichia coli 
055:B5) 
Real Time PCR, 
Cytokine Production, 
FN, Proliferation 
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Nitrocellulose membrane   WB  Schleicher & Schuell 
BioScience , Dassel, Germany 
NuPAGE
Ô Pre-Cast Gel System   WB  Invitrogen, Paisley, UK 
Oligonucleotide primers  Real Time PCR  TAGN Ltd., Newcastle, UK 
Oligonucleotide primers  RT-PCR  MWG-Biotech, Ebersberg, 
Germany 
ProteoPlexÔ 16-well human 
cytokine array kit 
Cytokine Production  Merck Biosciences Ltd, 
Nottingham, U.K 
Rapamycin  Real Time PCR, 
Cytokine Production, 
FN, Proliferation 
Wyeth Pharmaceuticals, U.S.A 
Rnase free water  RT PCR, Real Time 
PCR 
Invitrogen, Paisley, UK 
RNeasyÒ Fibrous Tissue kit  Real Time PCR  QIAGEN Ltd., Crawley, U.K 
SDS-PAGE  WB  Invitrogen, Paisley, UK 
Simvastatin  Real Time PCR, 
Cytokine Production, 
FN, Proliferation 
Merck, USA 
Tacrolimus  Real Time PCR, 
Cytokine Production, 
FN, Proliferation 
Fujisawa,  Munich, Germany 
Taq DNA polymerase  RT-PCR  Promega, Madison, WI, USA 
TGF-b  RT-PCR, Real Time 
PCR, FN 
Serotec, Oxford, UK 
TMB substrate system for 
ELISA 
Cytokine Production  Sigma-Aldrich, Irvine, U.K 
Trypan blue  Proliferation  Invitrogen, Paisley, UK 
Vectorshield mounting medium  IHC  Vector Labs, Peterborough, 
U.K 
X-ray film  WB  Kodak, UK 
 
Table   2-1 Materials, Antibodies, Cytokines, Immunomodulatory 
WB;  Western  blotting,  IHC;  Immunohistochemistry,  RT PCR;  reverse 
transcriptase PCR, FN; Fibronectin, ELISA; Enzyme linked immunosorbent assay. C C Ch h ha a ap p pt tte e er r r    2 2 2          M M Ma a at tte e er r ri iia a al ll    a a an n nd d d    M M Me e et tth h ho o od d ds s s, 97 
 
Target  Name  Sequence (5’ ® 3’)  Product 
size 
       
b actin-for  GGG GTA TGC CCT CCC CCA TGC CAT CCT 
GCG 
b actin 
b actin-rev  TTG GCG TAC AGG TCT TTG CGG ATG TCC 
ACG 
482bp 
       
       
I-for  CAT GTG GTT CTT GAC AAC TCT GCT CC  FcgRI 
I-rev  TGA AAC CAG ACA GGA GTT GGT AAC TGG 
876bp 
       
       
II-for  GCA CAG GAA ACA TAG GCT ACA CG   FcgRIIa 
IIa-rev  GGT ATC TTC TTA GAA AGT CCC 
717 + 
594bp 
       
       
II-for  GCA CAG GAA ACA TAG GCT ACA CG  FcgRIIb 
IIb-rev  GGT GAT TGT GTT CTC AGC CCC 
287bp 
       
       
III-for  ATG TGG CAG CTG CTC CTC CCA ACT G  FcgRIII 
III-rev  GGT GAT GTT CAC AGT CTC TGA AGA CAC 
567bp 
       
       
CD89-F2  CGC TTA AGA TGG ACC CCA AAC AGA CCA C  FcaR 
CD89-R2  GCT CTA GAT TAC TTG CAG ACA CTT GGT G 
880bp 
       
       
amr-for1  GAC AAC TAC CAA GGC TGA TAG G  Fca/mR 
amr-rev  TCT GTC CCT CAG GGT CCT GGA T 
702bp 
       
       
PIGR-for  GCC CGA GCT GGT TTA TGA AG  pIgR 
PIGR-rev  AGC CGT GAC ATT CCC TGG TA 
694bp 
       
       
FcRn-for  CAA AGC TTT GGG GGG AAA AG  FcRn 
FcRn-rev  TGC AGG TAA GCA CGG AAA AG 
359bp 
       
       
GAM3-for  GCC CAA GAT GAT TCC AGC AG   Gamma- 
chain  GAM3-rev  CCG TAA ACA GCA TCT GAG C 
458bp 
       
 
Table   2-2 Primer (forward and reverse) sequences used in RT-PCR C C Ch h ha a ap p pt tte e er r r    2 2 2          M M Ma a at tte e er r ri iia a al ll    a a an n nd d d    M M Me e et tth h ho o od d ds s s, 98 
 
Primer  Annealing Temperature °C 
b actin  60 
FcgRI  57 
FcgRIIa  49 
FcgRIIb  60 
FcgRIII  60 
FcaR  60 
Fca/mR  60 
pIgR  60 
FcRn  59 
g-chain  60 
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Target  Name  Sequence (5’ ® ® ® ® 3’)  Product 
size 
       
b actin-for  GAC AGG ATG CAG AAG GAG ATT ACT  b actin 
b actin-rev  TGA TCC ACA TCT GCT GGA AGG T 
100bp 
       
       
I-for  AAT GGC ACC TAC CAT TGC TC  FcgRI 
I-rev  TGT CAC AGA TGC ATT CAG CA 
100bp 
       
       
II-for  GGG CAC CTA CTG ACG ATG AT  FcgRIIa 
IIa-rev  TTG TCA TCC ACT CAG CAA GC 
100bp 
       
       
II-for  TCC ATT CAG TGG TTC CAC AA  FcgRIIb 
IIb-rev  GTG TAC TCC CCG CTG TCA TT 
100bp 
       
       
III-for  GAC AAA CCT CTC CAC CCT CA  FcgRIII 
III-rev  CTT CCA GCT GTG ACA CCT CA 
100bp 
       
       
CD89-F  TCA CAG ACT CCA TCC ACC AA  FcaR 
CD89-R  GAC GCT TCC TTG TTC AGT GC 
136bp 
       
       
amr-for  TGC TAC CTC TGC GGC ATT G  Fca/mR 
amr-rev  AGA CGC TGT TCC ATA GGA TCT CA 
100bp 
       
       
PIGR-for  CTG GTA CTG GTG TGG AGT GA  pIgR 
PIGR-rev  GCA CCT TCT CAT CAG GAG CA 
120bp 
       
       
FcRn-for  GTC AAA AGT GGC GAT GAG CA  FcRn 
FcRn-rev  TAG CAA GAC ACC GAT GAC GA 
100bp 
       
 
Table   2-4 Primer (forward and reverse) sequences used in Real Time PCR 
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Chapter 3: Ig Receptors Expression and Function in 
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3.1 Introduction 
Expression of Ig receptors on PTEC may play a role in the pathogenesis of human GN. 
However,  little  is  known  about  which  receptors  are  expressed,  the  regulation  of  Ig 
receptors, the relationship of Ig binding and the consequences of the receptor-Ig binding on 
PTEC functions. 
3.2 Study objectives 
In this study I have set out to answer the following questions: 
1. Are Ig receptors FcgRI, FcgRIIA, FcgRIIB, FcgRIII, g-chain, FcaR, FcRn, pIgR and the 
novel Fca/mR expressed by immortalised HK-2 cell lines and by primary PTEC?  
2. Is the expression of Ig receptors regulated by proinflammatory cytokines?  
3. Does the presence of Ig receptors correlate to Ig binding in human PTEC and how is this 
related to Ig receptor expression? 
4. Does the novel Fca/mR antibody specifically bind and localise in biopsy samples in 
kidney and other tissues that express Fca/mR? 
5. What is the effect of Ig/IC on FN production, proliferation, signalling and cytokine 
release by PTEC, thus leading to tubular interstitial fibrosis? 
6. Do Igs affect the morphology of human PTEC? C C Ch h ha a ap p pt tte e er r r    3 3 3          E E Ef fff ffe e ec c ct tt    o o of ff    I IIg g g    R R Re e ec c ce e ep p pt tto o or r rs s s, 102 
 
3.3 Results 
3.3.1 Gene  expression  and  regulation  of  Ig  receptors  by  IL-1a a a a, 
TGF-b b b b, and IFN-g g g g using qualitative RT-PCR 
3.3.1.1  Are Fcg g g gR or Fca a a aR genes expressed by human PTEC? 
I investigated whether the mRNA of Ig receptors was expressed by PTEC and whether the 
modulation of these receptors by proinflammatory cytokines involved gene expression for 
classical FcRs using both immortalised HK-2 cells and multiple primary human cells from 
nephrectomy specimens, as described in Section 2.2.1.1. In this study, unstimulated HK-2 
cell lines and cells stimulated with 20ng/ml and 200ng/ml  IFN-g, 5ng/ml and 50ng/ml 
TGF-b1 for 24 hrs were studied using RT-PCR. I assessed the mRNA for the classical IgG 
receptors FcγRI, RγIIa, RγIIb, RγIII and γ-chain, the related FcRγ chain, or the classical 
IgA receptor (FcαRI) as described in Section 2.3.1.3. The primers sequences are shown in 
Table 2-2. The U937 cell line, known to express FcgRI, RgIIA, RgIIB and γ-chain, was 
used as the positive control and NK-92 served as positive control for FcγRIII. 
U937 cells were treated with 1mM dbcAMP for 48 hrs to induce expression of FcαRI. b-
actin was used as the house-keeping gene in this study. Expressed mRNA for the classical 
IgG  receptors  FcγRI,  RγIIA,  RγIIB,  RγIII,  the  related  γ-chain,  and  the  classical  IgA 
receptor (FcαRI) could not be detected in immortalised HK-2 cells (Fig. 3-1), nor could 
FcgRIII shown in (Fig. 3-2). 
3.3.1.2  Are FcRn, pIgR and Fca a a a/m m m mR expressed by human PTEC? 
The  expression  of  FcRn,  pIgR  and  Fca/mR  by  PTEC  was  also  studied  by  RT-PCR. 
Unstimulated HK-2 cell lines and stimulated cells with 50 ng/ml IL1a, 20 ng/ml, 200 
ng/ml IFN-g, and 5 ng/ml, 50 ng/ml TGF-b were studied. Stimulated cells were incubated 
for 24 hrs. 
The  FcRn  mRNA  showed  no  significant  difference  in  expression  in  cells  treated  with 
either IFN-g or TGF-b1 compared with the U937 positive control. The band shown in Fig. 
3-3A is of expected size, as shown in Table 2-2. C C Ch h ha a ap p pt tte e er r r    3 3 3          E E Ef fff ffe e ec c ct tt    o o of ff    I IIg g g    R R Re e ec c ce e ep p pt tto o or r rs s s, 103 
Cells  treated  with  20  ng/ml  and  200  ng/ml  IFN-g  for  24  hrs  showed  qualitative  up-
regulation in the expression of pIgR mRNA, while the expression was down regulated by 5 
ng/ml and 50 ng/ml TGF-b1 respectively. The band was at the expected size of ~694 bp 
(Fig. 3-3B). 
I investigated whether the Fca/mR could be expressed in PTEC. Untreated cells expressing 
mRNA  for  Fca/mR  were  highly  up-regulated  by  50  ng/ml  IL-1a  and  moderately  up-
regulated by IFN-g. However, the expression was totally inhibited by TGF-b as shown in 
Fig. 3-4. The bands were at the expected size of 702 bp. This was comparable to the results 
obtained by McDonald et al., 2002 in which IL-1a increased the expression of Fca/mR 
mRNA in human mesangial cells. The primers used in this study were described in Table 
2-2. The expressions of all Ig receptors in primary PTEC are shown in Fig. 3-5. 
3.3.2 Expression of FcRn, pIgR and Fca a a a/m m m mR using qRT-PCR 
The  identification  of  Ig  receptors  differentially  expressed  in  immortalised  and  primary 
PTEC was quantitatively verified by RT-PCR. The relative quantities of the Ig receptor 
gene transcripts in PTEC cells were measured before and after proinflammatory cytokines 
stimulation for 24 hrs by semi-qRT-PCR. Total RNA was extracted as described in section 
2.3.2.1 and was processed directly to cDNA as described in section 2.3.2.2. The primers 
for Ig receptors and the house-keeping gene (b-actin) were designed (Primer 3 software) 
and synthesised by TAGN Ltd. are shown in Table 2-4. The primers were designed to 
cross different exons to completely abolish amplification from genomic contaminations. 
The  house-keeping  gene  b-actin  is  widely  used  as  a  standard  because  this  protein  is 
essential for maintenance of cell function and is generally constitutively expressed at a 
similar  level  in  all  cell  types  and  tissues.  cDNA  was  amplified  using  qRT-PCR  with 
SYBER green as described in section 2.3.2.3. 
The  relative  expression  of  FcRn  showed  no  significant  or  unaffected  fold  differences 
relative  to  b-actin  in  unstimulated  cells  or  cells  up-regulated  with  proinflammatory 
cytokines at the concentration previously used in RT-PCR in both HK-2 cells and primary 
PTEC. cDNA for NK92 cells was used as positive control and the fold differences in 
expression is shown in HK-2, as shown in Figure 3-6, and primary PTEC, as shown in 
Figure 3-7. C C Ch h ha a ap p pt tte e er r r    3 3 3          E E Ef fff ffe e ec c ct tt    o o of ff    I IIg g g    R R Re e ec c ce e ep p pt tto o or r rs s s, 104 
Amplification of pIgR showed up-regulation with the various concentration of IFN-g while 
no regulation or expression with either concentration of TGF-b1. The fold differences of 
pIgR expression are greater in primary PTEC than seen in HK-2 cells. The cDNA for U937 
cells was used as negative control as shown in Fig. 3-6, 3-7. 
The expression of Fca/mR in both cell lines and primary PTEC increased by 50 ng/ml 
IL1a compared with the unstimulated cells. It was moderately up-regulated with either 
concentration of IFN-g, while only slightly regulated or reduced in response to TGF-b1. 
The fold differences in expression are showed in Fig. 3-6, Fig. 3-7 relative to b-actin. Each 
reaction was performed in triplicate and the mean of five Ct was determined. To determine 
sensitivity of the expression, the amplification of known mRNA concentration in serial 
dilutions was measured. Thus, at different concentrations of proinflammatory cytokines, 
the Ig receptor genes present at low expression levels could be reliably quantified. PCR 
efficiency was assessed for all primer pairs by generating mRNA titration curves as shown 
in Fig. 3-8A, shows Ct values of these amplifications plotted against the logarithm of the 
relative initial amount of cDNA. The slope of the straight line obtained provided a measure 
of PCR efficiency. Efficiency was 100%, ensuring the doubling of the amplified target 
gene at each cycle. Figures 3-8B and C show the Ct values and melting curves for Fca/mR 
and b-actin, respectively. 
These  results  showed  significant  effects  in  expression  of  mRNA  for  FcRn,  pIgR  and 
Fca/mR after stimulation with proinflammatory cytokines in HK-2 cells and primary PTEC 
induced an expression at biologically significant levels. 
Fig. 3-9 shows that there were no fold differences in expression of FcgRI, FcgRIIB and 
FcgRIII relative to the control U937 cells in HK-2 cells and primary PTEC. 
3.3.3 Does the protein of Fca a a a/m m m mR express in human PTEC? 
The cloned Fca/mR cDNA was used to identify the protein expression on HK-2 cells and 
lysates were made after treating the cells with 5 and 50 ng/ml TGF-b1 and 50 ng/ml IL-1a 
(see section 2.4.2). Immunoblotting was carried out for 48 hrs as described in section 2.4.4.  
In  immunoblots  Fig.  3-10A  the  expression  of  the  Fcα/ R  is  increased  by  IL-1α,  and 
induction inhibited by co-incubation with TGF-b1. These findings were also confirmed 
using densitometry (Fig. 3-10B). However, TGF-b1 alone did not induce any expression. 
CHO cell lysate transfected with Fca/mR were used as positive control. The molecular C C Ch h ha a ap p pt tte e er r r    3 3 3          E E Ef fff ffe e ec c ct tt    o o of ff    I IIg g g    R R Re e ec c ce e ep p pt tto o or r rs s s, 105 
weight of the Fca/mR protein was approximately 70 kDa. The expression of protein for 
any of the classical IgG or IgA receptors was not detected in this study. 
3.3.4 Are Fcα/ R receptors expressed in human PTEC?  
I tested the expression of the Fcα/ R in PTEC by using murine antibodies against the 
Fcα/ R,  which  were  previously  used  for  immunoblotting.  Immunofluorescence  laser 
scanning confocal microscopy was used as described in section 2.4.8 to find out whether 
there was evidence of expression of the Fcα/ R on PTEC. Fig. 3-11 identifies the Fcα/ R 
by specific antibody. An isotype control (anti-mouse IgG) was used to visualise any non-
specific binding (Fig. 3-11A). Fig. 3-11B shows the specific binding of Fcα/ R antibody to 
Fcα/ R on HK-2 cells. Fig. 3-11C shows decreased binding of antibody to the receptor due 
to  TGF-b1  treatment,  which  decreased  the  receptor  expression  (Fig.  3-4).  Fig.  3-11D 
shows an increase in the binding of antibody to the Fcα/ R due to increased expression 
induced by the 50 ng/ml IL-1a treatment. 
3.3.5 Is the Fca a a a/m m m mR expressed in vivo in human kidney? 
IHC was used to confirm the expression of Fcα/ R in normal kidney and other tissues. Fig. 
3-12 shows the expression Fcα/ R in various tissues including normal  kidney  (Fig. 3-
12A), kidney for patients with IgAN (Fig. 3-12B), small intestine (Fig. 3-12C) and tonsil 
(Fig.  3-12D).  IHC  was  prepared  by  Ian  Downie  at  the  Royal  Glasgow  Infirmary  as 
described in Section 2.4.9. IHC was performed using the same murine antibodies against 
Fcα/ R. Fig. 3-12A shows the brown-coloured, positively stained PTEC, distal tubular 
cells and glomerular podocytes in the normal kidney, in IgAN, and also the B-lymphocytes 
in the small intestine and tonsil. This pattern of staining confirms the expression of Fcα/ R 
in various tissues from human body, which indicates that Fcα/ R expression to human 
kidney and expression on the B-lymphocytes in other tissues. 
3.3.6 Do IgG, IgA and IgM bind to human PTEC? 
Confocal laser scanning microscopy was used to visualise the binding of IgG, IgA and IgM 
to  HK-2  cells  and  primary  PTEC.  The  effect  of  cytokine  regulation  on  the  pattern  of 
binding was also studied. U937 cells (positive control) were incubated with biotinylated-
IgG and fluorescent streptavidin as described in section 2.4.8 to show the viability of the 
technique  (Fig.  3-13A).  IgG,  IgA  and  IgM  bind  to  PTEC  which  is  shown  as  green C C Ch h ha a ap p pt tte e er r r    3 3 3          E E Ef fff ffe e ec c ct tt    o o of ff    I IIg g g    R R Re e ec c ce e ep p pt tto o or r rs s s, 106 
fluorescence in (Fig. 3-13B–D) respectively. PTEC cells bind to IgG, possibly by FcRn, 
and the cells could bind to IgA and IgM, possibly by pIgR or Fcα/ R via the J-chain that is 
present in polymeric IgA and IgM. The Fc  fragment of IgM with PTEC showed binding 
(green fluorescence which could be due to pIgR) is shown in Fig. 3-13E. 
IFN-g increased and TGF-b1 decreased the binding of IgM to the PTEC, and this was 
confirmed by gene expression (Fig. 3-13F, G). The same was observed for IgA binding 
(Fig. 3-13J, K). Fig. 3-13L shows the binding of IgA to Fcα/ R. This was acheived by 
incubating 50-fold excess unlabelled monomeric IgA to saturate the Fcα/ R on the cells 
with  1-fold  of  labelled  IgA.  The  ability  of  unlabelled  monomeric  IgA  to  displace  the 
majority of IgM binding is consistent with a significant proportion of IgM binding being to 
the  Fcα/ R.  COS-7  cells  were  used  as  negative  controls  and  were  incubated  with 
biotinylated-IgA and biotinylated-IgM followed with fluorescent streptavidin. The results 
showed no binding of IgA or IgM to COS-7 cells (Fig. 3-13H, I). 
3.3.7 Does IgM bind to Fca a a a/m m m mR? 
In Fig. 3-14A, it is shown that IgM binds to Fcα/ R. However, to determine the specificity 
of the binding, 50-fold unlabelled IgA was added with 1-fold labelled IgM, which was 
overlayed on to the HK-2 cells. IgA displaced the binding of IgM to Fcα/ R, indicating 
that IgM binds to Fcα/ R (Fig. 3-14B). IFN-g and TGF-b1 treatment did not affect the 
binding of IgM to Fcα/ R as the 50-fold unlabelled IgA displaced IgM (Fig. 3-14C, D). 
3.3.8 Do the Igs have any affect on human PTEC to produce FN? 
FN production was assessed in the cells  as described in section 2.5.1  using  a specific 
ELISA. FN production by HK-2 cells was measured under various treatments with Ig/IC 
for 72 hrs at 37°C. TGF-b1 was used as a positive control to stimulate FN production. Fig. 
3-15 shows that TGF-b1 (50 ng/ml) increased the FN by ~1.8-fold. Native IgG and IgA 
had no effect. Cross-linked (XL)-IgG increased FN production by ~1.9-fold compared with 
untreated cells. In contrast, XL-IgA showed a 2-fold increase in FN production. HAg-IgG 
showed  a  1.1-fold  increase  in  FN  production,  whereas  HAg-IgA  showed  a  1.4-fold 
increase in FN production. Native IgM was increased in FN by 1.5fold compared with the 
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3.3.9 Do Igs affect the proliferation of human PTEC? 
Proliferation studies were undertaken in order to assess the significance of FN production. 
A decrease in proliferation of PTEC is indicative of an increase in FN production. Fig. 3-
16  shows  the  proliferation  of  HK-2  cells  by  using  a  [
3H]-thymidine  uptake  assay,  as 
described  in  section  2.4.10,  for  24  hrs  after  various  Ig/IC  treatments  at  37°C.  It  was 
compared with untreated and TGF-b1 treated cells (positive control, 50 ng/ml) which has 
an antiproliferative effect. Native IgG showed no effect on proliferation whereas native 
IgA decreased the proliferation by 80%. XL-IgG, XL-IgA and native IgM have the same 
antiproliferative  effect  as  TGF-b1.  HAg-IgG  and  HAg-IgA  showed  similar  levels  of 
antiproliferative effect when compared with TGF-b1. None of the XL-Ig antibodies alone 
had any independent antiproliferative effect. The differences in antiproliferative effect of 
various treatments were statistically significant. 
3.3.10  Does the binding of IgG, IgA or IgM affect the signalling of 
PTEC? 
HK-2 cells were incubated with Ig with or without (±) XL over a time course (0, 2, 5, 10, 
20,  30  mins)  (Fig.  3-17)  and  lysates  were  prepared  as  described  in  Section  2.4.2. 
Immunoblotting was performed after determining protein concentration, as described in 
sections 2.4.3 and 2.4.4, and the samples were normalised for equal protein concentration 
(10–20 mg). Normalisation involved incubation at 4°C for the primary antibody to prevent 
internalisation of the Ig receptors, and at 37°C to allow the XL to work. Many proteins 
were phosphorylated when blotted by anti-phosphotyrosine antibody. These blots did not 
show any change in protein phosphorylation during the time course treated with IgG ± XL 
and  IgA  ±  XL.  The  same  pattern  was  shown  for  cells  when  blotted  with  ERK.  This 
indicates that no specific ERK signalling pathways were involved in the binding of IgG 
and  IgA  to  PTEC  in  any  of  the  conditions  investigated.  However,  IgM  activated 
phosphotyrosine and ERK signalling during the time course at 2 and 5 minutes. 
3.3.11  Do PTEC release cytokines when stimulated with Ig? 
The Proteoplex™ 16-well human cytokine array system, as described in section 2.5.2.2 
was used to screen the ability of PTEC to release each of the following twelve cytokines: 
IL-1a, IL-1b, IL-2 IL-4, IL-6, IL-7, IL-8, IL-10, IL-12, GM-CSF, IFN-g and TNF-a. I 
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cells. TGF-b1 (50 ng/ml) was used as positive  control and the supernatant media was 
assayed for each of the twelve cytokines. After 24 hrs stimulation, PTEC released the 
cytokines  IL-6,  IL-7,  IL-8,  GM-CSF  and  TNF-a,  but  in  general  the  results  were  very 
inconsistent (Fig. 3-18A). 
To compensate for this inconsistency, I used a specific ELISA as described in Section 
2.5.2.1  for  IL-6,  IL-8,  GM-CSF,  and  TNF-a  individually,  as  these  were  the  cytokines 
whose levels were shown to be altered in the Proteoplex™ studies. In Fig. 3-18B, TGF-b1 
increased IL-6, IL-8 and GM-CSF secretion. However, the stimulation with IgG alone, 
HAg-IgG,  IgA  alone,  XL-IgA,  HAg-IgA  and  IgM  alone  did  not  show  any  statistical 
significant changes in cytokine release. XL-IgG elevated cytokine release. 
TNF-a was released in very low levels (data not shown). I also tested IFN-g release under 
the  same  conditions  with  results  showing  no  release  in  unstimulated  cells  in  all  cases 
except XL-IgG treatment where it was elevated (data not shown). 
3.3.12  Do Igs affect the morphology of human PTEC? 
A confluent monolayer of PTEC was taken and stimulated by various treatments for 72 hrs 
at 37°C with TGF-b1 (50 ng/ml) and Ig ± XL to study the effect of stimulation on the 
morphology of PTEC. The H&E method (as described in section 2.4.10.2) showed that 
neither  TGF-b1  nor  Ig  ±  XL  affected  the  morphology  of  the  PTEC  (Fig.  3-19). 
Surprisingly, TGF-b1 resulted in a slight elongation, though this was nonsignificant. These 
results confirm those shown in Fig. 3-16 that TGF-b1 up-regulated the FN production by 
80%.  The  lack  of  any  significant  change  in  morphology  was  confirmed  by  pathology 
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3.4 Discussion: 
Patients with GN commonly have deposits of Ig/IC in the glomeruli and tubules, but the 
means by which Ig/IC may mediate tubulointerstitial injury has not yet been investigated 
fully (Chan et al., 2005; Takai, 2002). Although albuminuria has been more extensively 
examined, the role of high molecular weight proteins (e.g. transferrin) in renal damage has 
been  clearly  established  (Birn&Christensen,  2006).  Proteinuria  is  associated  with  more 
rapid disease progression in patients with renal disease (Nath, 1992). I hypothesised that 
renal tubular cells might be exposed to, and in turn be activated by, these IC, and thus may 
contribute  to  tubular  damage,  fibrosis  and  enhance  CRF.  However,  the  mechanism  by 
which Ig/IC contribute directly to tubular injury is unknown. 
Cell membrane receptors specific for the Fc portion of Ig that play an important role in 
immunity interact with the IC and mediate several immune processes including antigen 
presentation, ADCC and cytokine/chemokine production (Hulett&Hogarth, 1994). These 
receptors are potentially involved in IC-mediated activation of PTECs. Using qualitative 
RT-PCR and qRT-PCR in primary PTEC and immortalised HK-2 cell lines, this study has 
shown that the expression of Ig receptors is regulated by proinflammatory cytokines like 
IL-1a, IFN-g and TGF-b1. Moreover, Ig binds to the receptors, leading to changes in cell 
functions. 
In my thesis, I focused mainly on the novel IgA receptor Fca/mR. I was unable to identify 
mRNA expression in primary PTEC and HK-2 cells, using either PCR technique, for any 
of the classical IgG receptors FcgRI, FcgRIIA, FcgRIIB and FcgRIII, or the IgA receptor 
FcaR.  The  ability  of  FcaR  to  bind  both  human  IgA1  and  IgA2  subclasses  has  been 
reported  in  other  studies  (Monteiro&Van  De  Winkel,  2003).  This  receptor  can  be 
expressed  on  neutrophils  and  monocyte/macrophages  due  to  increased  glycosylation 
(Westerhuis et al., 1999). U937 cells have been used as a positive control in this study 
because  Cameron  et  al.,  (2001)  showed  that  treatment  with  dbcAMP  enhanced  the 
expression of FcaR after 48 hrs. 
The novel Fca/mR present is a type 1 transmembrane protein that, unlike FcaR, has a 
single  Ig-like  domain  that  is  expressed  on  the  majority  of  murine  B-lymphocytes  and 
macrophages  (Shibuya  et  al.,  2000).  Shibuya  et  al.,  (2000)  and  Mantis  et  al.,  (2002) 
reported  that  human  and  murine  mature  B  cells  express  an  Fca/mR  that  can  mediate C C Ch h ha a ap p pt tte e er r r    3 3 3          E E Ef fff ffe e ec c ct tt    o o of ff    I IIg g g    R R Re e ec c ce e ep p pt tto o or r rs s s, 110 
endocytosis of both IgA- and IgM-containing ICs. In this project, I showed that human 
primary PTEC and HK-2 cells express mRNA for the novel IgA and IgM receptor Fca/mR, 
a candidate receptor for the pathogenesis of IgAN. The mRNA for Fca/mR expression is 
increased by IL-1a, and to a lesser extent with IFN-g, and is reduced by TGF-b1. These 
findings are in agreement with those of Yano et al., (1997) and Yoshioka et al., (1993), 
who showed that the expression of these pro-inflammatory mediators may have a role in 
the pathogenesis of IgAN. Fca/mR upregulation by IL-1a is of significance as increased 
internal expression of this inflammatory cytokine has been described in IgAN (McDonald 
et al., 2002). The regulation of the expression of Fca/mR by these cytokines corroborates 
the studies in MSC by McDonald, Cameron et al., (2002) where they showed that Fca/mR 
is one of the major IgA receptor expressed in MSC. Nakamura et al., (1993) showed that 
the FcmR is expressed in non-haematopoietic cells (e.g. PTEC and central nervous system 
tissue), suggesting an important role for this receptor in the immune response of these 
tissues. 
It has been shown that various cells such as monocytes, macrophages and T cells infiltrate 
into the kidney during inflammation (Gerritsma et al., 1996a; Kooijmans-Coutinho et al., 
1995; Passwell et al., 1988). Infiltrated immune cells secrete IL1-a, which might induce 
synthesis  of  complement  components  by  tubular  cells.  IL-1a  produced  by  infiltrating 
monocytes or by local intraglomerular cells could result in the upregulation of the PTEC 
Fca/mR expression and promote IgA deposition. Apart from immune cells, MSC are also a 
source of IL1-a (Lovett et al., 1986; Sedor et al., 1992; Werber et al., 1987; Zoja et al., 
1993), which may also indirectly lead to the production of complement proteins by tubular 
cells. In IgAN, the correlation between the influence of IL1-a on the expression of Fca/mR 
in the kidney and the degree of tubulointerstital damage is unknown. Rincheval-Arnold et 
al., (2002) showed that the  IFN-g  receptor is expressed in a wide range of cell types, 
suggesting  that  IFN-g  has  an  array  of  functions.  It  has  been  hypothesised  that  IFN-g 
produced  by  T  cells  may  act  directly  via  the  IFN-g  receptor  present  on  the  PTEC  to 
enhance  not  only  MHC  expression  but  also  that  of  complement  component  and  other 
mediators such as chemokines (Gerritsma et al., 1997). 
Although IL1-a and IFN-g enhanced the expression of Fca/mR, TGF-b1 showed opposite 
results,  suggesting  antagonistic  functions  of  this  cytokine.  Indeed,  TGF-b1  has  been 
hypothesised to possess an inhibitory effect on immune system activation (Tian&Phillips, 
2003). As it is a novel receptor, there is very little information available regarding the 
signal  transduction  mechanism  controlling  Fca/mR  following  the  stimulation  of  pro-C C Ch h ha a ap p pt tte e er r r    3 3 3          E E Ef fff ffe e ec c ct tt    o o of ff    I IIg g g    R R Re e ec c ce e ep p pt tto o or r rs s s, 111 
inflammatory  cytokines.  However,  it  is  known  that  IL1-a-mediated  upregulation  of 
Fca/mR expression is dependent on the activation of the promoter region, which contains 
all the essential transcription regulatory components. 
According to Chan et al., (2005), IgAN is the most common form of GN, and is one of the 
leading causes of renal failure. This disease is characterised by the mesangial deposition of 
pathogenic pIgA1. In the kidney, receptor-mediated transport of Igs has been studied in the 
pIgR, which transports pIgA and pentameric IgM from the basolateral to the apical surface. 
The pIgR neutralises extracellular and intracellular pathogens in mucous membranes by 
epithelial  transport  of  pIgA  pathogen  complex,  which  is  then  excreted  via  epithelial 
transcytosis (Leung et al., 2000). pIgR plays an important role in the mucosal immunity of 
the urinary tract (Rojas&Apodaca, 2002). Cultured primary PTEC and HK-2 cells express 
mRNA for the pIgR and this expression is increased by IFN-g. Phillips-Quagliata et al., 
(2000) reported pIgR in epithelial cells that bind IgM with higher affinity than IgA. The J-
chain is essential for the assembly of pIgR and epithelial transport, but is not known to 
play a role in inflammation. Vaerman et al., (1998b) established the presence of the J-chain 
in human pIgA, in agreement with the notion that the J-chain is required in pIg for binding 
to SC/pIgR. The J-chain is also present in human pIgM (Wines et al., 1999). Hempen et 
al., (2002) developed a model of transcriptional regulation of the human pIgR gene that 
involves cooperative binding among multiple transcription factors. 
Numerous  studies  have  highlighted  the  preponderant  effect  of  IFN-g  on  pIgR  gene 
expression in human MSC. Rincheval-Arnold et al., (2002) showed that IFN-g strongly 
increased pIgR mRNA levels through a direct effect on PTEC. Piskurich et al., (1997) 
showed that the pIgR promoter can be modulated by IFN-g in MSC. Since both pIgR and 
Fca/mR are capable of binding IgM, it can be speculated that IFN-g might utilise similar 
mechanisms in regulating the expression of Fca/mR. 
A recent study argued that neither FcamR nor pIgR are expressed in PTEC (Chan et al., 
2005).  In  this  study,  the  authors  investigated  the  binding  of  IgA  receptors  by  primary 
PTEC and MSC from patients with IgAN to cultured PTEC, compared with the binding of 
IgA from healthy controls. My results are in contrast with these data with regard to the lack 
of expression of the Fca/mR. This could be because of the experimental conditions or 
culture condition altering the cell phenotype. I hypothesised that the expression of Fca/mR 
would be lost as the number of cell passages increased, and that varying culture conditions 
may lead to loss of the receptor from the cell surface. C C Ch h ha a ap p pt tte e er r r    3 3 3          E E Ef fff ffe e ec c ct tt    o o of ff    I IIg g g    R R Re e ec c ce e ep p pt tto o or r rs s s, 112 
Raghavan  &  Bjorkman,  (1996)  reported  that  FcRn  binds  IgG  in  the  lumen  and  then 
transports the IC across the intestinal barrier into the lamina propria for processing by 
dendritic cells and presentation to CD4+ T cells. MHC class I-related FcRn plays a central 
role in delivering IgG within and across the cells. Kobayashi et al., (2002) showed that a 
specific IgG receptor, FcRn, mediates IgG transcytosis and is localised to the proximal 
tubular brush border. Any injury to proximal tubules resulting in loss of PTEC will lead to 
ablation of IgG reabsorption because of insufficient endocytosis. FcRn is associated with 
b2-microglobulin and binds IgG in a pH-dependent manner with higher affinity binding at 
an acidic pH (6.0) and low or no affinity at neutral pH (8.0). I demonstrated that primary 
cultured PTEC and immortalised HK-2 cells expressed mRNA for FcRn, but there was no 
synergistic  effect  by  various  proinflammatory  cytokines  in  the  upregulation  of  FcRn 
mRNA. In this thesis, I confirmed the expression of Ig receptors on PTEC using sensitive 
qRT-PCR  analysis.  Fold  differences  in  the  expression  of  these  receptors  between 
unstimulated and stimulated cells indicated that the expression of FcRn, pIgR and Fca/mR 
mRNA is biologically significant relative to b-actin mRNA. 
After checking the expression of mRNA for the Fca/mR in PTEC, I checked the expression 
of proteins of the same receptors using a mAB specific for Fca/mR. This mAB has only 
recently become available and so previous research in this area has been limited. Protein 
expression  of  the  Fca/mR  was  regulated  in  the  same  way  as  its  mRNA  by  the 
proinflammatory cytokine IL-1a. In PTEC, the product of the tagged Fca/mR gene was 
approximately 70 kDa.  In unstimulated HK-2 cells, there was no visible expression of 
Fca/mR protein. This could be for a number of reasons. Cherayil et al., (1993) suggested 
that, after synthesis, the receptor protein in the endoplasmic reticulum lacked the signal 
peptide for its transport to the membrane. Another possible explanation is that PTEC may 
typically express the mRNA of Fca/mR and not transcribe its protein. If this were the case, 
patients with IgAN might be able to express Fca/mR either by abnormally glycosylated 
IgA-containing  ICs  or  by  inflammatory  mediators.  The  expression  of  this  functional 
receptor may be determined by genetic or other factors, and these may enable us to predict 
the  subset  of  patients  who  are  susceptible  to  disease  and  who  subsequently  develop 
progressive renal failure. 
IL-1a-treated cells showed increased expression of the Fca/mR protein, as detected by 
immunoblotting. This expression was markedly reduced by TGF-b1 in combination with 
IL-1a. These differences were confirmed by densitometric analysis of Western blot bands. 
CHO  cells  transfected  with  Fca/mR  were  used  as  a  positive  control,  as  reported  by C C Ch h ha a ap p pt tte e er r r    3 3 3          E E Ef fff ffe e ec c ct tt    o o of ff    I IIg g g    R R Re e ec c ce e ep p pt tto o or r rs s s, 113 
McDonald et al. (2002), who showed that Fca/mR transfected into CHO cells can bind IgA 
and IgM but not IgG. Recently, Cho et al., (2006) successfully developed an anti-FcamR 
mAB, which should prove useful for the molecular and functional characterisation of IgA 
and IgM interactions with Fca/mR, an area that needs further investigation. 
In several experiments, I attempted to detect Fca/mR in PTEC using FACS analysis with 
no  positive  results.  However,  using  an  immunofluorescence  technique  applying  anti-
Fca/mR directly to the cells, I was able to show that there is binding of Fca/mR in PTEC. 
The binding increased in cells stimulated with IL-1a and was reduced in cells stimulated 
with TGF-b1. From this result, I proposed that the surface protein was detected for Fca/mR 
suggesting  that  Fca/mR  transcript  is  essential  for  the  translation  or  membrane 
transportation of Fca/mR. 
I have shown that Fca/mR is expressed on the normal kidney and in some patients with 
IgAN. This was demonstrated by using IHC in normal kidney, IgAN and B lymphocytes in 
tonsil and small intestine sections incubated with mAB against Fca/mR. Positive staining 
in both proximal and distal tubular cells, and also the podocyte, (shown in brown colour in 
Fig.  3-12)  confirmed  the  expression  of  Fca/mR  in  the  human  kidney.  This  finding  is 
important and implicates Fca/mR as a candidate for mediating IC deposition in IgAN and 
suggests that it is regulated by cytokines implicated in progressive renal disease and may 
lead to ESRF. 
I  identified  the  binding  specificity  of  IgA,  IgM  and  IgG  in  PTEC  incubated  with 
fluorescein-labelled IgA, IgM or IgG antibodies, as well as unlabelled monomeric IgA. 
The binding pattern of Ig to PTEC was then examined using confocal laser microscopy. 
The IHC results showed that both IgA and IgM bind to PTEC and that binding to IgA 
might occur through the Fca/mR as binding was seen with the monomeric IgA antibody, 
which does not contain the J-chain. The J-chain is required for binding to pIgR. Binding of 
PTEC to IgM may occur through either the Fca/mR or pIgR and is stronger than that of 
IgA, possibly due to the presence of the J-chain. I also showed that PTEC were able to 
bind IgG, possibly through the FcRn. 
The displacement of labelled IgA (1-fold) and IgM (1-fold) with monomeric unlabelled 
IgA (50-fold excess) showed relatively less binding of labelled IgA and IgM to Fca/mR 
which  suggests  that  monomeric  IgA  saturates  Fca/mR.  Binding  of  IgA  and  IgM  was 
increased by IFN-g and reduced by TGF-b1 as shown in Fig. 3-13F/G for IgM and Fig. 3-C C Ch h ha a ap p pt tte e er r r    3 3 3          E E Ef fff ffe e ec c ct tt    o o of ff    I IIg g g    R R Re e ec c ce e ep p pt tto o or r rs s s, 114 
13J/K for IgA, which correlates with the gene expression data. Overall, these data show 
that the expression of Fca/mR on the surface of PTEC is regulated by pro-inflammatory 
cytokines implicated in the pathogenesis of progressive renal disease. The mechanism by 
which this regulation occurs needs further investigation. 
Despite the implication of Ig/IC in progressive renal disease, there is little evidence of a 
direct effect of these complexes on PTEC. In order to examine this further, I looked at the 
consequence of Ig/IC binding to PTEC in terms of FN production (as a marker of ECM), 
proliferation, signalling pathways and cytokines released. FN production has been shown 
in renal disease, to play an important role in the fibrogenesis described as a modulator of 
the synthesis of ECM proteins (Gomez-Guerrero et al., 2005) leading to ESRF (Roopenian 
et  al.,  2003),  and  is  known  to  be  involved  in  GN.  TGF-b1  was  used  to  confirm  FN 
production  in  PTEC.  The  results  showed  that  XL-IgG  and  XL-IgA  increased  FN 
production, while HAg-IgG, HAg-IgA and IgM did not significantly change the rate of FN 
production.  IgG  alone  had  no  effect  on  FN  production.  From  these  results  it  can  be 
hypothesised that Ig/IC do have an effect on production of FN in PTEC. Thus, Ig/IC may 
contribute to tubulointerstitial injury since the change in FN by PTEC can possibly alter 
their proliferative function. 
I further studied the effect of Ig/IC on proliferation of PTEC. My result shows that XL-
IgG, XL-IgA, HAg-IgG, HAg-IgA and IgM caused inhibition of proliferation relative to 
the  FN  result,  whereas  IgG  and  IgA  alone  had  no  effect  on  proliferation.  This  is  in 
agreement with the finding of Chan (2005), who saw that IgA binding did not enhance the 
proliferation of PTEC. TGF-b1 was used as a positive control in this study as it has been 
shown to have antiproliferative effects on some cell types, as reported by Vesey et al. 
(2002). These authors also reported that IL-1b exerted potent TGF-b-dependent fibrogenic 
and antiproliferative actions on PTEC, which could possibly play an important role in the 
pathogenesis of tubulointerstitial fibrosis and tubular atrophy. Furthermore, TGF-b inhibits 
the proliferation of MSC (Basile et al., 1998; Jaffer et al., 1989; Kuncio et al., 1996; 
Massague,  1990)  and  has  been  shown  to  increase  the  mRNA  expression  of  FN  and 
collagen IV in cultured PTEC. Thus, TGF-b influences redifferentiation of renal PTEC 
either directly or indirectly through the production of FN. However, the mechanism of this 
effect  has  not  yet  been  identified,  though  it  is  unlikely  to  be  wholly  due  to  a  single 
receptor. In other experiments, I found no significant changes in cell morphology with 
Ig/IC stimulation and fewer significant changes in the morphology with TGF-b1. C C Ch h ha a ap p pt tte e er r r    3 3 3          E E Ef fff ffe e ec c ct tt    o o of ff    I IIg g g    R R Re e ec c ce e ep p pt tto o or r rs s s, 115 
A broad range of signalling pathway mechanisms were examined. PTEC were stimulated 
with Ig/IC and the lysates Western blotted and probed for anti-phosphotyrosine and ERK. 
The results show phosphorylated proteins at 64 kDa and 97 kDa, all of which remained 
unaltered over a period of time after treatment with IgG and IgA, with or without XL. IgM 
activated  the  ERK  and  phosphotyrosine  signalling  pathways,  though  this  may  have 
occurred  through  pIgR  rather  than  Fca/mR.  However,  further  investigation  into  the 
signalling pathway mechanisms of PTEC may be worthwhile. These cells can probably be 
stimulated with Ig/IC with cytokine treatment and the lysate used to perform proteomic 
studies such as diffuse immune gel electrophoresis and mass spectroscopy. 
Some studies have shown that TGF-b binds to factors such as ET-1 and ET-2 and inhibits 
the activation of the p42/44 pathway (Yard et al., 2001). TNF-a and IL-1b also activate 
ERK1/2  in  PTEC,  indicating  that  this  pathway  plays  an  important  role  in  matrix 
metalloproteinase-9  upregulation.  Moreover,  both  TNF-a  and  IL-1b  were  shown  to 
increase the phosphorylation of p38 in PTEC (Nee et al., 2004). 
Ronda et al. (2005) reported that MAP kinases are an important mechanism of transduction 
of extracellular signals into cellular responses.  They  reported the activation of a MAP 
cascade in human PTEC stimulated for 1hr with normal IgG showing the early activation 
of ERK, which is the final product of translocating to the nucleus. They reported normal 
and pathological IgG but not transferrin or albumin induced an early significant increase in 
IL-6 release by PTEC, suggesting that IgG filtered during nonselective proteinuria may 
play a specific role in tubulointerstitial diseases. The signalling pathways of Fca/mR have 
not been extensively studied to date and there is little data in the literature. I suggested that 
potential signalling mechanisms for Fca/mR could exist. 
Using a ProteoPlex™ assay I screened PTEC under non-stimulated conditions and after 
stimulation with Ig ± XL to see which cytokines are released. Three cytokines – IL-6, IL-8, 
and GM-CSF – were then individually examined using a specific ELISA technique. I used 
TGF-b1 (50 ng/ml) as positive control; this caused an increase in the release of IL-6, IL-8 
and GM-CSF, as shown in Fig. 3-18. PTEC did not show any increase in the release of 
these cytokines after stimulation with IgA ± XL and IgM. Interestingly, XL-IgG in culture 
caused an increase in the release of the cytokines. However, this may be an artefact of the 
experimental conditions, for example the intensity of stimulation concentrations of Ig, XL 
incubation time or temperature. Moreover, even a very low level of contamination (e.g. 
LPS) in the antibody preparation could stimulate the cells to release the cytokines. This is C C Ch h ha a ap p pt tte e er r r    3 3 3          E E Ef fff ffe e ec c ct tt    o o of ff    I IIg g g    R R Re e ec c ce e ep p pt tto o or r rs s s, 116 
in agreement with (Brauner et al., 2001; de Haij et al., 2002; Gerritsma et al., 1998b), who 
showed that PTEC releases cytokines when stimulated with LPS. In addition, PTEC are 
known  to  express  HLA,  ICAM-1  and  VCAM-1,  thus  indicating  their  involvement  in 
inflammatory processes. 
Several studies have shown that human MSC are able to produce IL-8 in vitro in response 
to LPS, IL-1 and TNF-a (Brown et al., 1991; Kusner et al., 1991; Schmouder et al., 1992). 
Therefore, the production of IL-8 may not only result in the recruitment of neutrophils but 
also in their activation, which leads to local inflammation. Other studies indicate that IL-8 
staining  in  the  tubule  is  associated  with  renal  inflammation  (Gerritsma  et  al.,  1996b; 
Schmouder  et  al.,  1992).  Frank  et  al.,  (1993)  reported  that  IL-6  and  GM-CSF  are 
mitogenic for lymphocytes and macrophages and can be expressed in human PTEC. Other 
researchers have evaluated the production of IL-6 and GM-CSF by tubular epithelial cells. 
These  studies  reported  that  both  proinflammatory  mediators  are  able  to  induce  the 
recruitment and activation of mononuclear cells. Daha & van Kooten, (2000) reported that 
mediators released by the inflammatory cells are directly responsible for the activation of 
PTEC, which in turn join in the inflammatory cascade by the local production of various 
inflammatory mediators. 
In  conclusion,  these  results  suggest  that  Fca/mR  is  likely  to  be  expressed  on  cultured 
PTEC,  that  PTEC  bind  IgA  and  IgM  through  the  Fcα/ R  and  that  this  binding  may 
contribute  to  immune-mediated  nephropathy.  The  expression  of  Fcα/ R  by  PTEC  was 
increased by the proinflammatory cytokines IL-1α and IFN-γ, but reduced by TGF-β1. I 
demonstrated that IgA and IgM increase the production of FN by PTEC, and that this may 
contribute  to  tubulointerstitial  fibrosis.  IgM  and  IgA  were  also  shown  to  modulate 
proliferation, suggesting that Ig binding to PTEC may contribute to the pathophysiology of 
IC-mediated  renal  disease.  Further  studies  are  required  to  investigate  these  and  other 
effects  of  IC  and  Ig  on  PTEC.  Although  this  thesis  focused  on  the  novel  Fca/mR 
expression on PTEC and its potential implication in IgAN, further investigations could be 
done by using specific antibodies against human pIgR and human FcRn to study their 
protein expression and regulation by proinflammatory cytokines. Binding of Ig/IC to PTEC 
and the activation of the Fca/mR may contribute to the factors leading to ESRF and could 
therefore represent a future target for the treatment of progressive renal disease. C C Ch h ha a ap p pt tte e er r r    3 3 3          E E Ef fff ffe e ec c ct tt    o o of ff    I IIg g g    R R Re e ec c ce e ep p pt tto o or r rs s s, 117 
     
   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure   3-1 The expression of mRNA for Fcg g g gRI, g g g gIIA, g g g gIIB, g g g g-chain, Fca a a aR and b b b b-actin by RT-
PCR in HK-2 and U937 cells 
RT PCR was performed with specific primers to confirm the expression of FcgRI, 
FcRgIIa, FcRgIIb, Fcg chain and FcaRI using cDNA extracted from unstimulated 
cells and from cells treated for 24 hrs with (20, 200 ng/ml) IFN g. In addition, 
cDNA from cells treated with (5, 50 ng/ml) TGF b1 was used. A 100bp ladder was 
used as a marker (lane 1). U937 cells were used as positive control (lane 7) and 
dH2O was used as a template (negative control lane 8). The above results were 
confirmed after comparing to a positive control b actin at expected size. The band 
size for each receptor is shown in Table 2 2, as well as in each figure. 
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Figure   3-2 The expression of mRNA for FcRg g g gIII and b b b b-actin by RT-PCR in HK-2 cells 
RT PCR was performed with specific primer to confirm the expression of FcRgIII. 
RT PCR was carried out with cDNA extracted from unstimulated cells and from 
cells treated for 24 hrs with (20, 200 ng/ml) IFN g. A 100bp ladder was used as a 
marker (lane 1). In addition, cDNA from cells treated with (5, 50 ng/ml) TGF b1 
was used. For FcRgIII, NK 92 cells were used as a positive control (lane 7) and 
dH2O was used as a template (negative control lane 8). The above results were 
confirmed after comparing to a positive control b actin at expected size. The band 
size for this receptor is shown in Table 2 2, as well as in each figure. 
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Figure   3-3 The expression of mRNA for FcRn and pIgR by RT-PCR in HK-2 cells 
(A) RT PCR was used to investigate the expression of FcRn in PTEC. Expression 
was unaltered by various concentrations of IFN g and TGF b1 respectively for 24 
hrs (lanes 3–6), as compared with untreated cells. (B) The expression of pIgR was 
upregulated by treating the cells with IFN g in a dose dependent manner (lanes 3, 
4), compared with untreated cells. However, treatment of cells with TGF b1 (5, 
50ng/ml) inhibited the expression of the receptor (lane 5, 6). A 100bp ladder was 
used as a marker (lane 1). U937 cell cDNA was used as a positive control (lane 7) 
and dH2O (lane 8) was used as a template. 
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Figure   3-4 The expression of mRNA for Fca a a a/µR expression by RT-PCR in HK-2 cells 
The expression of Fca/ R was upregulated by 50ng/ml IL 1a (lane 2) in contrast 
with (20, 200ng/ml) IFN g, which only slightly increased the expression of the 
receptor  (lane  3,  4).  However,  TGF b1  in  various  concentrations  (lanes  5,  6) 
completely inhibited the expression of the receptor. Unstimulated cells expressed 
the receptor at low levels (lane 7). A 100bp ladder was used as a marker (lane 1) 
and dH2O was used as a template (lane 8). b actin was used as a loading control in 
the RT PCR experiments. 
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Figure   3-5 The expression of Ig receptors in primary PTEC 
RT PCR showed the same pattern of Ig receptor expression in primary PTEC as is 
seen in immortalised HK 2 cells. FcRn is expressed at the same level as is seen in 
cells treated with IFN g and TGF b1, which did not show any effect. Fca/mR is 
expressed in untreated cells and is increased when stimulated with 200ng/ml IFN 
g or 50 ng/ml IL 1a. In contrast, stimulation with TGF b1 reduced the expression 
of the receptor. pIgR was expressed normally in untreated cells. IFN g altered the 
expression of pIgR in a dose dependent manner. FcgR, g chain and FcaR were not 
expressed in either untreated cells or cytokine stimulated cells. A 100bp ladder 
was used as a marker (lane 1). U937 cells were used as a positive control for all 
receptors, except FcgRIII for which NK 92 cells were used as a positive control. 
The housekeeping gene b actin was used as a loading control and dH2O was used 
as a template. 
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Figure   3-6 Fold differences of mRNA amplification for FcRn, pIgR, Fcα/µR by semi-qRT-PCR 
in HK-2 cells after 24 hrs stimulation. 
For  FcRn,  no  significant  change  in  IFN g  (20ng/ml  0.73±0.22;  200ng/ml 
0.73±0.20) or TGF b1 (5ng/ml 0.46±0.07; 50ng/ml 0.60±0.25) was seen. Results 
were compared to the expression of the receptor in NK 92 cells (negative control). 
pIgR was upregulated by IFN g (20ng/ml IFN g 8.7±4.2; 200ng/ml IFN g 11.7±6.7 
fold; P<0.01). Fca/mR was expressed in immortalised HK 2 cells, upregulated by 
IFN g  (20ng/ml  IFN g  2.7±0.7,  200ng/ml  IFN g  3.1±0.9  fold)  and  inhibited  by 
TGF b.  50ng/ml  IL 1a  produced  greater  Fca/mR  upregulation  (4.8±1.2  fold; 
P<0.01). This graph was representative of five experiments and data are shown as 
mean ± SD. 
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Figure   3-7 The fold differences of mRNA amplification for FcRn, pIgR, Fcα/µR by semi-qRT-
PCR in primary PTEC after 24 hrs stimulation. 
For  FcRn,  no  significant  change  in  IFN g  (20ng/ml  1.13±0.37;  200ng/ml 
1.50±0.82) or TGF b1 (5ng/ml 0.61±0.27; 50ng/ml 0.34±0.18) was seen. Results 
were compared to the expression of the receptor in NK 92 cells (negative control). 
pIgR was upregulated by IFN g (20ng/ml IFN g 6170.98±3113.6; 200ng/ml IFN g 
7086.44±5030.22  fold;  P<0.01).  Fca/mR  was  expressed  in  immortalised  HK 2 
cells, upregulated by IFN g (20ng/ml IFN g 0.94±0.46, 200ng/ml IFN g 3.01±1.87 
fold)  and  inhibited  by  TGF b.  50ng/ml  IL 1a  produced  greater  Fca/mR 
upregulation (3.0±0.91 fold; P<0.01). Results were compared with the expression 
of the receptor in U937 cells, which were also used as a negative control. This 
graph was representative of five experiments and the data are shown as mean ± 
SD. 
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A-Standard curve graph for Fc a a a a/m m m mR by SYBR-490 
 
 
 
 
 
 
 
 
 
 
 
 
B- PCR Amp/Cycle graph for Fc a a a a/m m m mR by SYBR-490 
 
 
 
 
 
 
 
 
 
 
 
 
 
C- Melt curve graph for Fc a a a a/m m m mR by SYBR-490 
 
 
 
 
 
 
 
 
 
 
Figure   3-8 Amplification of Ig receptors by semi-qRT-PCR 
(A)  Dynamic  range  of  b actin  mRNA  quantitation  assay  measuring  the 
amplification of b actin in 10 fold serial dilutions of a known cDNA sample. Ct of 
b actin mRNA amplification has been plotted against the log of the relative initial 
amount of the pooled cDNA. The slope was –3.325 and the correlation coefficient 
was 0.996. PCR efficiency was 100.0%. (B) Representative curves of SYBER green 
fluorescence  Ct  for  Fcα/ R  receptor  (blue)  and  the  relative  expression  of  the 
housekeeping gene b actin (red). (C) Melting curves for primers of Fc receptors 
(blue) and b actin (red). The two peaks confirm the absence of gene dimerisation. 
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Figure   3-9 Expression of Fcg g g gRI,g g g gRIIB,g g g gRIII in HK-2 and primary PTEC 
These graphs show the amplification of cDNA using a specific primer of FcgRI, 
FcgRIIB  and  FcgRIII  in  immortalised  HK 2  cells  (right  panel)  and  in  primary 
PTEC (left panel). U937 cells were used as positive control, except for FcgRIII for 
which  NK 92  cells  were  used  as  positive  control.  None  of  the  receptors  were 
expressed  in  PTEC.  The  amplification  of  the  receptor  was  relative  to  the 
housekeeping gene b actin. Triplicate reactions at each condition were amplified 
along  the  iCycler  iQ  real time  PCR  system.  The  correlation  coefficient  of  the 
standard  curve  was  0.999,  the  slope  was  –3.284  and  the  PCR  efficiency  was 
100.0%. 
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Figure   3-10 Immunoblotting for Fcα/µR antibody in HK-2 cells with densitometry for Fcα/µR 
protein band expression 
Stimulation of HK 2 cells with IL 1a  (50 ng/ml), but not TGF b (5, 50 ng/ml), was 
able to induce protein expression of Fca/mR. The expression of the Fca/mR protein 
induced by IL 1a was reduced when additionally treated with TGF b, in a dose 
dependent  manner,  compared  with  the  positive  control  (CHO  cells  transfected 
with Fca/mR). The band size is ~70 kDa, as seen in Fig. 3 10A. These results were 
confirmed by densitometry, as seen in Fig. 3 10B. These data are representative of 
three experiments. 
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Figure   3-11 Binding of Fcα/ R to HK-2 cells, as seen by confocal microscopy 
Immunofluorescence staining with Fca/ R antibody on immortalised HK 2 cells. 
(A)  Isotype  control  was  used  to  determine  the  specificity  of  the  antibody;  (B) 
Specific  binding  of  the  Fca/ R  antibody  to  the  receptor  can  be  seen.  The 
regulation of the receptor expression was increased by IL 1a (D) and reduced by 
TGF b1 (C). Green fluorescence indicates the binding and red shows the cells and 
nuclei. 
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Figure   3-12 Immunocytochemistry for Fca a a a/m m m mR 
Expression of Fca/mR in (A) normal kidney; (B) kidney of patients suffering from 
IgA nephropathy; (C) B lymphocytes of small intestine; and (D) B lymphocytes of 
tonsil. 
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Figure   3-13 Binding of Igs, as seen by confocal microscopy 
Confocal scanning laser microscopy showing the binding pattern of various Igs to 
PTEC. (A) U937 cells incubated with IgG followed by streptavidin were used as 
positive control. (B, C, D) Cells incubated with Biotin SP conjugated IgG, IgA and 
IgM and then fluorescein conjugated streptavidin. Potentially, IgA and IgM may 
bind to the pIgR or Fca/mR. The former binds Ig through the J chain, whereas the 
latter is believed to bind the Fc portion of Ig. (E) Binding with Biotin Fcm fragment 
IgM. (F, G, J, K) The incubation of Biotin IgA and IgM with IFN g and TGF b1 
treated cells. There is binding of IgA or IgM with IFN g while there is no binding 
with  TGF b1.  (H,  I)  Cos 7  Cells  incubated  with  IgA  and  IgM  followed  by 
straptavidin were used as negative controls. (L) To displace IgA and IgM binding 
to PTEC, there is competition between unlabelled mIgA  and biotinylated mIgA 
binding to PTEC. The competition was induced by incubation of 50 fold unlabelled 
IgA together with 1 fold Biotin IgA in PTEC. There is less binding of IgA in the 
presence of the unlabelled IgA, suggesting that binding is through the Fca/mR. 
Green fluorescence indicates the binding and red shows the cells and nuclei. 
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Figure   3-14 Binding of IgM by competition with 50-fold IgA by confocal microscopy 
Confocal scanning laser microscopy showing the binding pattern of IgM to PTEC. 
(A) The binding of Biotin SP conjugated IgM to HK 2 cells and then fluorescein 
conjugated  streptavidin.  (B)  The  specificity  of  IgM  binding  to  Fca/mR  and  its 
displacement by 50 fold unlablled IgA followed by 1 fold Biotin IgM. (C,D) The 
regulation of Fca/mR expression and its subsequent binding to the antibody by 
IFN g and TGF b1, respectively. Green fluorescence indicates the binding and red 
shows the cells and nuclei. 
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Figure   3-15 Percentage of FN production by HK-2 cells stimulated with Ig ± ± ± ± XL  
The first bar represents the immortalised HK 2 cells, which were used as a control. 
The second bar represents the positive control TGF b1 (50 ng/ml) and shows an 
increase in FN production (p<0.01). Bars 3–5 show the effect of IgG, XL IgG and 
HA IgG  stimulation  of  HK 2  cells,  XL IgG  shows  increasing  FN  production 
(p<0.002). Bars 6–8 shows the effect of IgA, XL IgA and HA IgA stimulation of 
HK 2 cells, also XL IgA shows increasing FN production (p<0.002). Bars 9 show 
the effect of IgM stimulation of HK 2, increasing FN production compared with 
the control HK 2 cell line (p<0.01). The addition of Ig without XL had an effect on 
FN production. This result is representative of nine individual experiments and 
data are shown as mean ± SD. 
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Figure   3-16 Percentage of the proliferation of HK-2 cells stimulated with Ig 
Effect of Ig/IC and TGF b1 on the proliferation of immortalised HK 2  cells,  as 
assessed by [3H] thymidine uptake. The first bar represents the untreated HK 2 
cell  line  as  control.  The  second  bar  represents  the  positive  control  TGF b1  (50 
ng/ml) and shows inhibition of the proliferation of PTEC. IgG had no effect on 
proliferation compared with the control. However, incubation with IgA, IgM, XL 
IgG, XL IgA, HA IgG and HA IgA inhibited the proliferation of PTEC. This result 
is representative of five individual experiments of 12 values and data are shown as 
mean ± SD. 
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Figure   3-17 Immunoblotting for IgG, IgA, IgM ± ± ± ±XL on PTEC with anti-phosphotyrosine and 
ERK over time 
Immunoblot showing the binding of Ig to PTEC in the presence and absence of XL. 
Cells were treated with Ig at 4°C and Ig + XL complex at 37°C and immunoblotted 
for  anti phosphotyrosine  (top  panel)  and  ERK  (bottom  panel).  The  results 
suggested no  change in the signalling component of  phosphotyrosine  and ERK 
with IgG and IgA at all timepoints. However, IgM activated phosphotyrosine and 
ERK at 2 and 5 mins. (A) IgG ± XL; (B) IgA ± XL; (C) IgM ± XL. This blot was 
representative of three experiments. 
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Figure   3-18 Effect of Ig on PTEC to release IL-6, IL-8 and GM-CSF 
(A)  Proteoplex™  analyser  data  showing  cytokine  release  by  PTEC  in  culture 
supernatants measured after 24 hrs. (B) Percentage of IL 6 (upper panel), IL 8 
(middle)  and  GM CSF  (lower)  released  by  untreated  HK 2  cells  and  by  cells 
treated with Ig ± XL for 24 hrs by specific ELISA. TGF b1 (50ng/ml) was used as a 
positive control and increased the release of the cytokines. IL 6, IL 8 and GM CSF 
were  released  by  HK 2  cells.  Ig  ±  XL  stimulation  did  not  show  a  significant 
increase  compared  with  the  unstimulated  cells.  Data  are  mean  ±  SD  of  three 
measurements in three separate experiments. * p<0.01. 
  Well Label HK2 TGF-b IgG IgGXL IgG+XL HA-IgG IgA IgAXL IgA+XL IgM
Diln. Fact. 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0
IL-1a    *       *       *    330.0 355.1    *       *       *    3.9    *   
IL-1b    *       *       *    1.2 602.1    *       *       *       *       *   
IL-2    *       *       *    280.8 376.2    *       *       *    3.4    *   
IL-4    *    5.2    *       *    175.9    *       *       *       *       *   
IL-6 33.0 412.1 22.5 212.2 350.2 30.1 26.1 33.6 40.4 36.1
IL-7 18.7 10.9 18.8 28.6 694.8 12.9 25.8 18.5 22.8 15.7
IL-8 2112.6 2111.5 2112.9 1837.7 1955.3 1761.0 2112.1 2112.1 2112.5 2110.0
IL-10    *       *       *    124.6 207.8    *       *       *       *       *   
IL-12    *       *       *    497.8 667.3    *       *       *    3.0    *   
GMCSF 935.3 370.4 862.0 42.1 1042.0 778.0 789.4 721.7 1091.0 957.5
IFN-g    *       *       *    3162.6 2926.9    *       *       *       *       *   
TNF-a 52.2    *    40.6 115.8 495.4    *    46.1    *    59.6 36.1
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Figure   3-19 Effect of Ig ± ± ± ± XL and TGF-b b b b1 on the cell morphology of PTEC 
Morphology of cultured PTEC stimulated with Ig ± XL and TGF b1 for 72 hrs at 
37°C. (A) unstimulated HK 2 cells; (B) TGF b1; (C) IgG; (D) IgG + XL; (E) HA 
IgG; (F) IgA; (G) IgA + XL; (H) HA IgA; (I) IgM. Photographs are shown at the 
original magnification × 100. 
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Chapter 4: Effect of immunosuppressive agents on 
human PTEC 
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4.1 Introduction: 
4.1.1 Background 
For patients with ESRD, transplantation of the kidneys has, in recent years, become the 
first-line  treatment  of  choice  (Wolfe  et  al.,  1999).  Over  the  last  two  decades,  patient 
outcomes, post-transplantation, have improved dramatically, in the short-term at least, due 
to the introduction of several new immunosuppressive drugs. Immunosuppressive drugs 
are  classified  into  antimetabolites  (e.g.  azathioprine),  biological  immunosuppressants 
(antibodies),  non-biological  immunosuppressants  and  immunophilin  binders.  The  last 
group include calcineurin inhibitors (CNIs), such as cyclosporine and FK506 (tacrolimus), 
and non-CNIs, such as sirolimus (rapamycin). 
The introduction of these agents has significantly reduced the likelihood of acute rejection 
and improved the rate of graft survival at 1 year. However, these treatment advances have 
not had the same effect on long-term patient outcomes (Morales et al., 2001). This is 
perhaps due to the serious side effects that may arise from the long-term use of some 
immunosuppressants, including nephrotoxicity and arterial hypertension (Meier-Kriesche 
et al., 2004). 
The two major therapeutic goals after renal transplantation are to avoid acute rejection 
episodes and to limit the side effects of immunosuppression. This is particularly important 
as immunosuppressive drugs are often used in combination with each other, rather than 
alone (Waller&Nicholson, 2001). 
In this chapter, I concentrate on the effects of the immunophilin binders as this class of 
drugs has been shown to have nephrotoxic effects when used over a long period of time. 
4.1.1.1  Cyclosporine 
Of  the  three  immunosuppressive  drugs  under  study,  cyclosporine  is  the  oldest.  When 
introduced in the early 1980s, it was the most specific immunosuppressant available and 
dramatically benefited not just renal transplantation patients but also those receiving other 
donor organs. Today, cyclosporine continues to be an important part of most maintenance 
immunosuppression  treatment  regimens  for  almost  all  types  of  organ  transplant. 
Cyclosporine  inhibits  the  activity  of  calcineurin  through  binding  with  its  cytoplasmic 
receptor protein, cyclophilin, and this inhibition leads to a suppression in T cell activation C C Ch h ha a ap p pt tte e er r r    4 4 4          E E Ef fff ffe e ec c ct tt    o o of ff    I IIm m mm m mu u un n no o os s su u up p pp p pr r re e es s ss s si iiv v ve e e    a a ag g ge e en n nt tts s s, ,, 138 
by impairing the expression of a number of critical activation genes, most importantly the 
one for IL-2 (Fig. 4.1) (Elliott et al., 1984; Hess et al., 1982; Shevach, 1985). 
The action of cyclosporine molecules on the cellular membranes of PTEC causes rapid 
injury, within hours or days, when the drug reaches trough concentrations of >300 ng/ml in 
the blood (Cavallo&Roy, 1998). Therapeutic doses of cyclosporine (5–10 mg/kg) lead to 
trough concentrations in the whole blood of 200–500 ng/ml (0.166–0.416mM) or 20–60 
ng/ml (0.0166- 0.050mM) in serum. In a model using immortalised rat PTEC, even short-
term use of cyclosporine caused loss of the brush border (leading to a reduction in renal 
reabsorption) and dilation of the proximal tubules (Burdmann et al., 2003). 
4.1.1.2  FK506 (tacrolimus) 
Like  cyclosporine,  FK506  is  a  CNI  commonly  used  in  immunosuppressive  treatment 
regimens and indeed the two agents have a very similar mechanism of action. Whereas 
cyclosporine acts by binding cyclophilins, FK506 acts by binding FK506-binding proteins 
(FKBPs). By inhibiting calcineurin, FK506 prevents the activation of transcription factors 
in response to the elevated levels of intracellular calcium seen with stimulation of TCR. As 
with cyclosporine, this prevents the synthesis of IL-2 and other important cytokines (Fig. 
4.1).  In  terms  of  potency,  FK506  differs  considerably  from  cyclosporine  and  is 
approximately 100 times more potent on a molar basis (Kaplan et al., 1995). Moreover, 
whereas cyclosporine is ineffective in the treatment of steroid-resistant allograft rejection, 
FK506 has been shown to be able to reverse it (Almawi&Melemedjian, 2000). Thus, it is 
possible that FK506 inhibits T-cell activation at additional stages to that of cyclosporine. 
FK506,  a  metabolite  of  the  Japanese  soil  fungus  Streptomyces  tesukubaensi,  was  first 
approved  in  1994  for  use  as  an  immunosuppressant  in  liver  transplantation.  In  renal 
transplantation, FK506 is typically given in doses of 0.03–0.05 mg/kg leading to trough 
concentrations  of  5–20  ng/ml  (0.0062–0.02  mM)  in  blood  (Limbird,  2001).  After 
transplantation, FK506 should not exceed a maximum trough concentration of 40 ng/ml 
(0.050mM) (Japanese, 1991; Nashan et al., 1988; Sano et al., 1995). FK506 significantly 
inhibits the production of GM-CSF at concentrations of ³10 ng/ml (0.01  M), compared 
with cyclosporine concentrations of 0.1 mg/ml (0.083  M) or higher. C C Ch h ha a ap p pt tte e er r r    4 4 4          E E Ef fff ffe e ec c ct tt    o o of ff    I IIm m mm m mu u un n no o os s su u up p pp p pr r re e es s ss s si iiv v ve e e    a a ag g ge e en n nt tts s s, ,, 139 
4.1.1.3  Sirolimus 
Derived  from  a  soil  actinomycete  isolated  from  Streptomyces  hygroscopicus  originally 
found on Easter Island (whose native title of Rapa Nui led to the drug first being named 
rapamycin), sirolimus is a macrolide lactone antibiotic with immunosuppressant properties. 
Although sirolimus is structurally similar to FK506 and binds to the same immunophilin 
(FKBP),  it  has  no  effect  on  calcineurin  and  does  not  block  the  calcium-dependent 
activation  of  cytokine  genes.  Instead,  the  active  sirolimus–FKBP  complex  inhibits  cell 
division by reducing expression of the enzyme P7056 kinase through binding to target of 
rapamycin (TOR) proteins. In doing so, the cell cycle cannot progress from the G1 to the S 
phase and the cells do not divide (Fig. 4.1) (Gummert et al., 1999). 
To date, sirolimus has been used in a variety of combinations and situations. It is most 
commonly used in conjunction with one of the CNIs, usually to help withdraw or avoid 
completely  the  use  of  corticosteroids  in  maintenance  immunosuppressive  treatment 
regimens (Lee&Chapman, 2005). 
In adults, sirolimus is given at a dose of 2 mg/day following a loading dose of 6 mg. At 
trough levels of >6 ng/ml (0.006 M), sirolimus is effective at reducing the risk of acute 
rejection, while levels >15 ng/ml (0.019 M) were associated with more frequent adverse 
events (Davison, 2005). 
4.1.2 The role of immunosuppressant agents in renal disease 
In the last 10 years, PTEC have become a key focus for investigators interested in the 
pathogenesis of renal injury and disease. In vitro and in vivo studies have shown that PTEC 
play  an  important  role  in  tubulointerstitial  injury  by  mediating  the  production  of 
proinflammatory cytokines and other markers of inflammation (Daha&van Kooten, 2000; 
Kuroiwa et al., 2000; Zhou et al., 2001). Further studies revealed that PTEC is a major 
source  of  complement  C3  (an  important  inflammatory  trigger  normally  derived  from 
hepatocytes (Alper et al., 1969)) in the injured kidney (Ludwig et al., 2001; Zhou et al., 
2001); indeed, one study found that, in inflammatory conditions, PTEC expression of C3 
constituted up to 15% of the total circulating levels of the complement (Tang et al., 1999). 
In addition, PTEC are able to function as APCs as they can express MHC-II, adhesion 
molecules and co-stimulatory molecules such as CD40 and CD40 ligand, enabling them to 
interact with T-cells (Memoli et al., 2000; Shu et al., 2000; van Kooten et al., 1997). C C Ch h ha a ap p pt tte e er r r    4 4 4          E E Ef fff ffe e ec c ct tt    o o of ff    I IIm m mm m mu u un n no o os s su u up p pp p pr r re e es s ss s si iiv v ve e e    a a ag g ge e en n nt tts s s, ,, 140 
The location of PTEC in the renal system also makes these cells an interesting target for 
researchers. Because these cells are found between the urinary space, the renal interstitium 
and the peritubular capillaries, they react to both blood-borne substances and to substances 
not normally found in the urine, such as filtered proteins and inflammatory reactants. 
There have been few reports on how human PTEC react to therapeutic agents (Hughes et 
al., 1998; Johnson et al., 2000) and it is not yet clear whether immunosuppressive drugs 
directly inhibit the ability of PTEC to secrete inflammatory markers. Research in vivo has 
shown that renal PTEC are targeted by several nephrotoxins (Baliga et al., 1999; Eckert et 
al., 1989; Yamauchi et al., 1998), potentially leading to acute renal damage and chronic 
tubulointerstitial nephropathy characterised by tubular atrophy, loss of tubular cells and 
interstitial fibrosis. 
In  this  study,  I  examined  the  effects  of  CNI  (cyclosporine,  FK506)  and  non-CNI 
(sirolimus) as a model of nephrotoxicity as measured by various markers of progressive 
renal damages. Four mechanisms of renal damage were looked at: the expression of Fc 
receptors, the release of cytokines, the production of FN and the proliferation of PTEC 
leading  to  tubulointerstitial  inflammation/fibrosis  and  ESRF.  By  focusing  on  the 
immunosuppressants already known to have nephrotoxic side effects of their own, this 
study  aims  to  contribute  important  new  data  on  the  responsiveness  and  selectivity  of 
human PTEC to these agents. In section 3.3.2, I showed that the Ig receptors FcRn, pIgR 
and Fca/mR are expressed in immortalised HK-2 cells and primary PTEC and may play a 
role in renal disease. 
First,  I  will  provide  a  more  general  overview  of  how  these  agents  may  cause 
nephrotoxicity. 
4.1.3 Immunosuppressant-induced nephrotoxicity 
Nephrotoxicity  is  recognised  as  the  major  adverse  effect  of  cyclosporine  and  FK506; 
however, the mechanism for this remains unclear. In the case of cyclosporine, therapeutic 
doses lead to impaired renal function in almost every patient; hypertension is seen in up to 
50% of patients, serum creatinine increases by approximately 30% and both GFR and renal 
plasma flow are reduced. In addition, cyclosporine may cause early post-transplant graft 
dysfunction  or  worsen  existing  poor  graft  function  due  to  its  calcium-dependent 
potentiation of vasoconstriction of the renal vasculature. Fortunately, this vasoconstriction 
is  likely  to  be  a  transient,  reversible  and  dose-dependent  phenomenon.  In  a  study  by C C Ch h ha a ap p pt tte e er r r    4 4 4          E E Ef fff ffe e ec c ct tt    o o of ff    I IIm m mm m mu u un n no o os s su u up p pp p pr r re e es s ss s si iiv v ve e e    a a ag g ge e en n nt tts s s, ,, 141 
Mourad et al., (1998) chronic cyclosporine nephrotoxicity was estimated to be the sole 
cause of chronic allograft dysfunction in up to 6% of all renal transplant patients. 
Researchers  have  proposed  a  number  of  different  nephrotoxic  effects  leading  to  renal 
failure.  Firstly,  it  has  been  suggested  that  tubulointerstitial  damage  occurs  as  a 
consequence of chronic renal ischaemia. In addition to the release of factors such as TGF-
b,  endothelin-1  and  plasminogen  activator  inhibitor  type  1,  fibroblast  proliferation  and 
matrix synthesis may occur and GFR are reduced (Anglicheau et al., 2006). 
Second,  it  is  significant  that  cyclosporine  enhances  the  expression  of  TGF-b,  a  potent 
fibrogenic and angiogenic cytokine released after tissue injury, as heightened expression of 
TGF-b1  may  contribute  to  the  antiproliferative/immunosuppressive  activity  of 
cyclosporine. Indeed, blockade of cytokine gene activation does not fully account for the 
antiproliferative effect of cyclosporine (Wolf et al., 1995). 
A third potential cause of nephrotoxicity is the involvement of P-glycoprotein (Pgp), a 
protein  expressed  on  the  brush  border  of  PTEC  and  on  the  distal  tubule.  It  has  been 
suggested  that  Pgp  has  an  important  role  in  cyclosporine  nephrotoxicity.  Interestingly, 
sirolimus is a Pgp substrate and an interaction between cyclosporine and sirolimus has 
been observed. However, the significance of these findings has yet to be fully explored 
(Anglicheau et al., 2006). 
Long-term administration of cyclosporine and FK506 is known to produce histological 
changes  similar  to  those  of  allograft  fibrosis.  If  cyclosporine/FK506-induced 
nephrotoxicity remains untreated, it can contribute to CAN, the most common cause of late 
graft loss by causing irreversible renal dysfunction in association with tubular atrophy, 
interstitial fibrosis of the renal parenchyma. 
Sirolimus may be used as an alternative to cyclosporine or FK506 as part of a calcineurin-
sparing protocol. To date, both preclinical and human studies of sirolimus have revealed 
that the agent has few long-term nephrotoxic effects. Using a calcineurin-sparing protocol 
may also reduce hypertension, hyperlipidaemia, glucose intolerance and the overall risk of 
cardiovascular  disease.  Hence,  sirolimus  may  prove  to  be  better  than  cyclosporine  or 
FK506 for the long-term preservation of renal function in transplant recipients. C C Ch h ha a ap p pt tte e er r r    4 4 4          E E Ef fff ffe e ec c ct tt    o o of ff    I IIm m mm m mu u un n no o os s su u up p pp p pr r re e es s ss s si iiv v ve e e    a a ag g ge e en n nt tts s s, ,, 142 
4.1.4 The role of proteinuria in nephrotoxicity 
Although cyclosporine, FK506 and sirolimus have been shown to slow the progression of 
renal disease in the short-term, loss of renal function continues and proteinuria is rarely 
completely  normalised.  Working  against  the  drugs,  studies  have  shown  that  persistent 
proteinuria can cause progression of tubulointerstitial disease by inducing inflammation 
and fibrotic changes through the stimulation of cytokines, chemokines and growth factors 
such as IL-8, RANTES, MCP-1 and TGF-b (Bonegio et al., 2005). The development of 
new therapeutic agents that either slow or prevent renal injury due to proteinuria is a key 
research focus but the mechanisms of proteinuria-induced tubulointerstitial disease have 
proved difficult to study and are beyond the scope of this project. 
4.1.5 The effect of immunosuppressive agents on the expression 
of FcRs 
The family of Fc receptors include the FcRn, pIgR and Fca/mR. FcRn are responsible for 
the transportation of IgG from mother to neonate and are thought to maintain the long 
plasma  half-life  of  IgG.  Research  has  also  shown  that  FcRn  are  able  to  activate 
complement. pIgR are transporters found on the surface of epithelial cells and hepatocytes; 
they are thought to mediate transcytosis of polymeric IgM and IgA. Fca/mR is a novel 
receptor that binds both IgM and IgA. 
As discussed in Chapter 3, my early experiments showed that FcRn, pIgR and Fca/mR are 
expressed in PTEC. These findings prompted me to investigate how the expression of these 
receptors in PTEC can be affected by the use of immunosuppressive agents with known 
nephrotoxicity. At present, the published literature contains very little information on this 
topic. Therefore, this study may provide new insights. 
4.1.6 The  effect  of  immunosuppressive  agents  on  cytokine 
production 
The macrophage-derived cytokines known to have proinflammatory properties include IL-
1b,  IL-6,  IL-8  and  TNF-a  and  these  may  play  a  role  in  the  mechanisms  of  renal 
inflammation in tubulointerstitial diseases (Losa Garcia et al., 1999). It has been reported 
that cyclosporine inhibits the production of IL-1b, TNF-a and IL-6 (Rofe et al., 1992; 
Tipton  et  al.,  1990),  but  the  mechanism  by  which  this  occurs  is  not  clear.  Moreover, C C Ch h ha a ap p pt tte e er r r    4 4 4          E E Ef fff ffe e ec c ct tt    o o of ff    I IIm m mm m mu u un n no o os s su u up p pp p pr r re e es s ss s si iiv v ve e e    a a ag g ge e en n nt tts s s, ,, 143 
cyclosporine has been shown to upregulate the production of GM-CSF, but it is not yet 
clear  whether  this  is  simply  part  of  a  more  general  increase  in  cytokine  production 
(Nguyen  et  al.,  1990).  Several  reports  have  documented  that  cyclosporine  inhibits  the 
production  of  IL-2  by  T-cells  by  inhibiting  specific  mRNA  synthesis.  Furthermore, 
additional work has shown that cyclosporine downregulates IL-4 and IFN-g, also both at 
the protein and mRNA level. The aim of the present study was to investigate the effect of 
cyclosporine, FK506 and sirolimus on the secretion of GM-CSF, IL-6 and IL-8 by human 
PTEC. 
4.1.7 The effect of immunosuppressive agents on FN production 
The long-term administration of CNIs is known to produce histological changes similar to 
those seen in allograft fibrosis (Palestine et al., 1984; Shihab, 1996). Cyclosporine directly 
stimulates renal scarring by increasing collagen production (Ghiggeri et al., 1994) and by 
increasing  the  synthesis  of  transcription  factors  that  promote  TGF-b  gene  transcription 
(Khanna et al., 1997). In various rodent models, studies of the molecular events that lead to 
renal  fibrosis  have  uncovered  three  recurrent  themes:  a  marked  infiltration  of 
monocyte/macrophage-derived cells, upregulated TGF-b1 expression and disturbances in 
ECM turnover caused by increased fibrogenesis and/or decreased fibrolysis (Eddy, 1996a). 
Distinct differences have been noted in the immunohistochemical localisation of TGF-b1 
in  PTEC  with  FK506  and  sirolimus,  suggesting  that  these  agents  may  have  different 
mechanisms  of  nephrotoxicity  (Ninova  et  al.,  2004).  This  hypothesis  requires  further 
study. 
Until recently, most research into cyclosporine-induced renal fibrosis has focused on ECM 
disturbances. In this thesis, I investigated the effects of cyclosporine, FK506 and sirolimus 
on FN production (as a marker of ECM) by PTEC. 
4.1.8 The  effect  of  immunosuppressive  agents  on  the 
proliferation of PTEC 
Under  normal  conditions,  the  proliferation  of  PTEC  is  uncommon.  During  acute  renal 
failure,  however,  the  severity  of  tubulointerstitial  injury  and  the  recovery  of  tubular 
function is subject to the ability of viable PTEC to enter the cell cycle and proliferate. The 
proliferation  of  PTEC,  as  measured  by  [
3H]-thymidine  uptake  into  cell  DNA,  has 
previously  been  studied  in  relation  to  both  cyclosporine  and  FK506  that  inhibited  cell C C Ch h ha a ap p pt tte e er r r    4 4 4          E E Ef fff ffe e ec c ct tt    o o of ff    I IIm m mm m mu u un n no o os s su u up p pp p pr r re e es s ss s si iiv v ve e e    a a ag g ge e en n nt tts s s, ,, 144 
growth by 50% at 1mg/ml, but pharmacological doses were not toxic to renal cells (Blaehr 
et al., 1993; Rezzani et al., 2002). In this study, I sought to extend these findings to include 
sirolimus and to confirm these earlier results. 
4.1.9 The use of lipopolysaccharide 
LPS is a bacterial cell wall product that acts as an important mediator in the development 
of  acute  renal  injury.  Secondary  to  infection,  by  expressing  high-output  nitric  oxide 
synthase, LPS exerts a cytotoxic effect that may cause tubular cell injury and, in some 
cases, acute renal allograft rejection. As discussed in Chapter 1, previous research has 
shown  that  LPS  stimulates  PTEC  and  provides  a  pathophysiological  model  of  kidney 
injury. 
4.1.10  Study objectives 
In  general,  nephrotoxicity  is  the  major  concern  regarding  adverse  effects  of 
immunosuppressive drugs, especially the effects on PTEC. In this study I have set out to 
answer the following questions: 
1.  Do  cyclosporine,  FK506  or  sirolimus  alone,  or  in  combination  with  LPS,  affect  Ig 
receptor expression on human PTEC? 
2. Do cyclosporine,  FK506 or sirolimus alone, or in combination with LPS, affect the 
release of cytokines by human PTEC? 
3. Do cyclosporine,  FK506 or sirolimus alone, or in combination with LPS, affect the 
production of FN by human PTEC?  
4. Do cyclosporine,  FK506 or sirolimus alone, or in combination with LPS, affect the 
proliferation of human PTEC? C C Ch h ha a ap p pt tte e er r r    4 4 4          E E Ef fff ffe e ec c ct tt    o o of ff    I IIm m mm m mu u un n no o os s su u up p pp p pr r re e es s ss s si iiv v ve e e    a a ag g ge e en n nt tts s s, ,, 145 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure   4-1 Mechanisms of action of maintenance immunosuppressive agents  
Cyclosporine and tacrolimus bind to their respective immunophilins, and inhibit 
calcineurin.  Calcineurin  is  then  unable  to  dephosphorylate  NFAT,  which  will 
prevent  translocation  of  NFAT  to  the  nucleus  and  thereby  production  of  IL 2. 
Sirolimus is an mTOR inhibitor. It binds to FKBP and inhibits mTOR, which in 
turn inhibits transition of the cell cycle from G1 to S phase. MPA and LFL are also 
cell cycle inhibitors, and act via inhibition of nucleotide synthesis. Abbreviations: 
CNI,  calcineurin  inhibitor;  FKBP,  FK506 binding  protein;  IL 2,  interleukin 2; 
LFL, leflunomide; MHC, major histocompatibility complex; MPA, mycophenolic 
acid; mTOR, mammalian target of rapamycin; NFAT, nuclear factor of activated T 
cells; TCR, T cell receptor, Adapted from (Samaniego et al., 2006). 
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4.2 Results 
4.2.1 Do immunosuppressants or LPS, alone or in combination, 
affect Ig receptor expression on human PTEC? 
In  order  to  assess  the  extent  to  which  immunosuppressive  agents  affect  the  mRNA 
expression of these receptors, I carried out a series of experiments with semi-qRT-PCR (as 
described in section 2.3.2) using specific forward and reverse primers for each receptor 
(Table 2-4). HK-2 cells were incubated for 24 hrs after treatment with one of the three 
study agents – cyclosporine, FK506 or sirolimus – with or without additional treatment of 
10 mg/mL LPS. Doses were tested in serial ten-fold dilution (0.01®0.1®1 mM). 
Treating  the  HK-2  cells  with  LPS  alone  led  to  a  significant  increase  in  the  mRNA 
expression of all three of the Ig receptors studied FcRn, pIgR and Fca/mR relative to the 
housekeeping gene b-actin, versus the untreated (control) HK-2 cells. The upregulation of 
pIgR  mRNA  was  much  greater  than  that  of  FcRn  and  Fca/mR;  pIgR  expression  was 
increased by 7.86-fold versus 1.55 and 1.95-fold for FcRn and Fca/mR, respectively (Fig. 
4-2–4). 
When treated with immunosuppressants alone (i.e. without LPS), there were no significant 
changes in the mRNA expression of any of the Ig receptors studied, relative to b-actin, 
compared  with  the  untreated  controls.  However,  when  LPS  was  applied  alongside  the 
immunosuppressants,  a  significant  reduction  was  seen  in  the  levels  of  pIgR  mRNA 
expression, relative to b-actin, versus the untreated controls at the highest concentration 
only (P<0.025). The expression of FcRn and Fca/mR mRNA was not significantly altered. 
In  these  experiments  I  used  U937  cells  as  a  positive  control  when  measuring  FcRn 
expression, 200 ng/ml IFN-g when measuring pIgR and 50 ng/ml IL-1a when measuring 
Fca/mR. As expected, a significant increase was seen in all three conditions. U937 cells 
upregulated FcRN expression by 3.16-fold, IFN-g upregulated pIgR expression by 11.24-
fold and IL-1a increased Fca/mR expression by 9.76-fold, relative to b-actin, versus the 
untreated controls (P<0.005 in all cases). C C Ch h ha a ap p pt tte e er r r    4 4 4          E E Ef fff ffe e ec c ct tt    o o of ff    I IIm m mm m mu u un n no o os s su u up p pp p pr r re e es s ss s si iiv v ve e e    a a ag g ge e en n nt tts s s, ,, 147 
4.2.2 Do immunosuppressants or LPS, alone or in combination, 
affect the release of cytokines by human PTEC? 
In section 3.3.11, I discussed how PTEC release the cytokines IL-6, IL-8 and GM-CSF in 
the  supernatant  of  cultured  HK-2  cells  in  basal  conditions.  Using  the  specific  ELISA 
described  in  section  2.5.2.1,  I  screened  the  release  of  these  cytokines  under  the  same 
conditions  following  treatment  with  the  immunosuppressants  cyclosporine,  FK506  and 
sirolimus at three different concentrations in a 10-fold serial dilution, as before. These 
experiments were conducted with and without LPS (10 mg/ml) stimulation after 24 hrs 
incubation in the supernatant. 
When the HK-2 cells were treated with LPS alone, the release of IL-6, IL-8 and GM-CSF 
increased by approximately 1.5-, 1.8- and 2.0-fold, respectively (P<0.017 in all cases). 
Conversely, treating with immunosuppressants alone had no effect on the release of the 
above cytokines (Fig. 4-5–7). 
Even at the highest concentration (1 mM), none of the three immunosuppressive agents (in 
combination with LPS) significantly were not inhibited the release of IL-6, IL-8 and GM-
CSF. Any variation in cell number was corrected by assessing cellular protein as described 
in section 2.4.3.  
4.2.3 Do immunosuppressants or LPS, alone or in combination, 
affect the production of FN by human PTEC? 
Previously, in section 3.3.8, I demonstrated the way in which PTEC produce FN. In a 
series of experiments, I investigated whether applying cyclosporine, FK506 or sirolimus, 
with or without LPS, had an effect on the production of FN. Using a specific ELISA, as 
described  in  section  2.5.1.  I  measured  the  levels  of  FN  after  72-hrs  incubation  with 
immunosuppressant agents either alone or in combination with LPS. TGF-b was used as a 
positive control. 
My  results  show  that  LPS  and  TGF-b  both  increased  the  production  of  FN  by  PTEC 
compared with the untreated HK-2 cells. Treatment with immunosuppressants both alone 
and in combination with LPS attenuated the production of FN in a dose-dependent manner. 
In cells treated with immunosuppressants alone, an effect was seen only at the highest 
concentration (1 mM) (Fig. 4-8). C C Ch h ha a ap p pt tte e er r r    4 4 4          E E Ef fff ffe e ec c ct tt    o o of ff    I IIm m mm m mu u un n no o os s su u up p pp p pr r re e es s ss s si iiv v ve e e    a a ag g ge e en n nt tts s s, ,, 148 
4.2.4 Do immunosuppressants or LPS, alone or in combination, 
affect the proliferation of human PTEC? 
As described in section 2.4.10, I measured the proliferation of HK-2 cells according to 
their uptake of [
3H]-thymidine. After 48-hrs incubation in the supernatant, I investigated 
whether cyclosporine, FK506 and sirolimus, alone and in combination with LPS, had an 
effect on the proliferation of HK-2 cells. 
As predicted in section 3.3.9, LPS alone showed an antiproliferative effect when compared 
with  TGF-b1,  which  was  used  as  a  positive  control.  With  or  without  LPS,  the 
immunosuppressants  significantly  decreased  the  proliferation  of  treated  HK-2  cells 
compared with untreated HK-2 cells. This reduction occurred in a dose-dependent manner 
(Fig. 4-9). C C Ch h ha a ap p pt tte e er r r    4 4 4          E E Ef fff ffe e ec c ct tt    o o of ff    I IIm m mm m mu u un n no o os s su u up p pp p pr r re e es s ss s si iiv v ve e e    a a ag g ge e en n nt tts s s, ,, 149 
4.3 Discussion: 
The  importance  of  PTEC  in  the  pathogenesis  of  kidney  disease  and  injuries  sustained 
during  renal  transplantation  is  widely  accepted.  Many  studies  have  shown  that  PTEC 
release a number of inflammatory mediators that can lead to tubulointerstitial injury and, in 
some cases, to CAN (Daha&van Kooten, 2000; Hong et al., 2002; Kuroiwa et al., 2000; 
Zhou et al., 2001). In combination with immunosuppressant-induced nephrotoxicity, the 
proinflammatory and profibrotic products of PTEC can ultimately lead to acute rejection 
episodes that may be fatal (Healy et al., 1998; Hortelano et al., 2000; Markewitz et al., 
1993; Ortiz et al., 1998). 
In this study, I investigated the in vitro effects of the immunosuppressants cyclosporine A, 
FK506 and sirolimus alone and in combination with LPS, as well as LPS alone, on FcRn, 
pIgR  and  Fca/mR  expression,  cytokine  release,  FN  production  and  the  proliferation  of 
PTEC. From a review of the literature, I observed that the variance in the concentrations of 
immunosuppressants used was large, ranging from 0.1–30 mM. Although it was generally 
acknowledged that concentrations higher than 10 mM were too toxic, as confirmed by my 
early experiments [data not shown], there was considerable disagreement on the optimal 
concentration  for  efficacy  without  nephrotoxicity.  This  variance  may  be  explained  by 
different  study  protocols,  taking  into  account  such  factors  as  incubation  time  and  cell 
culture, as well as experimental error. Based on this evidence, I opted to use a serial ten-
fold dilution with a maximum concentration of 1 mM (0.01®0.1®1.0 mM) when applying 
the immunosuppressive agents to the cells. 
The  expression  of  the  FcRn,  pIgR  and  Fca/mR  by  human  PTEC  was  demonstrated 
previously in Chapter 3, which has important implications for the pathogenesis of IgAN. 
The development of renal injury could be accelerated or contributed to by IgA present in 
the glomerular filtrate that interact with and activate tubular cells, leading to local cytokine 
production and tubulointerstitial fibrosis. Using semi-qRT PCR, I was unable to show an 
effect of cyclosporine, FK506 or sirolimus on the expression of Ig receptor mRNA by 
PTEC. In observing that the expression of FcRn and Fca/mR by PTEC did not differ when 
exposed to immunosuppressive agents with or without LPS, these findings favour a non-
inflammatory  role  for  these  receptors  in  renal  disease.  However,  when  LPS  was 
administered on its own, the expression of the above receptors was slightly increased. C C Ch h ha a ap p pt tte e er r r    4 4 4          E E Ef fff ffe e ec c ct tt    o o of ff    I IIm m mm m mu u un n no o os s su u up p pp p pr r re e es s ss s si iiv v ve e e    a a ag g ge e en n nt tts s s, ,, 150 
A recent study by Kobayashi et al. confirmed the presence of FcRn on renal PTEC and 
proposed a functional role for the receptor in the reabsorption of IgG from tubular filtrate 
(Kobayashi et al., 2002). In accordance with my findings, the investigators were unable to 
show a significant enhancement of  FcRn transcript levels when cultured human PTEC 
were treated with known nephrotoxic immunosuppressants. 
In comparison with FcRn, much less is known about the function of the novel receptor 
Fca/mR in PTEC. A study by Macdonald et al. (2002) found that the expression of Fca/mR 
by MSC was upregulated by treatment with IL-1a in a similar way to that seen in human 
PTEC. The enhanced expression of Fca/mR in the tubules may be of significance in the 
pathogenesis of proteinuric IgAN where PTEC are exposed to filtered IgA. 
In addition, there is evidence to suggest that LPS significantly increases the upregulation of 
Fc receptor expression (specifically FcγR and FcαR) in certain cells, for example PMN and 
monocytes (Lazaron et al., 2001; Palermo et al., 1997; Refici et al., 2001; Shen et al., 
1994). This evidence appears to confirm my finding that LPS increases the expression of 
FcRn, pIgR and Fcα R in PTEC. The interactions between LPS-binding protein and Fc 
receptor at the cell surface results in inflammatory cytokine release and internalisation and 
detoxification of LPS (Lazaron et al., 2001). 
My investigations into the expression of Ig receptors by PTEC in response to treatment 
with immunosuppressive agents were limited as I was unable to determine whether the 
receptors had an  effect  at the cell surface in PTEC. Failure to detect  an effect on the 
expression of Ig receptors may be due to an altered cell phenotype; it is possible that the 
cells  differentiated  at  a  different  stage  and  so  would  not  have  responded  to  treatment. 
Alternatively,  it  is  possible  that  only  a  subgroup  of  patients,  differentiated  by  genetic 
and/or other factors, functionally express the Ig receptors. By identifying this subgroup, it 
may be possible to determine which patients will develop progressive disease and which 
patients are susceptible. In addition, the use of immortalised cell lines in vitro may give 
different results to those of in vivo experiments. Using primary cultures of human PTEC 
may  be  vital  in  order  to  improve  our  understanding  of  the  molecular  mechanisms  of 
progressive tubulointerstitial diseases and lead to more specific treatments (Border&Noble, 
1997;  Lipkowitz et al.,  1996). The possibility of unfavourable  experimental conditions 
must also be considered, e.g. the incubation period, temperature and concentrations of the 
drugs. C C Ch h ha a ap p pt tte e er r r    4 4 4          E E Ef fff ffe e ec c ct tt    o o of ff    I IIm m mm m mu u un n no o os s su u up p pp p pr r re e es s ss s si iiv v ve e e    a a ag g ge e en n nt tts s s, ,, 151 
There is little available data on the nephrotoxic effect of immunosuppressive agents on the 
expression of Ig receptors by PTEC, and their molecular mechanisms are incompletely 
defined. As I was unable to show a significant effect of cyclosporine, FK506 or sirolimus 
on Ig receptors, further research is needed to develop a greater understanding of how these 
receptors are expressed on PTEC and to develop new immunosuppressants that may offer 
potential new strategies for the prevention and treatment of nephrotoxicity. Clarification of 
the ways in which tubular cells express Ig receptors should contribute to new hypotheses 
regarding  the  physiological  and  pathological  renal  response  to  kidney  disease  and 
transplantation injury. 
Cyclosporine, FK506 and sirolimus have been described to exert a strong inhibitory effect 
on the immune response to renal allografts (Jain&Ridker, 2005; Kino et al., 1987; Liu et 
al., 1991). Using a specific ELISA, my early experiments in Chapter 3 showed that the 
cytokines IL-6, IL-8 and GM-CSF were released by PTEC in significantly large quantities 
to warrant further, more detailed investigations. My results show that the amounts of IL-6, 
IL-8  and  GM-CSF  produced  by  unstimulated  PTEC  and  PTEC  stimulated  by 
immunosuppressive agents alone do not significantly differ, despite a slight reduction in 
the production of IL-8 and GM-CSF at high doses (1 µM). The absence of a significant 
reduction in the release of IL-6, IL-8 and GM-CSF by PTEC following treatment with 
immunosuppressive agents is in contrast to the findings of earlier studies (Halloran, 1996; 
Kunz&Hall, 1993). In some studies, an impressive reduction of >50% in the secretion of 
IL-6 by U937 cells was observed when treated with high-concentration cyclosporine (200 
ng/ml or ~0.166 mM) (Garcia et al., 1999; Moutabarrik et al., 1993). 
LPS is known to produce a global, nonspecific activation signal. In my experiments, I used 
LPS as a model of kidney injury in an attempt to evaluate the full potential of PTEC (Bank 
et al., 1998; Bian et al., 1999; Brauner et al., 2001). The response to LPS has been shown 
to be important to the innate immune response. Several reports have indicated regulation of 
LPS  by  urinary  proteins  and  various  cytokines,  of  which  PTEC  can  produce  a  large 
number, and these observations have been linked to a pathogenetic role of LPS in various 
diseases (Vink et al., 2002; Xu et al., 2001). 
Following stimulation of PTEC by LPS, there was a large increase in the secretion of all 
three  cytokines.  None  of  the  three  immunosuppressive  drugs  significantly  inhibited 
cytokine release, despite a slightly greater reduction with FK506 and sirolimus than with 
cyclosporine.  FK506  is  estimated  to  be  approximately  100  times  more  potent  than 
cyclosporine  in  suppressing  cytokine  production  by  PTEC  through  inhibition  of  the C C Ch h ha a ap p pt tte e er r r    4 4 4          E E Ef fff ffe e ec c ct tt    o o of ff    I IIm m mm m mu u un n no o os s su u up p pp p pr r re e es s ss s si iiv v ve e e    a a ag g ge e en n nt tts s s, ,, 152 
calcineurin-dependent  pathway,  which  may  explain  the  lack  of  any  effect  with 
cyclosporine, even with the addition of LPS. These findings are in contrast with those of 
(Kino et al., 1987; Liu et al., 1991; Sasakawa et al., 2000). 
In vivo, PTEC are exposed to a wide variety of cytokines and other mediators, which may 
prime the cells for enhanced function (Sean Eardley&Cockwell, 2005; Zheng et al., 2005). 
If the elevated expression of certain cytokines by PTEC from stimulated subjects with 
immunosuppressive agents is due to in vivo priming, then the priming mechanism may be 
selective for certain cytokines. The lack of a significant reduction in cytokines seen in my 
results is in disagreement with the observations of previous studies suggesting that any 
interruption  in  PTEC  activation  by  immunosuppressive  agents  leads  to  downstream 
inhibition  of  cytokine  expression  and  T-cell  proliferation (Halloran,  1996;  Kunz&Hall, 
1993).  However,  the  pathogenetic  factors  of  chronic  nephrotoxicity  are  not  well 
understood.  More  research  is  needed  to  examine  in  further  detail  the  impact  of 
immunosuppressive  drugs  on  the  release  of  cytokines,  which  is  important  in  the 
development of nephrotoxicity and the risk of CAN. 
Evidence  suggesting  a  possible  link  between  fibrosis  and  proliferation  was  first  put 
forward by Kuze et al. (Kuze et al., 1997). According to the methods described in Chapter 
2, I assessed the synthesis of FN by PTEC and the proliferation of these cells in vitro. My 
results show that both the production of FN and the proliferation by PTEC stimulated with 
immunosuppressive agents, either alone or in combination with LPS, are inhibited in a 
dose-dependent manner. However, it is important to notice that while the proliferation of 
PTEC is affected by the use of immunosuppressants at all concentrations, the production of 
FN is only significantly reduced at the highest concentration (1 mM). At this level, it is 
likely that the cytotoxicity in the cell was enough to prevent the production of FN. 
Alternatively, the reduction in FN seen in my results may be due to the loss of epithelial 
adhesion, disruption of the tubular basement membrane and enhanced cell migration and 
invasion  due  to  immunosuppressant-induced  epithelial-mesenchymal  transition  (EMT) 
(Liu, 2004; McMorrow et al., 2005; Yang&Liu, 2001). Rastaldi et al., (2002) and Slattery 
et al., (2005) reported that, at therapeutic doses, cyclosporine is known to provoke EMT in 
PTEC and this causes large amounts of ECM to be released by myofibroblasts that migrate 
into the interstitium. As a result, fibrosis may develop and this in turn may provoke further 
EMTs  in  neighbouring  epithelial  cells.  The  migration  of  myofibroblasts  caused  by 
cyclosporine has been shown in vitro and in vivo to be reduced by antibodies that target 
TGF-b1 (Healy et al., 1998). C C Ch h ha a ap p pt tte e er r r    4 4 4          E E Ef fff ffe e ec c ct tt    o o of ff    I IIm m mm m mu u un n no o os s su u up p pp p pr r re e es s ss s si iiv v ve e e    a a ag g ge e en n nt tts s s, ,, 153 
My in vitro experiments clearly showed that clinically relevant concentrations of the study 
drugs were directly toxic to human PTEC, as evidenced by reduced cellular FN production 
and  growth  function.  TGF-b  is  a  potent  stimulus  for  the  synthesis  of  ECM  proteins 
(including  collagen,  FN  and  proteoglycans  (Ignotz  et  al.,  1987))  in  various  cell  types 
(Border&Noble,  1994)  and  appears  to  play  a  key  role  in  this  in  vitro  model  of 
tubulointerstitial diseases, raising the possibility that more specifically targeted therapies to 
reduce fibrogenic cytokine activity within the tubulointerstitium may improve the ability to 
prevent disease progression following nephrotoxic injury (Johnson et al., 1999). 
An important study by Wolf et al. suggested that the endogenous stimulation of TGF-b1 by 
cyclosporine mediates the antiproliferative effect of the immunosuppressant (Wolf et al., 
1995). The authors proposed that cyclosporine-mediated intrarenal synthesis and release of 
TGF-b1 may play a role in the cyclosporine-induced growth arrest and might therefore be 
relevant in the development of chronic nephrotoxicity (AyanlarBatuman et al., 1991; Li et 
al., 1991; Wolf et al., 1995). Perhaps it would have been useful to extend the results of 
Wolf et al. to include LPS alone and in combination with FK506 and sirolimus. In my 
experiments,  LPS  alone  increased  the  production  of  FN  by  PTEC,  indicating  that  the 
ability of bacterial cell wall products to alter FN production may account for renal fibrosis 
(Adachi et al., 1996; Kitamura et al., 1995). 
In  my  experiments,  cyclosporine,  FK506  and  sirolimus  were  shown  to  have  an 
antiproliferative  effect  on  PTEC.  These  observations  indirectly  suggested  that  the 
treatment with the study drugs caused significant reductions in DNA synthesis in a dose-
dependent manner, as indicated by lower [
3H]-thymidine uptake. This concurs with the 
findings of other in vitro studies that have shown that immunosuppressive agents inhibit 
growth factor-stimulated cell progression, prevent cell division and reduce DNA synthesis, 
thereby exerting an antiproliferative effect in PTEC and MSC (Blaehr et al., 1993; Sehgal, 
1998; Sun&Wang, 1997; Wann et al., 1992). 
I observed that cyclosporine and FK506 reduced [
3H]-thymidine uptake into renal cells in a 
dose-dependent manner, whereas sirolimus gave a stronger inhibition of PTEC responses. 
Whether  this  response  was  a  specific  effect  of  the  immunosuppressants  or  a  result  of 
cytotoxicity is still unknown. This observation is in agreement with that of Kim et al. (Kim 
et al., 2000) and with studies performed on the tubular cell line LLC-PK1 (Moutabarrik et 
al., 1991). In my study, the dose-dependent reduction of proliferation was similar to the 
results reported by (Radeke et al., 1993). However, the mechanism by which this occurs is 
still unknown. C C Ch h ha a ap p pt tte e er r r    4 4 4          E E Ef fff ffe e ec c ct tt    o o of ff    I IIm m mm m mu u un n no o os s su u up p pp p pr r re e es s ss s si iiv v ve e e    a a ag g ge e en n nt tts s s, ,, 154 
There are two possible mechanisms by which immunosuppressive agents may inhibit [
3H]-
thymidine uptake. The first is that the drugs may cause a blockade in the G0/G1 phases of 
the cell cycle, thereby inhibiting the proliferation of PTEC and slowing the recovery of the 
kidneys after acute ischaemia; the second possibility is that PTEC lose their brush border 
in vitro. In a model using immortalised rat PTEC, even short-term use of cyclosporine 
caused loss of the brush border and dilation of the proximal tubules, causing a reduction in 
tubular reabsorption rate (Burdmann et al., 2003). 
In reference to the first possible mechanism, Healy et al. (Healy&Brady, 1998) observed 
dose-dependent elevations in the proportion of cells in the G0/G1 phases of the cell cycle 
using  flow  cytometry  following  exposure  to  cyclosporine.  In  addition,  cyclosporine 
induced glomerular synthesis of ROS, such as hydrogen peroxide, which damages DNA 
(Parra et al., 1998). Enhanced generation of intracellular ROS may represent an alternative 
explanation for the growth-inhibitory mechanism of immunosuppressive agents. A recent 
study by (Lieberthal et al., 2001) used an experimental model of acute ischaemic renal 
failure  to  show  that  even  though  the  use  of  sirolimus  delays  recovery  of  glomerular 
filtration rate and the regeneration of PTEC, renal function does eventually return, even if 
the patient continues treatment with sirolimus. The authors propose that this recovery of 
function against the odds is indicative of an “adaptive” response by PTEC characterised by 
the  development  of  resistance  to  sirolimus.  They  also  speculate  that  this  resistance  is 
limited  to  the  renal  tubular  cells  and  does  not  involve  the  immune  system,  thereby 
providing a potential explanation for the relative lack of nephrotoxicity associated with 
sirolimus (Lieberthal et al., 2006). In my study, LPS was shown to reduce the proliferation 
of PTEC at the effective concentration of 10 mg/ml and, when given in combination with 
immunosuppressive agents, reduces the proliferation further. Thus, it can be concluded that 
LPS  in  combination  with  immunosuppressive  agents  had  a  more  potent  effect  on  the 
reduction of PTEC proliferation than LPS alone. Further experimental and clinical studies 
should be conducted to determine the exact relationship between FN production, TGF-b1 
secretion and the proliferation of PTEC cells. 
Although it was beyond the scope of this project, it would have been interesting to observe 
the  effect  of  cyclosporine,  FK506  and  sirolimus  on  apoptotic  cell  death  of  PTEC. 
However, in addition to the many papers on PTEC apoptosis already  in the published 
literature,  a  large  amount  of  research  is  currently  underway  in  this  area.  The  main 
limitation of the present study is the inherent difficulties in extrapolating the results of an 
in  vitro  study  to  in  vivo  effects  in  treated  patients.  As  cyclosporine  and  sirolimus  are 
lipophilic  compounds,  their  respective  concentration  might  be  higher  in  the  cellular C C Ch h ha a ap p pt tte e er r r    4 4 4          E E Ef fff ffe e ec c ct tt    o o of ff    I IIm m mm m mu u un n no o os s su u up p pp p pr r re e es s ss s si iiv v ve e e    a a ag g ge e en n nt tts s s, ,, 155 
membrane than in blood. It is therefore difficult to ensure that in vitro concentrations we 
used have an in vivo relevance. 
In  summary,  I  have  investigated  the  role  of  cyclosporine,  FK506  and  sirolimus  on 
susceptibility  to  nephrotoxicity  in  cultured  human  PTEC.  My  results  inferred  that 
immunosuppressive  agents  alone  have  a  non-inflammatory  response  on  Ig  receptor 
expression. However, in combination with LPS, the study drugs showed a slight inhibitory 
effect on the expression of the pIgR on human PTEC at the highest concentration. This 
finding may offer potential new strategies for the prevention and treatment of drug-induced 
nephrotoxicity. My results failed to show any significant inhibition of cytokine release 
with the study drugs, even at the highest concentration. However, the pathogenetic factors 
of chronic nephrotoxicity are not yet fully understood. More research is needed to examine 
in further detail the impact of immunosuppressants on the release of cytokines, which has 
important implications for inflammation, the development of nephrotoxicity and the risk of 
CAN. Cyclosporine, FK506 and sirolimus were shown to inhibit both the production of FN 
and  the  growth  of  PTEC,  thereby  exerting  an  antiproliferative  effect.  However,  the 
inhibition  achieved  at  the  concentrations  used  in  this  study  did  not  reach  statistical 
significance.  As  always,  a  major  limitation  of  in  vitro  studies  such  as  this  is  that  the 
relevance of the findings may not extend to the in vivo condition in treated patients. C C Ch h ha a ap p pt tte e er r r    4 4 4          E E Ef fff ffe e ec c ct tt    o o of ff    I IIm m mm m mu u un n no o os s su u up p pp p pr r re e es s ss s si iiv v ve e e    a a ag g ge e en n nt tts s s, ,, 156 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure   4-2 Effect of immunosuppressive agents on FcRn expression on PTEC 
The fold differences of expression of FcRn receptor measured by semi qRT PCR in 
relation to control treatment with immunosuppressive agents, with and without 
LPS for 24 hrs in HK 2 cells. The amplification of FcRn was relative to b actin 
gene, which was used as a house keeping gene. LPS alone shows a slight increase 
in expression 1.55±0.252 fold (*P<0.025). The result showed there is no significant 
change  in  expression  with  immunosuppressive  agents  alone  or  in  combination 
with LPS in a dose dependent manner. The positive control used to compare the 
expression  were  U937  cells,  which  were  up regulated  3.16±0.042  fold 
(**P<0.005).  This  graph  was  representative  of  two  experiments  and  triplicate 
reactions at each condition, which were amplified along the iCycler iQ Real time 
PCR system. Error bars show the (± SD). Standard curve had r = 0.990, slope=  
3.452, PCR efficiency = 94.8%. (*) Comparison between control and U937 cells, 
and also with LPS).  
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Figure   4-3 Effect of immunosuppressive agents on pIgR expression on PTEC 
The fold differences of expression of pIgR receptor measured by semi  qRT PCR in 
relation to control treatment with immunosuppressive agents, with and without 
LPS for 24 hrs in HK 2 cells. The amplification of the pIgR was relative to b actin 
gene which was used as a house keeping gene. LPS alone shows an increase in 
expression 7.86±0.858 fold (*P<0.025). The result showed there is no significant 
change in expression with immunosuppressive agents alone. In combination with 
LPS/immunosuppressive  agents  that  was  showed  a  significant  decrease  in 
expression with FK506 and sirolimus and cyclosporine A at the highest dose of 1 
mM. The positive control was used to compare the expression of pIgR in HK 2 cell 
line and was up regulated by 200 ng/ml IFN g 11.24±0.195 fold (**P<0.005). This 
graph  was  representative  of  two  experiments  and  triplicate  reactions  at  each 
condition, which were amplified along the iCycler iQ Real time PCR system. Error 
bars show the (± SD). Standard curve had r = 0.997, slope=  3.772, PCR efficiency 
= 100.5%. (*) Comparison between control and HK 2 cell lines treated with either 
200  ng/ml  IFN g  or  LPS).  (+)  Comparison  between  LPS  alone  and  LPS  in 
combination with immunosuppressive agents: + P<0.025). 
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Figure   4-4 Effect of immunosuppressive agents on Fca a a a/m m m mR expression on PTEC 
The fold differences of expression of Fca/mR receptor measured by semi  qRT PCR 
in relation to control treatment with immunosuppressive agents with and without 
LPS for 24 hrs in HK 2 cells. The amplification of Fca/mR was relative to b actin 
gene, which was used as a house keeping gene. LPS alone showed a slight increase 
in  expression  1.95±0.252  fold  (*P<0.025).  The  result  showed  that  there  is  no 
significant  change  in  expression  with  immunosuppressive  agents  alone  or  in 
combination with LPS in a dose dependent manner. The positive control was used 
to compare the expression of Fca/mR in HK 2 cell line and were up regulated 50 
ng/ml IL 1a 9.76±0.563 fold; (**P<0.005). This graph was representative of two 
experiments and triplicate reactions at each condition, which were amplified along 
the iCycler iQ Real time PCR system. Error bars show the (± SD). Standard curve 
had r = 0.988, slope=  2.928, PCR efficiency = 119.6%. (*) Comparison between 
control and HK 2 cell lines treated with either 50 ng/ml IL1 a or LPS).  
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Figure   4-5 Effect of immunosuppressive agents on IL-6 production by PTEC 
Dose dependent induction of IL 6 by immunosuppressive agents with and without 
LPS in cultured supernatant HK 2 cells for 24 hrs expressed as a percentage of 
control.  Level  of  IL 6  was  measured  by  ELISA.  None  of  the  three 
immunosuppressive agents showed significant changes in IL 6 production. LPS 
stimulated  cytokine  production  but  this  was  not  significantly  inhibited.  Media 
alone was used as a negative control and LPS as a positive control. These data 
represent  three  measurements  in  three  separate  experiments  (n=9).  Error  bars 
show  the  (±  SD)  (*P<0.017).  (*)  Comparison  between  control  treated  and 
untreated with LPS. 
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Figure   4-6 Effect of immunosuppressive agents on IL-8 production by PTEC 
Dose dependent induction of IL 8 by immunosuppressive agents with and without 
LPS in cultured supernatant HK 2 cells for 24 hrs expressed as a percentage of 
control.  Level  of  IL 8  was  measured  by  ELISA.  None  of  the  three 
immunosuppressive agents significantly reduced IL 8 production. LPS stimulated 
cytokine production but this was not significantly inhibited. Media alone was used 
as a negative control and LPS as a positive control. These data represent three 
measurements in three separate experiments (n=9). Error bars show the (± SD) (* 
P<0.017). (*) Comparison between control treated and untreated with LPS. 
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Figure   4-7 Effect of immunosuppressive agents on GM-CSF production by PTEC 
Dose dependent  induction  of  GM CSF  by  immunosuppressive  agents  with  and 
without  LPS  in  cultured  supernatant  HK 2  cells  for  24  hrs  expressed  as  a 
percentage of control. Level of GM CSF was measured by ELISA. None of the three 
immunosuppressive  agents  significantly  reduced  GM CSF  production.  LPS 
stimulated  cytokine  production  but  this  was  not  significantly  inhibited.  Media 
alone was used as a negative control and LPS as a positive control. These data 
represent 3 measurements in three separate experiments (n=9). Error bars show 
the (± SD) (*P<0.017). (*) Comparison between control treated and untreated with 
LPS. 
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Figure   4-8 Effect of immunosuppressive agents on FN production by PTEC 
Effect of immunosuppressive agents with and without LPS on FN production. Cells 
were  treated  with  LPS  and  immunosuppressive  agents  respectively  in  a  dose 
dependent  manner  for  72  hrs  and  expressed  as  a  percentage  of  control.  FN 
production was measured by using specific ELISA. TGF b1 was used as a positive 
control.  LPS  and  TGF b1  alone  increased  FN  production,  whereas 
immunosuppressive  agents  alone  or  incombination  with  LPS  reduced  FN 
production  in  a  dose dependent  manner.  Data  are  shown  as  the  mean  of  four 
experiments  performed  in  duplicate  (n=8).  Error  bars  show  the  (±  SD) 
(*P<0.0125,  **P<0.0025,  ***P<0.00025;  +P<0.0125,  ++P<0.0025).  (*) 
Comparison  between  control  and  cells  treated  with  either  TGF b  or  LPS.  (+) 
Comparison between LPS alone and LPS in combination with immunosuppressive 
agents). 
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Figure   4-9 Effect of immunosuppressive agents on proliferation of PTEC 
Effect of immunosuppressive agents alone and in combination with LPS on HK 2 
cell proliferation measured using [3H] thymidine uptake for 24 hrs, expressed as a 
percentage  of  control.  Cells  treated  with  immunosuppressive  agents  with  and 
without  LPS  showed  an  inhibitory  effect  on  proliferation  in  a  dose dependent 
manner.  HK 2  culture  media  was  used  as  a  negative  control  and  TGF b1  as  a 
positive control. Data shows the mean of two experiments performed in replicates 
of 12 (n=24). Error bars show the (± SD) (* P<0.025, ** P<0.005, *** P<0.0005: + 
P<0.025, ++ P<0.005, +++ P<0.0005). (*) Comparison between control treated 
and untreated with TGF b and/or LPS. (+) Comparison between LPS alone and 
LPS in combination with immunosuppressive agents). 
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5.1 Introduction 
5.1.1 Background 
As  seen  in  previous  chapters,  the  degree  of  tubulointerstitial  injury  in  human  GN  is 
associated with progression to ESRF, and that the underlying mechanisms behind this are 
not  yet  fully  understood.  We  know  that  it  involves  infiltration  of  the  nephron  by 
inflammatory mediators and the overproduction of ECM, and we have seen that PTEC 
have  a  potential  role  in  the  development  of  tubular  injury,  not  only  as  a  target  in 
themselves  but  also  through  their  ability  to  release  cytokines  and  produce  ECM 
components such as FN. 
In this chapter I will discuss the properties and efficacy in kidney disease of 3-hydroxy, 3-
methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, otherwise known as statins. 
Statins have been described as the principal and the most effective agents for reducing 
serum  cholesterol  levels  (LaRosa,  2002).  Moreover,  statins  have  been  shown  to  have 
diverse effects on the immune system, and because of this they have significant potential in 
the  treatment  of  autoimmune  disease  (Gurevich  et  al.,  2005;  Sherer&Shoenfeld,  2002; 
Steffens&Mach, 2004; Zamvil&Steinman, 2002). Currently, these agents are best known 
for their use in preventing atherosclerosis. They work by lowering plasma lipids in patients 
at increased cardiovascular risk, and by doing so reduce both mortality and morbidity rates 
(Baigent et al., 2005). Indeed, so popular have they become in this therapeutic area that 
they  are  now  prescribed  to  more  than  25  million  people  worldwide,  and  this  number 
appears to be constantly increasing. 
Due to their relatively good safety profile and oral administration, statins are viewed in an 
attractive light and much research has been conducted to discern the properties of these 
agents. Extensive clinical and laboratory studies have provided compelling evidence that 
statins are able to modulate a significant number of pathophysiological pathways beyond 
lipid  metabolism  (Jain&Ridker,  2005;  Laufs&Liao,  2003;  Palinski&Tsimikas,  2002; 
Takemoto&Liao, 2001). These so-called ‘pleiotropic’ properties of statins include anti-
inflammatory, anti-proliferative and immunomodulatory processes that may be beneficial 
in  treating  (predominantly  slowing)  progressive  renal  disease  (Agarwal&Curley,  2005; 
Buemi et al., 2002; D'Amico, 2006). However, whilst the ability of statins to attenuate 
experimental inflammatory disease is impressive, it has yet to be determined which statin-
modified pathway is most important in yielding improved clinical outcomes (Greenwood C C Ch h ha a ap p pt tte e er r r    5 5 5          E E Ef fff ffe e ec c ct tt    o o of ff    S S St tta a at tti iin n ns s s, 166 
et al., 2006). In experimental models, the anti-lipaemic effects of statins have been shown 
to be independent of all other actions of these agents (Muso et al., 1994; Phanish et al., 
2006).  In  humans,  however,  proving  the  dissociation  of  the  effects  of  statins  on  lipid 
metabolism from their other actions has proven difficult (Heusinger-Ribeiro et al., 2004). 
Whilst there is certainly a large body of evidence to recommend the use of statins in kidney 
disease, reports have emerged that statins can (indirectly) cause renal damage. However, in 
these  cases,  the  damage  is  typically  due  to  rhabdomyolysis-associated  acute  tubular 
necrosis and not a direct effect of the statins themselves. In one case, however, the severity 
of disease appeared to be dose-related (van Zyl-Smit et al., 2004). Although tubular injury 
may be slight and hard to detect, cumulative injury may result in significant renal damage 
over a period of years. 
In my thesis, I examined the effects of simvastatin 0.01–10 mM and fluvastatin 0.01–10 
mM on PTEC in response to activation by LPS 10 mg/ml. In particular, I looked at the 
effect of statins on the expression of Ig receptors on PTEC, the release of cytokines by 
PTEC, FN production by PTEC and the proliferation of PTEC. 
5.1.1.1  Cholesterol pathway 
Cholesterol is necessary for the synthesis of steroid hormones, vitamin D, bile acids and 
lipoproteins,  and  the  maintenance  of  intracellular  levels  is  important.  In  patients  with 
hypercholesterolaemia, the reduction of intracellular cholesterol upregulates low density 
lipoprotein (LDL) receptors and aids the clearance of LDL from plasma. 
The inhibition of HMG-CoA reductase intervenes at the rate-limiting step in cholesterol 
synthesis, namely the conversion of HMG-CoA into mevalonate (Massy&Guijarro, 2001). 
The mevalonate pathway branches out before the synthesis of squalene and cholesterol 
(Figure 5-1), leading to other biologically important products such as dolichols (involved 
in  the  synthesis  of  lipoproteins),  ubiquinone  (or  Coenzyme  Q)  and  the  isoprenoids, 
farnesyl-pyrophosphate  (FPP)  and  geranylgeranyl-pyrophosphate  (GGPP) 
(Palinski&Tsimikas,  2002)  Non-sterol  pathway  enzymes  have  a  higher  affinity  for 
mevalonate substrates than sterol pathway enzymes and are thus favoured in the presence 
of sterols, which suppress the production of squalene synthetase and limit the incorporation 
of mevalonate into further sterols. C C Ch h ha a ap p pt tte e er r r    5 5 5          E E Ef fff ffe e ec c ct tt    o o of ff    S S St tta a at tti iin n ns s s, 167 
5.1.1.2  Chemistry and (structural/functional) properties of statins 
There are two types of statin: fungal-derived (simvastatin, lovastatin and pravastatin) and 
fully  synthetic  (fluvastatin,  atorvastatin,  cerivastatin,  pitavastatin  and  rosuvastation) 
(Davidson, 2002). 
Statins  may  also  be  defined  according  to  whether  they  are  lipophilic  (fluvastatin, 
simvastatin,  atorvastatin  and  lovastatin)  or  hydrophilic  (pravastatin  and  rosuvastatin) 
(McTaggart  et  al.,  2001;  McTavish&Sorkin,  1991).  In  contrast  with  their  hydrophilic 
counterparts, which have been shown to substantially reduce the risk of cardiovascular 
disease (Sacks et al., 1996; Shepherd et al., 1995), studies with the lipophilic statins have 
shown a modest reduction in cardiac events, despite aggressive lowering of cholesterol 
(Herd et al., 1997; Waters et al., 1994). 
5.1.1.3  Pharmacokinetic properties of statins 
As stated above, I concentrated on simvastatin and fluvastatin in my experiments. In the 
clinical setting, simvastatin is given as a lactone pro-drug that is then hydrolysed in vivo 
into the active hydroxy acid form (Corsini et al., 1995), while fluvastatin is administered in 
its  active  form  directly  (Corsini  et  al.,  1999;  McTaggart  et  al.,  2001).  All  statins  are 
absorbed rapidly following administration, reaching peak plasma concentration within 4 h 
(Cilla et al., 1996; Tse et al., 1992). With respect to inhibition of HMG-CoA reductase, all 
statins are relatively hepatoselective (the extent of which is determined by their solubility). 
This is particularly important as most endogenous production of cholesterol takes place in 
the liver. 
Researchers have shown that hydrophilic statins are distributed more selectively in hepatic 
cells than lipophilic ones. Because the membrane of extrahepatic cells consists of lipid 
bilayers,  hydrophilic  statins  cannot  penetrate  it,  and  thus  cannot  reach  the  intracellular 
enzyme; however, the hepatic cell membrane contains organic anion transporters, which 
take hydrophilic substances into the  cell. Cellular entry  of such molecules is therefore 
dependent on active uptake by these transporters (Inui et al., 2000; Kusuhara&Sugiyama, 
2002), which, in vivo, are mainly present on the basolateral side of the renal epithelium 
(Inui et al., 2000). Conversely, lipophilic statins (e.g. simvastatin, fluvastatin) can enter 
extrahepatic and hepatic cells. Thus, lipophilic statins could inhibit not only cholesterol 
synthesis but also production of essential substances via the HMG-CoA reductase reaction 
in many extrahepatic tissues (Hamelin&Turgeon, 1998; Ichihara&Satoh, 2002). C C Ch h ha a ap p pt tte e er r r    5 5 5          E E Ef fff ffe e ec c ct tt    o o of ff    S S St tta a at tti iin n ns s s, 168 
In a large clinical trial programme, 2.9% of patients receiving either simvastatin 10–80 mg 
or fluvastatin 10–40 mg developed side effects necessitating withdrawal from the study 
(Brewer, 2003; Schachter, 2005). Only a small number of patients developed proteinuria, 
and  this  was  usually  transient  and  reversible  and  not  associated  with  long-term  renal 
damage (Brewer, 2003). Treatment-associated serious adverse events were rare and were 
reported in less than 1% of patients. There were no treatment-related deaths. 
Other  studies  have  reported  an  apparent  higher  propensity  for  statins  to  cause  tubular 
injury  at  high  doses.  Statins  may  reduce  the  reabsorption  of  proteins  in  vivo  when 
prenylation of proteins involved in endocytosis is reduced, and when HMG-CoA reductase 
is sufficiently inhibited in PTEC, leading to proteinuria (Verhulst et al., 2004). 
5.1.1.4  Immunomodulatory effects/mechanisms of action of statins 
The  lipid-independent  anti-inflammatory  effects  of  statins  appear  to  be  regulated  by 
interference in the synthesis of mevalonate metabolites and by inhibition of the NF-kB-
dependent regulation of inflammation (Steiner et al., 2005). Many of the pleiotropic effects 
of statins have been linked to the isoprenylation of regulatory proteins (Hall, 1998); by 
covalently binding to these proteins, isoprenoids create lipid-binding sites that regulate the 
intracellular trafficking and membrane binding of these proteins (Kimoto-Kinoshita et al., 
2000).  For  example,  blocking  the  synthesis  of  GGPP  with  statins  upregulates  the 
expression of endothelial cell nitric oxide synthase (eNOS) and reduces geranylation of 
Rho (Laufs&Liao, 2003; Laufs et al., 1998). 
Much more than simply cholesterol by-products, isoprenoids have an important role in the 
post-translational  modification  of  regulatory  proteins,  including  the  Ras  superfamily 
guanosine triphosphate hydrolase enzymes (GTPases, or ‘small G proteins’) Ras, Rho and 
Rab (Hillyard et al., 2004a; Khwaja et al., 2006), which play a critical role in regulating 
cell proliferation and differentiation (Barbacid, 1987; Kocher et al., 2005). Considering the 
central  role  these  proteins  have  in  determining  cell  function,  it  follows  that  they  can 
modify the immune response independently of their anti-lipaemic effects. 
One  of  the  key  determinants  of  effective  treatment  is  the  inhibition  of  macrophage 
recruitment  and  function  by  reducing  the  expression  of  proinflammatory  mediators, 
including NF-kB and MCP-1 (Park et al., 1998b; Sukhova et al., 2002; Yokota et al., 
2003).  By  blocking  the  NF-kB  signalling  pathway,  statins  prevent  the  release  of 
downstream proinflammatory mediators (Dichtl et al., 2003) and the upregulation of the C C Ch h ha a ap p pt tte e er r r    5 5 5          E E Ef fff ffe e ec c ct tt    o o of ff    S S St tta a at tti iin n ns s s, 169 
MCP-1  gene  (Eddy&Giachelli,  1995;  Klahr&Morrissey,  2002).  NF-kB  is  typically 
activated when the endoplasmic reticulum of cells becomes congested with viral proteins, 
initiating a fast and effective antiviral response. A more general mechanism of activation 
has been proposed, namely that protein stress in the endothelium upregulates NF-kB target 
genes, such as MCP-1, and may involve other gene products (Pahl&Baeuerle, 1995). The 
chemokine RANTES, a NF-kB-dependent gene, is known to be expressed by renal PTEC 
and is known to be produced following the stimulation of PTEC by TNF-a, IL-1a, LPS or 
aggregated IgG (Heeger et al., 1992; Satriano et al., 1997; Wolf et al., 1993). 
Recent reports have suggested that statins are also able to inhibit the expression of MHC-II 
on PTEC co-stimulated by IFN-g (Palinski, 2000). The ability of statins to downregulate 
MHC-II  expression  may  lead  to  reduced  Th1  cell  proliferation  and  inhibition  of 
proinflammatory cytokine release (Kwak et al., 2000). However, it has also been proposed 
that statins may induce the opposite effect by reducing Th2 proliferation, causing a shift 
towards a Th1 immune response (Figure 5-2) (Palinski, 2000). 
5.1.1.5  Lipid rafts  
The concept of lipid rafts was first introduced in 1972 by Singer and Nicolson, whose 
seminal review proposed that the outer layers of plasma membranes contain specialised 
lipid microdomains (‘rafts’) within which proteins are randomly interspersed and are free 
to move about (Lopez et al., 2005). These lipid membranes are primarily composed of 
cholesterol and sphingolipids, and are consequently thicker and less fluid than the other 
layers (Brown&London, 2000) (Figure 5-3). There are two types of lipid raft – caveolar 
and non-caveolar – and these co-exist in distinct areas of the membrane (Wang&Paller, 
2006). Both caveolar and non-caveolar rafts are enriched in cholesterol. Thus, depletion of 
cholesterol from cell membranes is an effective means of breaking down rafts (Li&Nord, 
2004). 
Lipid rafts play a role in a number of important biological processes; they help to modulate 
signal  transduction,  membrane  trafficking,  cytoskeletal  organisation  and  motility, 
polarisation  and  pathogen  entry  (including  viruses,  pathogenic  bacteria  and  parasites) 
(Pike, 2005; Rajendran&Simons, 2005). With regard to signalling, rafts are associated with 
a large number of membrane receptors, particularly Fc receptors and T and B cell antigen 
receptors  (Pierce,  2002;  Xavier  et  al.,  1998).  In  addition,  rafts  play  important  roles  in 
nearly every stage of haemostasis and thrombosis. C C Ch h ha a ap p pt tte e er r r    5 5 5          E E Ef fff ffe e ec c ct tt    o o of ff    S S St tta a at tti iin n ns s s, 170 
5.1.2 The effects of statins on renal disease progression 
Although  the  bulk  of  statin  research  has  focused  on  their  actions  in  cardiovascular 
indications, experimental models have shown that these agents also possess a number of 
beneficial effects in renal disease (Park et al., 2000; Vieira et al., 2005). The concept of 
lipid nephrotoxicity first emerged in 1982 and appears to share many of the characteristics 
of  atherosclerosis  (Moorhead  et  al.,  1982).  Progressive  renal  failure  occurs  once  some 
critical threshold of injury has been reached, characterised by proliferative and sclerotic 
processes  that  worsen  glomerular  and  tubulointerstitial  injury,  regardless  of  the  initial 
insult (Avram, 1989). Thus, there is potential for considerable renal benefits deriving from 
the anti-lipaemic properties of statins. 
However, to fully understand the mechanisms of the renal benefits of statins, we must also 
look at their lipid-independent actions. As well as reducing oxidative stress, some studies 
have suggested that statins are able to inhibit the proliferation of PTEC. Moreover, the 
immunomodulatory and anti-inflammatory properties of statins may also modify the course 
of  renal  disease,  independent  of  cholesterol  reduction  (Chang  et  al.,  2002; 
Palinski&Tsimikas, 2002; Park et al., 2000). Clinical and pharmacokinetic studies have 
demonstrated that statins are well tolerated and effective, even in patients who have CRF 
and are on maintenance dialysis (Lins et al., 2003; Saltissi et al., 2002). 
A protective effect of statins has been reported in experimental models of renal ischaemia–
reperfusion injury (Gueler et al., 2002; Yokota et al., 2003). In one such study, the anti-
inflammatory effects of statin therapy directly improved post-ischemic ARF, reducing cell 
infiltration and inhibiting the activation of NF-kB and MAP kinase (Gueler et al., 2002). In 
a  typical  response  to  ischaemia–reperfusion  injury,  FN  is  overproduced  in  the  renal 
interstitium (Zuk et al., 2001); however, statin pre-treatment has been shown to modulate 
this process and inhibit the subsequent assembly of ECM. 
The susceptibility to injury of renal PTEC is significantly increased when the cells are 
cholesterol  depleted  (Beutler,  2004).  In  various  in  vivo  experimental  models  of  renal 
injury, PTEC cholesterol content was shown to increase by 20–25%. This phenomenon 
suggests that cholesterol protects the renal tubules from superimposed attack (sometimes 
referred to as ‘acquired cytoresistance’). Normalising PTEC cholesterol levels reverses this 
cytoresistance, suggesting that intracellular changes in cholesterol levels are a spontaneous 
correlate of de novo ischaemic and toxic renal injury. C C Ch h ha a ap p pt tte e er r r    5 5 5          E E Ef fff ffe e ec c ct tt    o o of ff    S S St tta a at tti iin n ns s s, 171 
Overall, statins appear to have important potential in the treatment of progressive renal 
diseases, such as IgAN, although further studies are required to confirm this in humans 
(Buemi et al., 2002). Clinical trials indicate that the pleiotropic effects of statins may make 
them useful as immunosuppressive agents in transplant recipients (Masterson et al., 2005; 
Steffens&Mach, 2006; Tuncer et al., 2000). However, the impact of statin treatment on 
renal graft outcome needs to be examined in greater detail. 
5.1.3 The effects of statins on proteinuria 
As described previously, it is pertinent to remember that statins have been linked to renal 
damage as well as renal benefit. In high doses, all statins have the potential to cause tubular 
degeneration and proteinuria, especially in the short-term (Agarwal, 2004). 
As  seen  in  previous  chapters,  proteinuria  is  an  important  factor  in  progressive  renal 
disease; protein reabsorption triggers pro-fibrogenic and pro-inflammatory  genes in the 
kidney, possibly through the activation of PTEC. When challenged with albumin and IgG, 
PTEC  basolaterally  release  the  chemokine  RANTES,  which  may  contribute  to  the 
infiltration of inflammatory cells seen in CKD. Albumin uptake in PTEC is governed by 
receptor-mediated endocytosis (RME) (Agarwal, 2004). Provided that prenylated GTPases 
are present, RME of proteins in the proximal tubules occurs through megalin and cubulin 
receptors. By decreasing the activity of mevalonate, and thereby inhibiting the synthesis of 
FPP and GGPP, statins reduce the availability of prenylated GTPases and, consequently, 
impair RME. 
Sidaway et al. confirmed the hypothesis that statins impair RME by reducing prenylation 
of  GTP  binding  proteins  in  cell  cultures  of  PTEC  derived  from  the  opossum  kidney 
(Sidaway  et  al.,  2004).  Not  only  was  RME  reduced  in  a  dose-dependent  manner,  this 
reduction  was  not  related  to  binding  of  albumin  to  the  receptor  but  receptor-mediated 
albumin  endocytosis  (which  was  shared  by  other  proteins  such  as  b2-microglobulin). 
Moreover, the extent to which RME was inhibited was related to the in vitro inhibition of 
HMG-CoA reductase, which is dependent upon the lipophilicity of the statin. Thus, statins 
reduce albumin uptake by RME and therefore lead to proteinuria. 
Exposure of cultured PTEC to albumin is also reported to cause cellular activation via the 
JAK/STAT  signalling  pathways  (Nakajima  et  al.,  2004).  The  STAT  family  currently 
consists  of  seven  known  members  (in  mammalian  cells)  (Darnell,  1997),  and  can  be 
activated by a large number of cytokines, growth factors, ROS and more (Herrington et al., C C Ch h ha a ap p pt tte e er r r    5 5 5          E E Ef fff ffe e ec c ct tt    o o of ff    S S St tta a at tti iin n ns s s, 172 
2000; Ihle, 2001; Simon et al., 1998). Activation of the JAK/STAT pathway appears to be 
mediated by PTEC production or ROS in response to albumin challenge. 
These observations support my hypothesis that PTEC respond to the presence of excess or 
abnormal filtered protein by activating specific cellular signal transduction pathways that 
lead,  in  turn,  to  the  local  production  of  inflammatory  mediators  and  contribute  to 
tubulointerstitial injury. 
Statins are unique in that they have the potential to increase proteinuria in the short term, 
but reduce proteinuria (as well as inflammation, fibrosis and renal disease progression) in 
the  long  term.  Whether  or  not  these  effects  are  renoprotective  or  toxic  cannot  yet  be 
determined. 
5.1.4 The effects of statins on Ig receptor expression 
Following on from Chapter 3 in which I showed how LPS activation could be used as a 
model of tubular injury, I investigated the potential beneficial effects of statins with regard 
to Ig receptor gene expression on PTEC. In Chapter 3, I showed that PTEC express FcRn, 
PIgR and Fca/mR, all of which are relevant to the pathogenesis of renal injury, and that the 
gene  expression  of  these  receptors  is  upregulated  in  renal  cells  by  proinflammatory 
cytokines  (IL-1α,  IFNγ,  TGF-b1)  and  bacterial  LPS.  There  do  not  appear  to  be  any 
published studies on the effect of statins on Ig receptor gene expression on PTEC. 
5.1.5 The effects of statins on cytokine release 
In the present study, I examined the effects of statins on cytokine release by PTEC in 
response to activation by bacterial LPS. Statins have previously been reported to inhibit 
monocyte production of TNF-α and IL-8 (Grip et al., 2000; Romano et al., 2000), while a 
recent study showed that fluvastatin and simvastatin inhibited the FcγR-coupled release of 
IL-6, IL-8, IL-10 and MMP-1, with associated inhibition of the ERK and p38 (Hillyard et 
al., 2004a). An anti-inflammatory effect was also indicated by increased IL-6 expression in 
an experimental model of renal ischaemia–reperfusion injury after statin therapy, which 
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5.1.6 The effects of statins on FN production 
Tubulointerstitial fibrosis is caused by unbalanced ECM production and proteolysis and is 
recognised  as  one  of  the  main  prognostic  factors  for  renal  outcome  in  GN  and 
tubulointerstitial nephropathy (Risdon et al., 1968). TGF-β1 is known to play a key role in 
the development of renal fibrosis (Border&Noble, 1997) by stimulating the proliferation of 
interstitial  fibroblasts  and  signalling  them  to  secrete  ECM  (Border&Noble,  1994; 
Sharma&Ziyadeh, 1994). As well as their marked anti-inflammatory properties, statins are 
anti-fibrotic, perhaps as a result of interference in the renal fibrosis process. In an animal 
study, statins were shown to reduce progressive glomerulosclerosis and tubulointerstitial 
fibrosis in different models of renal injury (Vrtovsnik et al., 1999). Indeed, further studies 
are necessary to clarify the role of statins on fibrosis in cultured PTEC and on how this 
activity relates to cell proliferation. 
5.1.7 The effects of statins on proliferation of PTEC 
Cell number abnormalities resulting from an imbalance between cell birth and death can 
lead to various disorders with either too many cells (e.g. proliferative GN) or too few (e.g. 
renal  atrophy)  (Ortiz et al., 2001). In vitro studies have shown that statins can inhibit 
proliferation in smooth muscle cells, MSC and PTEC, independent of their anti-lipaemic 
effects (Corsini et al., 1993; Lan, 2003; Massy et al., 1997). The addition of mevalonate or 
its  isoprenoid  metabolites  was  able  to  at  least  partially  reverse  this  inhibition.  In  vivo 
models of GN have also shown that statin therapy attenuates neointimal thickening and 
MSC proliferation, independent of cholesterol levels, suggesting that the in vitro findings 
may extend to animal models (Nabeshima et al., 1997; Soma et al., 1993). 
Some  of  the  benefits  of  statin  therapy  may  be  accounted  for  by  a  reduction  in  renal 
interstitial inflammation and tubular activation. Isoprenylated proteins are necessary for 
cell cycle progression and for controlling cell growth (Agarwal&Curley, 2005); however, a 
study of simvastatin showed a significant antiproliferative action on PTEC (Vieira et al., 
2005),  while  another  study  showed  that  simvastatin  was  able  to  block  high  density 
lipoprotein (HDL) stimulation of proteins and monolayer resistance in PTEC (Buemi et al., 
2002). Thus, there is a clear need for more research in this area. 
Earlier  in  this  chapter,  I  discussed  how  statins  interact  with  Ras  monomeric  GTPases. 
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proliferation  and  may  therefore  represent  potential  targets  in  renal  therapies 
(Hendry&Sharpe, 2003; Khwaja et al., 2000; Pruitt&Der, 2001; Sharpe et al., 2000). 
5.1.8 Uses of LPS with statins 
As we have seen, PTEC are capable of producing a large number of pro-inflammatory 
mediators, including chemoattractants, cytokines and ECM components. Several reports 
have indicated the regulation of LPS by various cytokines, urinary proteins and molecules 
in PTEC, and these observations have been linked to a pathogenetic role of LPS in various 
renal diseases (Vink et al., 2002; Xu et al., 2001). Renal inflammation increases circulating 
cytokine  and  chemokine  levels,  leading  to  nephrotoxic  and  post-ischaemic  ARF 
(Bonventre&Zuk, 2004; Friedewald&Rabb, 2004; Ramesh&Reeves, 2002), and potentially 
to ARF-associated multi-organ failure (Zager et al., 2007). As discussed in Chapter 1, LPS 
is an appropriate model for the renal inflammation involved in ARF. 
Recent studies have identified TLR4 as the signalling receptor for LPS (Kawai&Akira, 
2005; Wolfs et al., 2002). However, despite good evidence to suggest that, in ARF, the 
kidney over-responds to TLR ligands (Zager et al., 2006), the manner in which tubular cell 
injury  directly  impacts  on  the  expression  of  TLR  proteins  is  as  yet  unclear.  When 
incubated with both statins and LPS together, an inhibition of LPS-mediated activation of 
human  peripheral  mononuclear  cells  and  endothelial  cells  has  been  noted  (Rice  et  al., 
2003; Zeuke et al., 2002). This observation suggested that statins attenuated LPS effect. 
5.1.9 Study objective 
In my experiments with statins, I set out to answer the following questions: 
1. Do statins alone or in combination with LPS affect Ig receptor expression on human 
PTEC? If yes, do they act synergistically or do they antagonise each other? 
2. Do statins alone or in combination with LPS affect the release of cytokines by human 
PTEC? If yes, do they affect each other’s influence when used together? 
3. Do statins alone or in combination with LPS affect the production of FN by human 
PTEC? 
4. Do statins alone or in combination with LPS affect the proliferation of human PTEC?  C C Ch h ha a ap p pt tte e er r r    5 5 5          E E Ef fff ffe e ec c ct tt    o o of ff    S S St tta a at tti iin n ns s s, 175 
 
 
Figure   5-1 Cholesterol metabolic pathway.  
The schematic representation of the cholesterol biosynthetic pathway includes a 
number of cholesterol by products including dolicholphosphate and ubiquinone. 
Adapted from (Corsini et al., 1999). 
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Figure   5-2 Pleiotropic effects of HMG-CoA reductase inhibitors. 
Adapted from (Blanco Colio et al., 2003). 
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Figure   5-3 A model of lipid raft organisation  
Lipid  rafts  present  at  the  plasma  membrane  outer  leaflet  are  lipid  membrane 
microdomains  that  are  highly  enriched  in  tightly  packed  sphingolipids  and 
cholesterol. The composition of the raft present at the plasma membrane inner 
leaflet is still not known. Among the raft associated proteins (RPs), there are GPI 
anchored proteins (such as CD52 and CD59) and proteins endowed with a lipid 
anchor composed of saturated acyl chains (such as Lck and Lyn in T and B cells, 
respectively). Transmembrane receptors (TRs) are usually raft excluded. Adapted 
from (Pizzo&Viola, 2003). 
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5.2 Results 
5.2.1 Do statins or LPS alone or statins in combination with LPS 
affect Ig receptor expression on human PTEC? 
In  section  3.3.2  I  showed  that  Ig  receptors  FcRn,  pIgR  and  Fca/mR  are  expressed  in 
immortalised  HK-2  cells  and  primary  PTEC.  Therefore,  I  investigated  the  effect  of 
simvastatin  and  fluvastatin,  with  and  without  LPS,  on  the  mRNA  expression  of  Ig 
receptors. 
I investigated the mRNA expression levels of Ig receptors in immortalised HK-2 cells 
using semi-qRT-PCR (as described in section 2.3.2.1) with specific forward and reverse 
primers for each receptor, as shown in Table 2-4. HK-2 cells were incubated for 24 hrs 
following treatment with either statins or 10 mg/ml LPS, or a combination of statins with 
LPS, in a dose-dependent manner (0.01 mM, 0.1 mM, 1 mM and 10 mM). Cells treated with 
statins showed a dose-dependent increase in fold differences of the levels of FcRn, pIgR 
and Fca/mR mRNA expression relative to b-actin, versus the untreated HK-2 cells. 
Whilst treating with LPS alone led to an increase in the expression of mRNA for FcRn, 
pIgR  and  Fca/mR,  additional  treatment  with  statins  led  to  a  further  increase  in  the 
expression of these receptors, in a dose-dependent manner, so that the fold differences at 
higher concentrations were significant. U937 cells were treated as a positive control for the 
expression of FcRn. HK-2 treated with IFN-g (200 ng/ml) and IL-1a (50 ng/ml) were used 
as positive controls for the expression of pIgR and Fca/mR, respectively. The observed 
fold differences of Ig receptor expression were compared with untreated cells (control) 
relative to the housekeeping gene b-actin (Fig. 5-4). 
5.2.2 Do statins or LPS alone, or statins in combination with LPS, 
affect the release of cytokines by human PTEC? 
I showed in section 3.3.11 that PTEC release IL-6, IL-8, GM-CSF and TNF-a into the 
supernatant of cultured HK-2 cells. I assessed the levels of the IL-6, IL-8 and GM-CSF 
released by PTEC after treatment with simvastatin or fluvastatin, with and without LPS 
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Using specific ELISAs for individual cytokines, as described in section 2.5.2.1, I showed 
that LPS alone increased the release of IL-6, IL-8 and GM-CSF by approximately two-
fold.  Conversely,  statins  inhibited  the  release  of  these  cytokines  in  a  dose-dependent 
manner.  Furthermore,  statins  attenuated  the  effect  of  LPS  on  cytokine  release  in 
comparison with untreated cells (Fig. 5-5). The doses used are of clinical relevance, with 
peak  plasma  levels  of  approximately  1  mmol/L,  and  below  the  concentrations  that  are 
associated  with  apoptosis  (Hillyard  et  al.,  2004a).  The  variation  in  cell  number  was 
corrected by assessing cellular protein, as described in section 2.4.3. 
5.2.3 Do statins or LPS alone, or statins in combination with LPS, 
affect the production of FN by human PTEC? 
I  investigated  the  effect  of  simvastatin  or  fluvastatin,  with  and  without  LPS,  and  LPS 
alone, on FN production by PTEC. FN was measured after 72-hrs incubation of cultured 
HK-2 cells treated with statins, with and without LPS, and also after treating with LPS 
alone, using an ELISA as described in section 2.5.1. LPS increased FN production, though 
to a lesser extent than TGF-b1, which was used as a positive control (as described in 
section 3.3.8). Statins inhibited FN production and attenuated the affect of LPS on FN 
production in a dose-dependent manner. The percentage of FN production to untreated 
HK-2 cells is shown in Fig. 5-6. 
5.2.4 Do statins or LPS alone, or statins in combination with LPS, 
affect the proliferation of human PTEC? 
HK-2 cell proliferation was assessed using [
3H]-thymidine uptake, as described in Section 
2.4.10. I investigated the effect of statins and LPS alone, and statins in combination with 
LPS, on cell proliferation after 48-hrs incubation. LPS showed an antiproliferative effect, 
though to a lesser extent when compared with TGF-b1. 
Statins also showed an antiproliferative effect on HK-2 cells. This effect occurred in a 
dose-dependent manner in keeping with the pleiotropic effects of statins in other cells. LPS 
in  combination  with  statins  led  to  a  dose-dependent  reduction  in  cell  proliferation  in 
comparison with unstimulated HK-2 cells (Fig. 5-7). This result is in parallel with the 
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5.3 Discussion 
The clinical benefit of statins is largely mediated by their effects on lipid metabolism, 
although there is growing evidence to suggest that these agents have pleiotropic effects that 
include anti-inflammatory, anti-fibrotic and immunomodulatory mechanisms of action. All 
four of these effects have potential to improve outcomes in renal disease and may even be 
renoprotective, though more research is needed to confirm this. 
Currently,  there  are  two  proposed  mechanisms  by  which  these  pleiotropic  effects  are 
mediated.  First,  the  reduction  of  the  isoprenoids  FPP  and  GGPP  in  the  cholesterol 
biosynthetic  pathway;  by  decreasing  the  levels  of  these  mevalonate  derivatives,  statins 
interfere with the isoprenylation of important signalling molecules, such as proteins of the 
Rho and Ras families (Boguski&McCormick, 1993; Laufs&Liao, 2003; Porter et al., 2004; 
Scita et al., 2000; Seabra&James, 1998; Sharpe&Hendry, 2003; Zerial&McBride, 2001), 
and therefore affect multiple cellular functions (Blanco-Colio et al., 2003). Second, the 
disruption, or reduction, of cholesterol-rich lipid rafts (Dykstra et al., 2001; Hillyard et al., 
2004a;  Kono  et  al.,  2002;  Lopez  et  al.,  2005);  by  reducing  the  density  of  these 
microdomains, statins limit the functions of localised receptors (Hillyard et al., 2004a). 
The latter hypothesis, however, has received relatively little attention. 
In addition to their complex phenotype, the actions of PTEC are numerous and include the 
enzymatic degradation of filtered proteins, the processing and expression of antigen and 
the  expression  of  various  transporters  (Healy&Brady,  1998).  Any  small  proteins  or 
polypeptides reabsorbed from the tubular fluid may be catabolised by membrane digestion 
at the surface of the brush border membranes. Along with other cells in the renal tubules, 
PTEC  are  a  known  target  for  specific  injury,  including  infection  (both  ascending  and 
systemic) and drug toxicity leading to interstitial fibrosis and progressive renal disease 
(Healy&Brady, 1998; Nangaku, 2004; Ong&Fine, 1994). Although tubular injury may be 
caused by a number of agents, CNIs (cyclosporine A and tacrolimus) are associated with 
the greatest clinical impact. 
Several factors complicate the evaluation of the immunomodulatory effects of statins, not 
least the fact that immune cells and their secretory products have a complex role in kidney 
disease and can sometimes exert renoprotective effects (Palinski&Tsimikas, 2002). There 
is a clear need for extensive in vivo studies to investigate the immune effects of statins and 
how they impact on renal diseases before we can expand the indication of these agents to 
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have been proposed to extend to a reduction in the severity and frequency of acute allograft 
rejection episodes following kidney transplantation (Kwak et al., 2000; O'Donnell et al., 
1995). Fluvastatin in particular has potential benefits in transplant recipients being treated 
with  CNIs  as  these  drugs  are  metabolised  via  different  cytochrome  enzyme  pathways 
(Holdaas et al., 2001; Jardine&Holdaas, 1999). However, there is a chance that, even when 
given at therapeutic doses, statins may increase or induce the effects of other drugs that 
affect cellular function (e.g. immunosuppressives) (Kakkis et al., 1997; Kobashigawa et 
al., 1995). 
There is a growing body evidence to suggest that statins attenuate progressive renal disease 
(Baigent  et  al.,  2005;  Jain&Ridker,  2005;  Palinski&Tsimikas,  2002;  Takemoto&Liao, 
2001).  For  example,  studies  have  shown  that  the  anti-inflammatory  effects  of  statins 
improved renal outcomes in a model of diabetes (Li et al., 2004) and attenuated the fibrosis 
associated with cyclosporine nephrotoxicity (Usui et al., 2003). In a mouse model of ARF, 
simvastatin was able to limit the severity of nephritis when given either before or at the 
time of disease induction (Christensen et al., 2006). The course of established nephritis, 
however, remained unchanged. 
Recent studies suggested that statins have the potential to reduce protein reabsorption in 
vivo providing there is sufficient inhibition of HMG-CoA reductase inhibitor in the PTEC 
and reduced prenylation of proteins involved in endocytosis (Verhulst et al., 2004). This, 
in turn, may result in tubular proteinuria in some patients treated with high-dose statins. 
However, long-term statin treatment was associated with a reduction in proteinuria. No 
studies reported a statistically significant increase in proteinuria. Thus, statins have the 
unique potential to increase proteinuria in the short term, but causes less inflammation, less 
progression and less proteinuria over the long term. This is achieved by reducing RME, 
particularly in high doses, and may exert a renoprotective benefit (Verhulst et al., 2004). 
Studies  in  humans  are  being  conducted  in  order  to  verify  the  findings  of  the  in  vitro 
experiments  of  Sidaway  et  al  and  Verhulst  et  al.  It  has  been  recommended  that  renal 
function and protein and red blood cell excretion be monitored throughout statin therapy, 
especially at high doses and in patients with CKD (Agarwal, 2004). 
Studies have shown that LPS is an important pathogenic factor in both acute and chronic 
renal disease, and so I chose this agent to stimulate PTEC in my experiments. It has been 
shown previously that bacteria can attach to PTEC and produce LPS, which stimulates 
immune host mechanisms. LPS binds to TLRs, and the upregulation of these receptors and 
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2006; Methe et al., 2005). In ARF, the loss of TLR4 either during or after injury may be 
considered a beneficial response as it restricts activity in the overstimulated TLR4–ligand 
pathway (Zager et al., 2005; Zager et al., 2006). As this response is unlikely to be specific, 
the benefit of statins seen in ARF may extend to other types of kidney disease, particularly 
those  with  recurrent  episodes  of  inflammation,  such  as  IgAN.  In  patients  with  IgAN, 
statins have the potential to limit the severity and number of disease exacerbations, and 
thereby slow the progressive loss of renal function. 
It is important to note that although LPS primarily binds to serum proteins that stimulate 
proinflammatory pathways, the endotoxin is also bound by triglyceride-rich lipoproteins. 
Because  statins  expand  LDL  receptors,  thereby  promoting  the  internalisation  of 
lipoprotein-bound  endotoxin,  an  alternative  hypothesis  is  provided  for  the  anti-
inflammatory actions of these agents (Spitzer&Harris, 2006); once internalised, fragments 
of lipoprotein-bound endotoxin affect proinflammatory cytokine signalling pathways and 
ameliorate the systemic inflammatory response. 
To investigate the effects of statins on the inflammatory response, I conducted a series of 
experiments to assess how these agents affect the expression of Ig receptors on PTEC. As 
was previously shown in Chapter 3 using semi-qRT-PCR, PTEC activation increases the 
expression of FcRn, pIgR and Fca/mR. Interactions between LPS-binding proteins and Fc 
receptors at the cell surface are known to cause the release of proinflammatory cytokines 
and the internalisation and detoxification of LPS (Lazaron et al., 2001). 
Some studies have reported that LPS upregulates the expression of pIgR mRNA and cell 
surface  protein  in  intestinal  epithelial  cells,  thus  enhancing  IgA-mediated  homeostasis 
(Schneeman et al., 2005), while other studies have shown that LPS affects FcgR and FcaR 
by  significantly  increasing  Fc  receptor  expression  in  certain  cells  (e.g.  PMN  and 
monocytes) (Lazaron et al., 2001; Palermo et al., 1997; Refici et al., 2001; Shen et al., 
1994). Following on from this, in Chapter 4 I showed that stimulation of PTEC by LPS 
increased the expression of FcRn, pIgR and FcamR in these cells. I suggested that the 
upregulation  of  the  transcription  factor  of  LPS  may  be  important  in  innate  immune 
triggers, synergistically activating several cytokines and chemokines, including IL-6, IL-8, 
TNF-a and MCP-1 (Shen et al., 1994). 
In  an  investigation  of  the  effects  of  simvastatin  on  FcgR  expression  and  signalling, 
Hillyard found that the changes in lipid raft content failed to reflect either the total cellular 
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the inhibition of cholesterol biosynthesis might reduce lipid levels within specific cellular 
compartments, independently of extracellular cholesterol. Moreover, it was suggested that 
this  novel  effect  of  fluvastatin  might  also  be  relevant  for  transmembrane  receptors  in 
tubular injury (Christensen et al., 2006). 
Using semi-qRT-PCR, I investigated the expression of FcRn, pIgR and FcamR in cultured 
PTEC treated with statins (fluvastatin or simvastatin) and/or LPS 10 mg/ml. As expected, 
and  in  concordance  with  those  of  previous  studies,  my  results  showed  that  LPS  alone 
increased the cellular expression of FcRn, pIgR and FcamR. The mRNA levels of all three 
receptors increased in a dose-dependent manner in PTEC treated with statins alone or in 
combination  with  LPS,  compared  with  unstimulated  cells.  These  increases  were  only 
slightly greater than those seen when PTEC were treated with LPS alone. Simvastatin and 
fluvastatin  increase  receptor  gene  transcriptional  activity  either  directly  or  via  some 
transcriptional  factors  independent  of  the  blockade  of  HMG-CoA  reductase.  This 
observation suggests that statin-mediated regulation of the gene expression of Ig receptors 
is a reflection of cell survival mechanisms in PTEC. 
Previous  studies  have  shown  that  statins  are  able  to  inhibit  the  expression  of  several 
cytokines,  chemokines  and  acute-phase  reactants  (Diomede  et  al.,  2001;  Gueler  et  al., 
2002; Ortego et al., 1999; Park et al., 1998b; Sukhova et al., 2002; Yokota et al., 2003). 
The  majority  of  the  effects  of  LPS  on  PTEC  are  mediated  by  cytokines  produced  by 
mononuclear phagocytes (Ballou&Lozanski, 1992). Recently, proinflammatory cytokines 
have been linked with the stimulation of transpithelial migration (TEM) of PMN through 
monolayers of PTEC, a phenomenon that occurs mainly through changes in the density of 
receptors on the cell surface of PTEC (Bijuklic et al., 2006). 
In Chapter 3, I showed that stimulated PTEC release a significant amount of IL-6, IL-8 and 
GM-CSF, in agreement with several existing studies (Ashizawa et al., 2003; Brauner et al., 
2001; Gerritsma et al., 1998a; Huang et al., 2005; Leonard et al., 1999; Li&Nord, 2002; 
Li&Nord,  2004).  Moreover,  it  seems  that  these  cytokines  play  a  crucial  role  in  the 
recruitment and activation of leukocytes in kidney disease. IL-6 is considered to be one of 
the most important proinflammatory cytokines with multiple effects in a wide range of 
conditions  (Van  Snick,  1990).  IL-8  is  considered  to  be  the  plasma  expression  of  the 
immune response to acute-phase reactants, is implicated in several inflammatory diseases 
and is thought to be a direct pathogenetic mediator of renal disease (Panichi et al., 2006). 
GM-CSF  mRNA  has  been  shown  to  be  upregulated  in  diseased  renal  cells  using 
quantitative analysis of the mRNA transcripts of PTEC-released cytokines (Frank et al., C C Ch h ha a ap p pt tte e er r r    5 5 5          E E Ef fff ffe e ec c ct tt    o o of ff    S S St tta a at tti iin n ns s s, 184 
1993). In a study of patients with IgAN, both GM-CSF and MCP-1 were upregulated in the 
glomerulus and interstitium (Ashizawa et al., 2003). Moreover, this effect correlated with 
the progression of tissue injury. In addition, the progression of tissue injury appears to be 
influence  by  the  induction  of  transcriptionally  regulated  genes  in  IgAN  and  their 
association with NF-kB. 
In  this  chapter,  I  showed  that  stimulation  of  cultured  PTEC  with  simvastatin  and 
fluvastatin induced a dose-dependent inhibition of IL-6, IL-8 and GM-CSF release. When 
compared with the cytokine release in response to LPS alone, both drugs significantly 
inhibited LPS-induced release of IL-6, IL-8 and GM-CSF by approximately 40%. Statins 
alone  also  inhibited  PTEC  release  of  all  three  cytokines  by  58%,  65%  and  57%, 
respectively,  with  a  maximal  effect  at  the  10  mM  concentration.  However,  because 
different  concentrations were used, it is difficult to decide whether  all effects must be 
considered  pharmacological  or  whether  some  of  them  only  occurred  at  much  higher 
concentrations  and  are  reflective  of  toxicity.  No  significant  differences  were  observed 
between  simvastatin  and  fluvastatin.  These  data  may  provide  an  insight  into  the 
mechanisms of the anti-inflammatory action of statins, suggesting as they do that these 
agents may reduce macrophage accumulation. Whether or not this anti-inflammatory effect 
can be generalised to include other statin agents remains to be seen. 
A literature review suggests that isoprenylated proteins may be implicated in the release of 
IL-6, IL-8 and GM-CSF through the dependence of MAPK on these molecules (Andrews 
et al., 1994; Hillyard et al., 2002; Palinski, 2000; Takemoto&Liao, 2001). Moreover, there 
is evidence that MAPK proteins – including ERK, JNK and p38 (Li&Nord, 2004) – play a 
key role in the production of IL-6, IL-8 and GM-CSF in PTEC (Leonard et al., 1999; 
Li&Nord, 2002; Li&Nord, 2004). Importantly, lipid rafts and caveolae also appear to be 
involved  in  the  release  of  IL-8  (Li&Nord,  2004).  Caveolin-1,  which  exerts  its  effects 
through the SAPK/JNK, P38 and ERK1/ERK2 signalling pathways, has been implicated in 
the  activation  of  proinflammatory  cytokines  through  its  association  with  CD40  in 
unstimulated,  but  not  stimulated,  PTEC.  Elimination  of  caveolin-1  with  filipin  (the 
collective  name  given  to  four  isomeric  polyene  macrolides  that  bind  to  cholesterol  in 
membranes)  reduced  all  signalling  activity  and,  consequently,  IL-8  release  in  human 
PTEC. 
These observations lend further weight to the hypothesis that the overall effects of statins 
are reflective of a dual action on lipid rafts and isoprenylated proteins (Hillyard et al., 
2006). From my results, it seems likely that neither simvastatin nor fluvastatin directly C C Ch h ha a ap p pt tte e er r r    5 5 5          E E Ef fff ffe e ec c ct tt    o o of ff    S S St tta a at tti iin n ns s s, 185 
inhibit the release of IL-8 by PTEC, but that they interfere in the signalling pathways of 
caveolin-1  by  disrupting  rafts  and  caveolae.  This  mechanism  might  also  explain  the 
inhibition of IL-6 and GM-CSF release in statin-treated PTEC. 
Given that nearly all cytokines activate the JAK/STAT signalling pathway, it seems highly 
likely that STATs are crucial to the inflammatory process. Indeed, there is some evidence 
that albumin activates PTEC in a similar manner to cytokines following ROS-mediated 
STAT activation (Nakajima et al., 2004). The activation of this signalling pathway may 
subsequently lead to formation of ECM and cell proliferation, as well as the induction of 
immune responses involved in progressive renal disease. 
In Chapter 3, I showed that stimulated PTEC produce FN, one of the major components of 
ECM and an important mediator in the pathogenesis of renal disease by virtue of its role in 
tissue remodelling associated with inflammation, such as that seen in interstitial fibrosis, 
the final common pathway of all progressive renal diseases. Recent research has shown 
that the mediation of proinflammatory molecules by PTEC from the glomerulus to the 
interstitium  is  vitally  important  to  the  progression  to  ESRF,  and  that  interstitial 
inflammation  and  fibrosis  has  a  central  role  in  this  process  (Sean  Eardley&Cockwell, 
2005). 
Previous studies have proven inconclusive with regard to whether or not statins have a 
direct effect on ECM accumulation in PTEC (Laufs&Liao, 2003; Takemoto&Liao, 2001). 
However, there is some evidence to suggest that the benefits of statins in renal diseases are 
due,  in  part,  to  the  enhancement  of  matrix  protein  degradation  (Nogaki  et  al.,  1999). 
Several studies in different cell types have reported that FN production is significantly 
increased following stimulation with LPS 0.1–1 mg/ml, potentially increasing the ability of 
bacterial products to modify FN production and lead to chronic infections (Adachi et al., 
1996; Kubo et al., 1996; Liang et al., 2001; Mahler et al., 1997; Nooteboom et al., 2000; 
Okamura et al., 2001; Sandstrom et al., 1994; Schmid-Kotsas et al., 1999). 
Previous  studies  have  shown  that  the  progression  of  glomerulosclerosis  and 
tubulointerstitial  fibrosis  is  closely  dependent  upon  the  increased  expression  of  TGF-β 
(Basile, 1999; Zhang et al., 2004). Thus, it can be assumed that TGF-β has a profibrotic 
action,  stimulating  matrix  production  of  fibroblasts  (Healy&Brady,  1998;  Massague, 
1990), and there is evidence to suggest that it also has anti-proliferative effects (Franklin, 
1997; Lawrence, 1995). C C Ch h ha a ap p pt tte e er r r    5 5 5          E E Ef fff ffe e ec c ct tt    o o of ff    S S St tta a at tti iin n ns s s, 186 
In my experiments relating to FN production and cell proliferation, TGF-β1 was used as a 
positive  control.  Both  simvastatin  and  fluvastatin  inhibited  FN  production  in  a  dose-
dependent manner, effective at the 0.1 mM concentration, compared with TGF-b1. At the 
1- M concentration, both drugs were associated with a 35% reduction in unstimulated FN 
production;  LPS-stimulated  production  was  also  inhibited.  Importantly,  the  observed 
reduction in FN production seen at 10 mM is probably a reflection of excessive toxicity and 
apoptosis  and  is  therefore  unlikely  to  be  of  pathophysiological  relevance.  This  is  in 
accordance with previously published research in mice suggesting that, in the proximal 
tubules, statins induce apoptosis via inhibition of isoprenoid production and that this may 
be related to the disruption of actin filaments (Iimura et al., 1997). Therefore, it is difficult 
to determine whether the pleiotropic effects of the statins all occurred at the same time and 
within the same concentration range. 
In  vitro  experiments  in  several  different  cell  types  (including  PTEC,  MSC,  immune 
mediator  cells  and  vascular  smooth  muscle  cells)  have  shown  that  statins  inhibit  cell 
proliferation (Buemi et al., 2002; Guijarro et al., 1998; Iimura et al., 1997; Ishikawa et al., 
1995;  Jain&Ridker,  2005;  Palinski&Tsimikas,  2002;  Takemoto&Liao,  2001).  This 
generally  accepted  phenomenon  concurs  with  the  mechanism  described  above  in  the 
mouse study of statin-induced apoptosis (Iimura et al., 1997). The effective concentration 
of statins is approximately 0.1  M, with around 50% inhibition of proliferation seen at the 
1   M  concentration,  which  corresponds  to  the  peak  plasma  levels  of  simvastatin  or 
fluvastatin in vivo (Hillyard et al., 2002; Hillyard et al., 2004b; Park et al., 2001). 
In concordance with these results, I found that both simvastatin and fluvastatin treatment 
were  associated  with  a  51%  reduction  in  cell  proliferation  at  the  1   M  concentration. 
Overall, the results observed in the FN production experiments were in parallel with those 
seen in the proliferation experiments. PTEC were treated over 24 hrs with statins using 
[
3H]-thymidine  incorporation  in  a  dose-dependent  manner  in  the  micromolar  range  in 
agreement  with  Vrtovsnik  et  al  (Vrtovsnik  et  al.,  1999).  The  inhibition  of  PTEC 
proliferation was associated with blockade of the cell cycle in the G1 phase, preventing 
transition  to  the  S  phase.  In  a  recent  study,  Khwaja  et  al  showed  that,  at  high 
concentrations, pravastatin arrested the cell cycle in the G1 phase (Khwaja et al., 2006). 
In addition, I showed that PTEC expressed Ig receptors, cytokines release, produced FN 
and proliferated and that these functions were increased when the cells were stimulated 
with LPS, which may contribute to the influx of inflammatory cells in bacterial infection 
and to the development of interstitial fibrosis. In vitro, statins were able to suppress these C C Ch h ha a ap p pt tte e er r r    5 5 5          E E Ef fff ffe e ec c ct tt    o o of ff    S S St tta a at tti iin n ns s s, 187 
actions  and  attenuate  the  effect  of  LPS  on  cytokine  release,  FN  production  and 
proliferation by PTEC. The significant anti-inflammatory effects of statins are certainly 
partly  attributable  to  the  downregulation  of  FN  production,  leading  to  a  reduction  in 
interstitial fibrosis, less severe tubular phenotypical changes, less myofibroblast expression 
and downregulation of TGF-b, while the control of PTEC proliferation may represent a 
novel  strategy  to  slow  the  progression  of  renal  disease.  By  increasing  the  proteolytic 
activity of PTEC, it may be possible to reduce or prevent ECM deposition and interstitial 
fibrosis. 
In conclusion, I demonstrated that LPS can induce the release of IL-6, IL-8 and GM-CSF 
in PTEC and statins can inhibit these responses in a dose-dependent manner, which may 
provide an insight into the mechanisms of anti-inflammatory actions of these agents. In 
concordance with my results in Chapter 4, I again showed that PTEC stimulated with LPS 
upregulated the expression of Ig receptors, cytokine release, production of FN and cell 
proliferation; these functions may contribute to the influx of inflammatory cells in bacterial 
infection  and  also  to  the  development  of  interstitial  fibrosis.  The  control  of  PTEC 
proliferation  may  represent  a  promising  strategy  to  attenuate  the  progression  of  renal 
diseases.  Currently,  quality  clinical  trial  data  to  suggest  that  statin  therapy  is  able  to 
ameliorate  the  deterioration  of  function  in  patients  with  mild  renal  disease  are  scarce. 
There is a clear need for further research to investigate the therapeutic advantages of the 
lipid-independent  pleiotropic  effects  of  these  agents.  In  particular,  it  needs  to  be 
established whether the anti-inflammatory properties of statins is related to the ability of 
these agents to attenuate tubulointerstitial inflammation, especially if this frequently recurs 
(as in IgAN), and whether or not the beneficial effects of statins are seen in the early stages 
of progressive disease. The results of in vitro and animal experiments may only provide 
proof in principle for improved patient outcomes in renal disease, but these urgently need 
to be verified in humans. C C Ch h ha a ap p pt tte e er r r    5 5 5          E E Ef fff ffe e ec c ct tt    o o of ff    S S St tta a at tti iin n ns s s, 188 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure   5-4 Dose–response curve of the effect of statins ± ± ± ± LPS on IgR expression by PTEC 
The fold differences of expression of FcRn, pIgR and Fca/mR was measured by 
semi qRT PCR in relation to control treatment with statins, with and without LPS, 
for  24  hrs  in  HK 2  cells.  The  amplification  of  each  of  these  Ig  receptors  was 
relative to the housekeeping gene, b actin. All of the receptors showed a significant 
increase  in  expression  following  treatment  with  SIM  or  FLU  alone  or  in 
combination with LPS in a dose dependent manner. LPS alone resulted in a slight 
increase  in  expression.  FcRn  expression  in  U937  cells  was  upregulated  by 
4.43±0.36 fold  (p<0.005);  pIgR  was  upregulated  by  200  ng/ml  IFN g  by 
11.18±0.67 fold (p<0.005); and Fca/mR was upregulated by 50  ng/ml IL 1a by 
12.26±0.61 fold  (p<0.005).  This  graph  is  representative  of  two  experiments. 
Triplicate reactions at each condition were amplified along the iCycler iQ RT PCR 
system. Error bars show the (± SD). Standard curve had r = 0.999, slope = –3.272 
and PCR efficiency = 100%. (*) Significant comparison between HK 2 cells treated 
and untreated with LPS alone (*p<0.025, **p<0.005). (+) Significant comparison 
between LPS alone and LPS in combination with statins (+p<0.025). 
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Figure   5-5 Dose–response curve of the effect of statins ± ± ± ± LPS on cytokine release by PTEC 
These  graphs  show  a  dose dependent  stimulation  of  IL 6,  IL 8  and  GM CSF 
release by cultured supernatant HK 2 cells following treatment with SIM or FLU 
with and without LPS and 24 hr incubation, expressed as a percentage of control. 
Levels of IL 6, IL 8 and GM CSF were measured by ELISA. Statins alone inhibited 
cytokine release in a dose dependent manner. LPS stimulated cytokine release was 
also inhibited in a dose dependent manner when additionally treated with SIM or 
FLU. Media alone was used as negative control and LPS as positive control. These 
data  represent  three  measurements  in  three  separate  experiments  (n=9).  Error 
bars show the (± SD). (*) Significant comparison between HK 2 cells treated and 
untreated  with  LPS  alone  (*p<0.017,  **p<0.003,  ***p<0.0003).  (+)  Significant 
comparison between LPS alone and LPS in combination with statins (+p<0.017, 
++p<0.003, +++p<0.0003). 
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Figure   5-6 Dose–response curve of the effect of statins ± ± ± ± LPS on FN production by PTEC 
Cells  were  treated  with  statins  alone  and  in  combination  with  LPS  and  then 
incubated for 72 hrs. FN production was measured by using specific ELISA and 
expressed as a percentage of control. TGF b1 was used as a positive control. LPS 
alone increased FN production, whereas statins alone or in combination with LPS 
inhibited FN production in a dose dependent manner. Data are shown as the mean 
of four experiments performed in duplicate (n=8). Error bars show the (± SD). (*) 
Significant comparison between HK 2 cells treated and untreated with LPS alone 
(*p<0.0125, **p<0.002, ***p<0.0002). (+) Significant comparison between LPS 
alone  and  LPS  in  combination  with  statins  (+p<0.0125,  ++p<0.002, 
+++p<0.0002). 
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Figure   5-7 Dose–response curve of the effect of statins ± ± ± ± LPS on proliferation of PTEC 
The effect of statins alone and in combination with LPS on HK 2 cell proliferation 
was measured by 24 hr [3H] thymidine incorporation, expressed as a percentage 
of control. Cells treated with statins with and without LPS showed an inhibitory 
effect on proliferation in a dose dependent manner. HK 2 culture media was used 
as a negative control and TGF b1 as a positive control. These data represent the 
mean of 2 experiments performed in replicates of 12 (n=24). Error bars show the 
(± SD). (*) Significant comparison between HK 2 cells treated and untreated with 
LPS  alone  (*p<0.025,  **p<0.005,  ***p<0.0005).  (+)  Significant  comparison 
between LPS alone and LPS in combination with statins (+p<0.025, ++p<0.005, 
+++p<0.0005).  
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6.1 General discussion 
GN is a major cause of progressive CRF and accounts for less than 20% in the UK of all 
patients requiring dialysis or kidney transplantation. There are several forms of GN, of 
which the most common is IgAN. In most forms of GN, kidney injury is a consequence of 
the deposition of ICs within the glomerulus. These ICs contain Ig, complement and other 
proteins,  can  vary  in  composition  and  may  directly  contribute  to  progression  to  ESRF 
(Nangaku&Couser, 2005). Despite the large volume of research that exists on this disease 
pathway, few studies implicate pre-formed ICs (which enter the kidney via the circulation) 
in  the  development  of  significant  tissue  injury  where  the  complexes  are  localised, 
including  the  glomerulus  (Couser&Salant,  1980).  Once  glomerular  damage  occurs, 
additional plasma proteins are filtrated into the lumen of the proximal renal tubule. As the 
concentration  of  protein  increases,  specific  PTEC  receptors  stimulate  increased  protein 
uptake into the cells, eventually triggering interstitial fibrosis and inflammation. 
In  proteinuric  renal  disease,  progression  to  ESRF  leads  to  glomerulosclerosis  and 
tubulointerstitial fibrosis/inflammation in the late stages, independently of the nature of 
original injury (Tang et al., 2002). The mechanisms by which proteinuria causes GN and 
tubulointerstitial  injury  are  not  completely  understood.  Current  evidence  suggests  that 
proteinuria  contributes  to  progressive  renal  disease  by  initiating  signals  that  increase 
inflammation and fibrosis in the kidney (Remuzzi&Bertani, 1998). One theory is that, as 
the proximal tubular epithelium is strategically located between the urinary space and the 
surrounding interstitium, proteinuric injury may be mediated by the activation of PTEC. 
This  thesis  describes  the  role  of  Ig  receptors  on  PTEC  when  stimulated  with  pro-
inflammatory cytokines, which are a key feature of the immune system. Fig. 6.1 provides 
an overview of my results. 
It is clear that proteinuria has numerous effects within the proximal tubule and a number of 
questions arise from this finding. Firstly, which Ig receptors are expressed on tubular cells? 
Receptors for the Fc region of Igs are expressed on many different cell types within the 
immune system and kidney. PTEC have been shown to express Fca/mR, pIgR and FcRn 
and these receptors may play a role in protein endocytosis. Whether or not these three 
receptors  are  primarily  responsible  for  the  initiation  of  pro-inflammatory  responses  by 
PTEC in the presence of proteinuria is not yet clear. Indeed, these responses may not be 
receptor-mediated at all. One of the causes of IgAN may be abnormal glycosylation of 
serum IgA1, which may help to explain why the presence of IC deposits is associated with C C Ch h ha a ap p pt tte e er r r    6 6 6          G G Ge e en n ne e er r ra a al ll    d d di iis s sc c cu u us s ss s si iio o on n n, 194 
renal damage in only a subset of patients. However, this abnormal glycosylation alone 
would most likely be insufficient to fully explain the pathology of IgAN, but may be a 
necessary factor for the disease to develop. 
In this thesis, I have demonstrated mRNA expression of the novel Fca/mR by PTEC. Any 
IgA receptor expressed by PTEC is a potential mediator of IgA deposition in IgAN and 
may  contribute  to  PTEC  activation  by  IgA  ICs,  in  agreement  with  the  findings  of 
McDonald et al., (2002). I have shown that the expression of Fca/mR transcript by PTEC is 
increased by the pro-inflammatory cytokines IL-1a and IFN-g, and inhibited by TGF-b1. 
These  results  confirm  those  of  Yoshioka  et  al.,  (1993)  and  Yano  et  al.,  (1997),  who 
considered the array of inflammatory mediators found within the kidneys of IgAN patients. 
Secondly, which Igs activate tubular cells, and how? In this thesis, I reported that PTEC in 
culture bind IgG, IgA and IgM. I have also shown that human Fca/mR was able to bind 
IgA and IgM with a specific monoclonal Fca/mR antibody, generated using IHC of normal 
and IgAN kidney showing Fca/mR expression by renal PTEC. Using this antibody, I was 
able to determine whether or not the receptor was expressed at the cell surface in cultured 
PTEC. Recently, Cho et al., (2006) developed a new anti-Fca/mR molecule that will prove 
useful for future experiments of this type. 
The  major  implications for  the  pathogenesis  of  IgAN  inferred  by  the  expression  of  Ig 
receptors by PTEC is that any IgA found in the glomerular filtrate might interact with and 
activate these cells, leading to tubulointerstitial injury. I was unable to confirm Fca/mR 
protein expression by PTEC, as discussed in Section 3.3. However, Fca/mR may still be 
able  to  mediate  the  binding  of  IgA  and  IgM  by  activated  PTEC  in  vivo.  Restricted 
expression of Fca/mR under certain conditions may be associated with a specific response, 
potentially leading to renal damage. 
Thirdly,  do  Ig/IC  deposits  increase  proteinuria  as  implicated  in  the  early  stages  of 
tubulointerstitial fibrosis? PTEC synthesis of FN and other ECM proteins occurs as a direct 
response to proteinuria,  especially TGF-b (Eddy, 2004), and contributes to progressive 
renal injury by activating the pro-apoptotic pathways that lead to PTEC death (Erkan et al., 
2001; Thomas et al., 1999). Following injury  by  Ig/IC deposits, PTEC proliferate and 
release high levels of cytokines and growth factors, and increase FN production, as seen in 
IgAN (Eitner et al., 1994; Lai et al., 1996). However, the pathogenic role of FN in IgAN is 
still  unknown.  Similarly,  the  pathogenesis  of  PTEC  proliferation  and  its  role  in  the C C Ch h ha a ap p pt tte e er r r    6 6 6          G G Ge e en n ne e er r ra a al ll    d d di iis s sc c cu u us s ss s si iio o on n n, 195 
development of glomerulosclerosis is poorly understood. A recent study by Chan et al., 
(2005) showed that the binding of IgA to PTEC had no effect on the proliferation of PTEC. 
In contrast, my results showed that XL- or HAg-IgA may have an antiproliferative effect 
on  PTEC.  As  such,  the  role  of  PTEC  proliferation  in  glomerulosclerosis  and 
tubulointerstitial fibrosis requires further investigation. The cross-linking of Fc receptors 
by Ig/IC in PTEC may cause inflammation and tubular injury, and this is subsequently 
worsened  by  pro-inflammatory  cytokines  and  activated  complement  components. 
Antagonism  of  these  receptors  may  prove  to  be  a  useful  strategy  for  therapeutic 
intervention. 
I have also demonstrated that PTEC are able to synthesise and release several cytokines, in 
agreement with several other in vitro studies which found that certain urinary proteins led 
to the release of IL-6, IL-8 and GM-CSF (Donadelli et al., 2003; Tang et al., 2003; Zoja et 
al.,  1998).  IL-8  and  IL-6  are  increased  in  patients  with  various  forms  of  glomerular 
diseases, such as IgAN and membranoproliferative GN (Wang et al., 1997). That human 
PTEC  are  able  to  release  these  molecules  suggests  a  similar  pathway  in  vivo,  thereby 
providing a plausible mechanistic link between proteinuria and interstitial inflammation. 
As part of the research project resulting in this thesis, I planned to do clinical research on 
patients suffering from IgAN or GN to measure Ig/IC concentrations in the urine, to work 
on  biopsy  samples  of  patients  with  these  diseases  to  localise  tubular  ICs  by 
immunofluorescence or electron microscopy stained with the specific monoclonal antibody 
to Fca/mR, and to find out the expression and binding of Igs. Unfortunately, there was not 
enough time to conduct this research. 
The second part of this thesis examined the response of PTEC to CNIs (cyclosporine A and 
FK506) and the non-CNI sirolimus, in addition to the immunomodulatory effects of statins 
(simvastatin  and  fluvastatin).  Previous  studies  have  shown  that  each  of  the 
immunosuppressive  agents  studied  substantially  reduces  proteinuria,  tubulointerstitial 
inflammation, cortical fibrosis, renal expression of pro-inflammatory and profibrotic genes 
and glomerular hypertrophy. Interestingly, sirolimus alone has been shown to effectively 
halt  disease  progression  altogether.  However,  long-term  treatment  with  these 
immunosuppressive  agents  may  result  in  nephrotoxicity  and  hypertension  in  renal 
transplant recipients. 
My results showed that LPS alone stimulated PTEC to increase the release of cytokines, in 
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no  significant  effect  of  immunosuppressant  agents  alone  on  Ig  receptor  expression, 
cytokine  release,  FN  production  and  proliferation  of  PTEC.  However,  when  treated  in 
combination with LPS, each of these immunosuppressive agents reduced the expression of 
pIgR at highest concentration, FN production and proliferation in PTEC when treated at 
the  highest  dose.  This  variance  might  be  explained  by  differences  in  the  experimental 
protocol and further work is needed to clarify these observations. 
Patients  with  CKD  have  a  significantly  increased  risk  of  cardiovascular  morbidity  and 
mortality  (Levy,  2006),  and  several  studies  have  shown  that  increased  proteinuria  and 
reduced renal function are associated with more rapid progression to ESRF and a higher 
incidence  of  cardiovascular  problems.  HMG-CoA  reductase  inhibitors  (statins)  have 
dramatically  improved  cardiovascular  outcomes  in  patients  without  significant  kidney 
disease and may prove to have similar effects in patients with kidney disease. Alongside 
the primary cardiovascular benefit of statin therapy (a reduction in cholesterol synthesis), 
there is evidence to suggest that these agents have a renoprotective effect through reducing 
proteinuria.  However,  high  doses  of  statins  may  induce  proteinuria  (Agarwal,  2004), 
although the nature of the proteinuria is not clear. 
To confirm the appealing hypothesis that statins reduce proteinuria and the rate of kidney 
function  loss,  I  demonstrated  a  reduction  in  cytokine  release  by  PTEC  stimulated  by 
simvastatin  and  fluvastatin,  alone  or  in  combination  with  LPS.  FN  production  and 
proliferation were also reduced in a dose-dependent manner, with or without LPS, and, 
importantly, without altering cell viability. These findings concur with those of Methe et 
al.,  (2005)  and  Hillyard  et  al.,  (2006).  The  expression  of  Ig  receptors  by  PTEC  was 
increased  in  a  dose-dependent  manner,  with  or  without  LPS.  This  hypothesis  may  be 
supported by further work investigating the effects of statins on PTEC in vivo. 
In conclusion, the main focus of this study was to determine the potential role of FcRn, 
pIgR and the novel Fca/mR, all of which have been identified in PTEC, and their potential 
implications for IgAN. 
·  Using primary and immortalised human PTEC, I was able to show Fca/ R gene 
expression and surface receptor detectable by immunoblot and IHC. 
·  My findings support the hypothesis that tubular binding of filtered Ig and activation 
of  FcRs  may  contribute  to  progression  of  renal  disease  and  provide  a  potential 
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·  I also investigated the role of cyclosporine A, FK506 and sirolimus on susceptibility 
to nephrotoxicity in cultured human PTEC. 
·  My results inferred that immunosuppressive agents alone have a non-inflammatory 
response on Ig receptor expression. However, in combination with LPS, the study 
drugs showed a slight inhibitory effect on the expression of pIgR, on FN production 
and on the proliferation of human PTEC. 
·  In  addition,  I  have  shown  that  human  PTEC  release  IL-6,  IL-8  and  GM-CSF  in 
response  to  LPS.  These  cytokines/chemokines  may  contribute  to  the  influx  of 
inflammatory cells in bacterial infection and also to the development of interstitial 
fibrosis.  However,  the  immunosuppressive  agents  were  unable  significantly  alter 
cytokine release. 
·  Statins inhibit these actions at biologically relevant in vitro concentrations, and may 
be of clinical significance. There are limited clinical trial data to suggest that statins 
may slow the decline of renal function in patients with mild renal impairment. My 
results  provide  a  possible  mechanism  for  this  effect,  and  is  worthy  of  further 
investigation. 
·  Moreover,  my  in  vitro  findings  may  help  to  explain  why  GN  is  frequently 
encountered  in  patients  with  chronic  tubular  proteinuria,  as  well  as  providing  an 
explanation  for  the  development  of  GN  in  diseases  that  primarily  affect  the 
tubulointerstitial compartment. This finding may offer potential new strategies for 
the prevention and treatment of drug-induced nephrotoxicity. 
·  As always, a major limitation of in vitro studies such as this, is that the relevance of 
the findings may not extend to the in vivo condition in treated patients. C C Ch h ha a ap p pt tte e er r r    6 6 6          G G Ge e en n ne e er r ra a al ll    d d di iis s sc c cu u us s ss s si iio o on n n, 198 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure   6-1 Summary study of PTEC in renal disease 
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